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Chronic pancreatitis (CP) is a disease of fibrosis of the pancreas for which alcohol is the main 
causative agent.  However, only a small proportion of alcoholics develop chronic pancreatitis. 
Genetic polymorphism may affect pancreatitis risk. 
 
Aim 
To determine the factors required to classify a chronic pancreatic population and identify genetic 
variations that may explain why only some alcoholics develop chronic pancreatitis.  
 
Methods 
The most appropriate method of diagnosing CP was assessed using a systematic review.  Genetics of 
different populations of alcohol-related chronic pancreatitics (ACP) were explored using four 
different techniques: genome-wide association study (GWAS); custom arrays; PCR of variable 
nucleotide tandem repeats (VNTR) and next generation sequencing (NGS) of selected genes. 
 
Results 
EUS and sMR were identified as giving the overall best sensitivity and specificity for diagnosing CP. 
GWAS revealed two associations with CP (identified and replicated) at PRSS1-PRSS2_rs10273639 (OR 
0.73, 95% CI 0.68-0.79) and X-linked CLDN2_rs12688220 (OR 1.39, 1.28-1.49) and the association 
was more pronounced in the ACP group (OR 0.56, 0.48-0.64)and OR 2.11, 1.84-2.42). 
The previously identified VNTR in CEL was shown to have a lower frequency of the normal repeat in 
ACP than alcoholic liver disease (ALD; OR 0.61, 0.41-0.93).  Homozygosity of the normal variant was 
more common in ALD than ACP (OR 0.53, 0.3-0.96) or Healthy Controls (OR 0.55, 0.3-1.00)). 
The NGS discovery phase lead on to validation of the 21 most significant SNPs with Sequenom array. 
This showed significance difference between ACP and ALD in allele frequency of the synonymous 
SNP, PRSS1_rs6666, (OR 1.99, 1.46-2.72)  
 
Conclusion 
A range of potential exonic and intronic sites have been identified that have association with a 
predisposition to developing chronic pancreatitis.  These findings show that further work is justified 
to fully assess the interaction of the different polymorphisms and their phenotypic significance in 
development of the disease. 
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1 Chapter 1: Introduction 
 Chronic Pancreatitis 1.1
Chronic pancreatitis (CP) is an inflammatory condition that causes irreversible fibrosis of the 
pancreas, leading to both structural and functional sequelae.1  CP is detrimental to an individual’s 
quality of life in many ways: severe abdominal pain, exocrine and endocrine failure and increased 
risk of developing pancreatic cancer. 
In countries where alcohol excess is common, about 70% of chronic pancreatitis is caused by 
alcoholism, however less than 3% of heavy alcohol users develop clinical CP.2,3 Chronic pancreatitis 
may suffer with additional alcohol-related co-morbidities and have complex social problems 
hindering medical and surgical management plans. 
.  
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1.1.1 Epidemiology 
Chronic pancreatitis has a prevalence of about 30 per 100,000 and annual incidence of 3-10 per 
100,000 per year; the incidence varies from 5-11 per 100,000 in men to 2-3 per 100,000 in women.4-7 
In a population of those with a history of alcohol-excess the incidence is increased to 92 per 100,000 
in men and 82 per 100,000 in women.7 The average life expectancy is 72 years, which is lower than 
that of idiopathic chronic pancreatitis (ICP; 80 years).8 The over-all mortality directly due to chronic 
pancreatitis has been calculated as 36% over 20 years.9  
Acute and chronic pancreatitis are discreet disease processes but there is some overlap, with acute 
developing into chronic, or acute-on-chronic flare ups of the disease.1 It is thought that in many 
cases ACP is a progression from an initial attack or multiple attacks of acute pancreatitis (AP), which 
may occur 1-19 years before manifestation of chronic pancreatitis.10 CP can develop as a result of 
acute attacks of pancreatitis; around a quarter of those who have AP go on to develop CP.11 
Acute pancreatitis is diagnosed by the presence of two out of three of the following: a clinical history 
of abdominal pain in keeping with acute pancreatitis; increased amylase greater than three times 
the upper limit of normal; radiological changes in keeping with pancreatic inflammation.12 Acute 
pancreatitis should be followed by full recovery of pancreatic function.13  Many individuals go on to 
experience recurrent episodes of acute alcoholic pancreatitis, which is classified as recurrent acute 
pancreatitis.  When symptoms fail to resolve between attacks then a diagnosis of chronic 
pancreatitis can be considered. Unfortunately no such internationally agreed diagnostic criteria for 
the diagnosis of chronic pancreatitis has been established. 
Chronic pancreatitis can present in a variety of ways; it can often be associated with acute or chronic 
abdominal pain, but some individuals may be pain free. Pain is the presenting feature in 77% of 
those with ACP.8  Pancreatic pain is often localized to the upper abdomen and may radiate to the 
back.  This pain is often refractory to analgesia. In severe cases the pain can lead to absence from 
work, hospitalizations and addiction to opioids.10,14,15 
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Painless chronic pancreatitis tends to present with steatorrhoea or be detected incidentally when a 
patient has a CT scan for another purpose and is sometimes difficult to distinguish from pancreatic 
cancer.16 
As yet there is no clear international consensus as to either the diagnosis or management of 
pancreatitis.  Individual groups from Italy, China, Germany, Spain, Belgium and Japan have produced 
guidance documents.17-23  To date there are no management guidelines produced for application in a 
British population and the first American guidelines on the diagnosis of pancreatitis were only 
published at the end of 2014, and therefore have not yet been widely adopted into clinical 
practice.24 
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1.1.2 Pathogenesis of Chronic Pancreatitis 
Despite the fact that CP can be caused by multiple different aetiologies (1.1.3) the consequence is 
fibrosis of the pancreas gland.  
Pancreatic stellate cells are the mediators of fibrosis in the pancreas, which leads to the formation of 
an extracellular matrix in interstitial spaces.25  This process leads to progressive loss of the lobular 
morphology and structure of the pancreas, deforming the large ducts and leading to changes in the 
islets.   
This pancreatic fibrosis is initiated by injury to the pancreas, the mechanism of which depends on 
the aetiology.  The exact pathogenesis of chronic pancreatitis is unknown, but several theories have 
emerged as to its mechanism, reflecting the different processes that may apply due to the variety of 
different aetiological factors implicated in the disease.26  The pathological development of CP is still 
unclear, but several common theories are discussed below including tryspin activation, by-products 
of alcohol metabolism, and oxidative stress. 
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1.1.2.1 Enzyme activation 
Trypsinogen is the inactive form of trypsin and cationic trypsinogen is the most plentiful isoform in 
human pancreatic juice, but there are several isoforms (Figure 1). When trypsin becomes active 
(normally by entropeptidases in the gut) it plays a central role in pancreatic exocrine physiology as it 
initiates the activation of other pancreatic digestive enzymes. In normal pancreatic acinar cells, only 
small amounts of trypsin are activated whilst still in the cell, and there is continued inactivation 
ongoing to prevent the digestion enzymes activation cascade and pancreatic auto digestion. When 
there is any disruption to this pathway there is risk of pancreatic damage. 
Pancreatic secretory trypsin inhibitor (SPINK1) inhibits up to 20% of the trypsin activity. If SPINK1 
fails to inhibit the trypsin activity, trypsin and other zymogens will be hydrolyzed. Hence, a mutation 
in the SPINK1 gene reduces this innate protection system and may lead to pancreatic auto digestion 
(acute pancreatitis) if the level of trypsin activity is increased above that of the protective threshold 
of SPINK1. 
Trypsin activation, such as in hereditary pancreatitis (HP), is believed by some to be insufficient to 
lead to chronic pancreatitis and in fact it is the sustained activation of inflammatory pathways by 
persistent pathogenic stimuli in the acinar cell that may be responsible for the development chronic 
pancreatitis.26 However other studies have shown that trypsin activation alone is insufficient to 










Codon  15 20 25 30 35 40 45 50 55 60 65 
CTry  AAPFD DDDKI VGGYN CEENS VPYQV SLNSG YHFCG GSLIN EQWVV SAGHC YKS 
ATry  AAPFD DDDKI VGGYI CEENS VPYQV SLNSG YHFCG GSLIS EQWVV SAGHC YKS 
MTry AVPFD DDDKI VGGYT CEENS LPYQV    SLNSG YHFCG GSLIS EQWVV SAAHC YKT 
TRY6  AVPFD DDDKI VGGYT CEENS VPYQV SLNSG YHFCG GSLIS EQWVV SAGHC YKP 
  
Exon 3 
Codon  70 75 80 85 90  95 100 105 110 115 120    125 130    135 140 145 150 
CTry RI QVRLG EHNIE VLEGN EQFIN AAKII RHPQY DRKTL NNDIM LIKLS SRAVI NARVS TISLP TAPPA TGTKC LISGW GNTAS SGA 
ATry  RI QVRLG EHNIE VLEGN EQFIN AAKII RHPKY DSRTL NNDIL LIKLS SPAVI NSRVS AISLP TAPPA AGTES LISGW GNTLS SGA 
MTry RI QVRLG EHNIK VLEGN EQFIN AAKII RHPKY DRKTL NNDIM LIKLS SPAVI NARVS TISLP TAPPA AGTKC LISGW GNTLS FGA 
TRY6  RI QVRLG EHNIE VLEGN EQFIN AAKII RHPKY DRITL NNDIM LIKLS TPAVI NAHVS TISLP TAPPA AGTKC LISGW GNTLS SGA 
 
Exon 4 
Codon   155 160 165 170 175 180 185 190 195 
CTry  DY PDELQ CLDAP VLSQA KCEAS YPGKI TSNMF CVGFL EGGKD SCQ 
ATry  DY PDELQ CLDAP VLSQA ECEAS YPGKI TNNMF CVGFL EGGKD SCQ 
MTry  DY PDELK CLDAP VLTQA ECKAS YPGKI TSNMF CVGFL EGGKD SCQ 
TRY6  DY PDELQ CLDAP VLTQA KCKAS YPLKI TSKMF CVGFL EGGKD SCQ 
 
Figure 1 Different isoforms of trypsinogen 1 
Variation in amino acid sequence of exons 2-4 between between the isoenzymes of trypsinogen; cationic trypsinogen (CTry), anionic trypsinogen (ATry), 
meso trypsinogen (MTry) and Trypsinogen C  (TRY6). Differences for cationic trypsinogen are underlined. 
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1.1.2.2 Fatty Acid Ethyl Esters and Calcium Overload 
It has been suggested that higher serum calcium levels may contribute to pancreatitis, as 
hypercalcaemia may predispose the pancreatic acinar cell to abnormal, sustained calcium levels, 
which lead to premature pancreatic protease activation and consequently pancreatitis.29 
Fatty acid ethyl-esters (FAEE), which are products of non-oxidative ethanol metabolism, increases 
calcium concentration through inositol trisphosphate receptors by causing calcium-ATPase pump 
failure due impaired mitochondrial ATP production. Fatty acid ethyl esters have been shown to 
induce pancreatic injury in vivo and in vitro.30 Lowering cellular fatty acid substrate concentrations 
may reduce cell injury in pancreatitis.29 
It has been shown that different FAEEs and the enzyme responsible for their synthesis (FAEE 
synthase) are present predominantly in the organs most often damaged by ethanol abuse, notably 
the pancreas and liver.31  Specific work done in animal models has shown that there is a direct link 
between the non-oxidative metabolism of alcohol to produce FAEE, and the damage of early 
pancreatic cell damage to cause pancreatitis (Figure 2).29,32 
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Figure 2 Schematic diagram of the effects of fatty acid ethyl esters on the pancreas 
(Photos courtesy of Dr D Criddle) 
Demostarates how the non oxidative metabolism of ethonal and fatty acids can lead to pancreatic 
damage. 
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1.1.2.3 Oxidative Stress 
The oxidative stress hypothesis is that by-products of hepatic oxidase activity damage the pancreas 
through chronic reflux of bile into the pancreatic duct.33  This theory has been better established in 
the development of AP.34 
1.1.2.4 Toxic-metabolic 
The toxic-metabolic theory is that alcohol is directly toxic to the acinar cell through a change in 
intracellular metabolism. This metabolic effect results in pancreatic lipid accumulation, fatty 
degeneration, cellular necrosis, and eventual widespread fibrosis. This association may be linked to 
the damage caused by calcium overload, which can lead to an abundance of FAEE, which in turn 
leads to pancreatitis.35 
1.1.2.5 Stone and Duct Obstruction 
It has been postulated that alcohol increases the lithogenicity of pancreatic juice, leading to stone 
formation within the pancreatic ducts. The stones continued contact with the surrounding ductal 
epithelium may lead to ulceration and scarring. Eventually, this can cause atrophy to the pancreas. 
Fibrosis occurs due to the chronic obstruction of flow from the acinar cells causing back pressure.36 
1.1.2.6 Necrosis-fibrosis 
The necrosis-fibrosis theory assumes that all chronic pancreatitis is caused by multiple attacks of 
acute pancreatitis leading to eventually chronic pancreatitis. The inflammation and necrosis 
associated with acute pancreatitis leads to scarring and fibrosis over time.  There is also extrinsic 
compression of the pancreatic ducts due to oedema leading to obstruction, with a consequence of 
stasis, leading to stone formation and atrophy of the pancreas.37 
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1.1.3 Aetiology  
The frequency of different aetiologies varies by geographical location, but in the UK, alcohol is the 
most common aetiology of chronic pancreatitis.38 
1.1.3.1 Alcohol-related Chronic Pancreatitis 
The most common cause of CP in the Western world is alcohol excess (70-90%).8,9,39 It is thought that 
ACP may only be clinically present in around 3% of those who drink to excess.3  Chronic pancreatitis 
is less prevalent than alcohol-related cirrhosis amongst those who drink to excess, and both 
pancreatitis and cirrhosis are not commonly found in the same individuals, suggesting that there 
may be other factors, which lead to susceptibility of either disease in some individuals.40  
Commonly accepted value of excess alcohol range from 20g/day to 80g/day.8,41,42 When the 
threshold was specifically sought by examining a large population of veterans and their relationship 
to alcohol consumption and the development of ACP, a threshold of 40g/day was given as the lower 
limit for very heavy drinking.43  No studies have given a specific time period over which alcohol 
needs to be consumed to develop ACP, but some patients appear to exhibit symptoms over the first 
few years, whereas in the majority there will be a decade or more before ACP is diagnosed.10  
The age of onset of ACP varies but on average is around 40 years of age.10  Once diagnosed with ACP, 
the 5-year survival rate has been estimated at 65%, 10-year survival 43% and the 20-year survival at 
20%.44   
1.1.3.2 Idiopathic Chronic Pancreatitis 
About 10% of cases are diagnosed as idiopathic.5  Calcifications, exocrine insufficiency and diabetes 
develop more slowly in early onset idiopathic chronic pancreatitis than in late onset and alcoholic 
pancreatitis.8 
Identified genes that contribute to idiopathic pancreatitis are SPINK1 (serine protease inhibitor, 
Kazal type 1), and CFTR (cystic fibrosis transmembrane conductance regulator).45,46 These are only 
The Role of Genetic Variation in Predisposition to Alcohol-related Chronic Pancreatitis                             2015 
Introduction - Chronic Pancreatitis 32 
associated factors and lead to no clear pattern of inheritance, therefore they are classified as 
idiopathic rather than hereditary pancreatitis. 
1.1.3.3 Hereditary Pancreatitis 
About 1% of chronic pancreatitis is classified as hereditary pancreatitis (HP).5 Hereditary chronic 
pancreatitis is inherited in an autosomal dominant fashion with penetrance of approximately 70%.47 
In the majority of HP families there is a known mutation within the cationic trypsinogen gene 
(PRSS1).  The most common recognised disease causing mutations are p.R122H, p.N29I and arguably 
p.A16V that lead to increased stability of the trypsin product causing autodigestion.48-50 There are 
some families displaying the typical patterns of inheritance for which no disease causing mutation 
has yet been identified.51 The onset of symptoms is typically at 10-14 years of age although diagnosis 
may be delayed in individuals who are part of an as yet unidentified HP family.19,20 
1.1.3.4 Hypertriglyceridaemia  
Hypertriglyceridaemia is a rare cause of chronic pancreatitis that tends to involve the whole gland, 
but more commonly causing acute than chronic pancreatitis.52,53 Familial hypertriglyceridaemia (type 
I, IV or V; Table 1) or secondary triglyceridaemia with levels of triglyceride more than 1000 mg/dL 
may predispose individuals to recurrent acute pancreatitis.3 
Table 1 Classification of different types of familial hypertriglyceridaemia 
Modified from Tsuang 200953 
Classification Lipoprotein 
Blood lipids Risk of 
developing CP Triacylglycerol Combined hyperlipidaemia 
I CM ↑↑↑ ↑ Yes 
IIa LDL - ↑ ↑ No 
IIb LDL, VLDL ↑↑ ↑↑ No 
III IDL ↑↑ ↑↑  No 
Ⅳ VLDL ↑↑ - Yes 
Ⅴ VLDL, CM ↑↑↑ ↑ Yes 
CM – Chylomicrons; LDL – Low Density Lipoprotein; VLDL – Very Low Density Lipoprotein; 
IDL -Intermediate-density Lipoprotein 
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1.1.3.5 Less Common Aetiology 
Obstructive pancreatitis is a distinct entity according to the Marseilles classification, although this no 
longer seems to be recognised as such.1 However, obstruction can be an aetiological factor, for 
example in the case of CP caused by an obstructing pancreatic head tumour.  
Tropical pancreatitis occurs in geographical areas where low protein diet and cassava intake are 
common.54  The aetiology of tropical calcific pancreatitis is related to genetic mutations in the 
SPINK1 gene, but it is still unknown if environmental factors have an influence.55 
Pancreatitis can be caused by hypercalcaemia, either in its own right or secondary to 
hyperparathyroidism.56  Gallstones, the most common cause of acute pancreatitis, have not clearly 
been shown to cause chronic pancreatitis, although there is some evidence to support the 
development of fibrosis following gallstone pancreatitis.57-59  
The Role of Genetic Variation in Predisposition to Alcohol-related Chronic Pancreatitis                             2015 
Introduction - Chronic Pancreatitis 34 
1.1.4 Risk Factors for Chronic Pancreatitis 
Risk factors associated with the development of chronic pancreatitis are commonly classified using 
the M-ANNHIEM classification (Table 2).42 
Table 2 M-ANNHEIM classification of risk factors of chronic pancreatitis 
 
A Alcohol consumption 
Excessive consumption (>80 g/day) 
Increased consumption (20–80 g/day) 
Low-Moderate consumption (<20 g/day) 
N Nicotine consumption 









Hereditary pancreatitis (defined according to Whitcomb)48 
Familial pancreatitis (defined according to Whitcomb)48 
Early-onset idiopathic pancreatitis 
Late-onset idiopathic pancreatitis 
Tropical pancreatitis 
E Efferent duct factors 
Pancreas divisum 
Annular pancreas and other congenital abnormalities of the pancreas 
Pancreatic duct obstruction (e.g., tumors) 
Posttraumatic pancreatic duct scars 
Sphincter of Odd dysfunction 
I Immunological Factors 
Autoimmune pancreatitis 
Sjögren syndrome-associated chronic pancreatitis 
Inflammatory bowel disease-associated chronic pancreatitis 
Chronic pancreatitis with autoimmune diseases 
(e.g., primary sclerosing cholangitis, primary biliary cirrhosis) 
M Miscellaneous and rare metabolic factors 
Hypercalcaemia and hyperparathyroidism 
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1.1.5 Diagnosis of Chronic Pancreatitis 
There have been several attempts to reach a consensus on the classification of CP. The Marseilles 
criteria of 1963, 19841 and 198860 provided a clear category defining acute pancreatitis and removed 
the terms acute relapsing and chronic relapsing pancreatitis. The Cambridge classification set in 
198461 classified the severity of disease but is predominately related to ERCP imaging results, and 
mainly idenfies large duct diease., The use of the Cambridge classification in ERCP is now becoming 
obsolete as a diagnostic test due to the high risk of ERCP induced pancreatitis.62  There is currently 
no clear consensus into the best way to diagnose or classify chronic pancreatitis.  The 2014 APA 
guidelines have provided new approaches to this, but they have not yet been validated in clinical 
practice.24 
Imaging is commonly used to confirm the diagnosis and may also assess of the morphology of 
disease to diagnose complications of pancreatitis such as pseudocysts or pancreatic cancer.  The 
diagnosis of advanced CP may be more straightforward if there are calcifications, which may be 
picked up with a plain abdominal X-ray, although these are not completely exclusive to CP.63,64 
Calcifications typically develop years after the onset of symptoms in alcoholics (median 8.7 years) 
and even longer in early onset idiopathic pancreatitis (24.9 years).8  The main diagnostic challenge is 
detecting early stage disease.  
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1.1.5.1 Endoscopic Retrograde Cholangiopancreatography 
Traditionally the most commonly used diagnostic test was Endoscopic Retrograde 
Cholangiopancreatography (ERCP), which could clearly demonstrate the morphology of the duct 
system. ERCP has been traditionally used as the gold-standard against which other modalities have 
been assessed.65  However, it has more recently been recommended that it is only used for 
therapeutic procedures due to the high risk of post-ERCP pancreatitis.62 This is not necessarily the 
case as in individuals with hereditary pancreatitis, who have such extensive damage to the pancreas, 
further pancreatitis is unlikely to be induced.66  However, in this instance it is unlikely that the ERCP 
will be carried out for diagnosis, but rather for screening of this population for the development of 
cancer.67 
1.1.5.2 Magnetic Resonance Imaging and Magnetic Resonance 
Cholangiopancreatography  
Magnetic Resonance Cholangiopancreatography (MRCP) is increasingly being used, as it is a safe, 
non-invasive modality, which does not involve radiation, and does not cause acute pancreatitis. 
Magnetic Resonance Imaging (MRI) can also show extra-pancreatic anatomy. The delineation of the 
pancreatic ducts can be maximized by the administration of secretin.  MRCP can be used to measure 
main pancreatic duct size.68  These measurements tend to be less than that in an ERCP probably 
because contrast injection distends the duct in ERCP and this is not the case in MRCP.69 Side 
branches smaller than 1mm are not well demonstrated at MRCP and therefore the sensitivity for 
side branch abnormalities is low in MRCP.69,70 After secretin injection, duodenal fluid volume can be 
calculated and used as a marker of secretary function, but the value of routine use of secretin in MRI 
is unclear.71  MRI may be superior to CT in detection of fibrosis, but more work needs to be done to 
assess this further.72 
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1.1.5.3 Computer Tomography  
In the early stages of disease, the Computer Tomography (CT) may be normal or show features 
related to acute pancreatitis. CT cannot demonstrate the subtle changes in the side branches that 
can be appreciated using ERCP.73  CT can be useful in the differential diagnosis of carcinoma. Chronic 
pancreatitis may be picked up incidentally when a CT is performed for other reasons.  Its specific use 
for the diagnosis of CP has not been well evaluated but it has been recommended as the first line 
imaging method by the APA 2014 guidelines.24 
1.1.5.4 Endoscopic Ultrasound 
Endoscopic Ultrasound (EUS) has an increasing role in the diagnosis and management of chronic 
pancreatitis. EUS in some studies has been shown to be as effective as ERCP in diagnosing CP.74  EUS 
can also demonstrate abnormalities in many individuals without definite ERCP features.75  EUS 
allows high resolution imaging of both the parenchyma and pancreatic ducts. Experienced clinicians 
can detect early stage CP with good inter-observer agreement (92%).75 
Features include focal hypoechoic areas, irregularity of the main pancreatic duct, dilated side 
branches and echogenic foci.75 The parenchymal features of early chronic pancreatitis are lobulated 
parenchymal pattern and alternating echo-rich and echo-poor areas. Parenchymal changes reflect 
chronic pancreatitis and are independent of age and Body Mass Index (BMI).76 The sensitivity for 
diagnosis of CP in individuals with typical histories and minimal changes on ERCP are quoted as being 
around 86-88%.75,77 
Recent guidance has been given in the diagnosis of CP using EUS, which is referred to as the 
Rosemont classification.78  This has been formed by consensus opinion, and has yet been validated 
for use in diagnostic accuracy. 
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In some centres elastography has been used as an adjunct to enhance the interpretation of EUS. 
Studies into the efficacy of this are limited at present, but results are promising and this warrants 
further investigation.79 
1.1.5.5 Pancreatic Exocrine Function Tests 
Impaired pancreatic enzyme secretion is a common feature in advanced disease but is not 
pathognomonic for chronic pancreatitis. Due to the large functional reserve of the exocrine 
pancreas, function tests may not become abnormal until a large proportion of the parenchyma is 
destroyed.80  Steatorrhoea only becomes clinically evident after about 90% of the pancreas has been 
damaged.80 Pancreatic tumours often cause pancreatic insufficiency and this is an important 
differential diagnosis.81 Those with mild morphological evidence of chronic pancreatitis on imaging 
are expected to have normal pancreatic function tests.81 The purpose of testing is to aid diagnosis 
but abnormalities are insufficient in themselves to diagnose chronic pancreatitis.23 
Formalised direct pancreatic function tests are seldom available outside a few academic centres and 
have problems of standardization, are time consuming and expensive. 
Indirect tests such as faecal elastase measurement or the pancreolauryl test (PLT) are the most 
acceptable form of testing for the majority of people. Elastase is stable in transit through the gut and 
can be measured in stool using ELISA. This test is superior to faecal chymotrypsin but is not able to 
diagnose chronic pancreatitis at an early stage.81-85 
1.1.5.6 Biopsy 
The gold standard for diagnosis of chronic pancreatitis is histopathology, which is rarely available 
unless surgery has been undertaken.65 A few studies have looked at the diagnostic benefit of 
pancreatic biopsy.86,87 However, the biopsy procedure can cause pancreatitis, haemorrhage or fistula 
and there is commonly high false negative results due to potential biopsying of spared areas of 
pancreas.86  
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1.1.5.7 Challenges to Diagnosis of Chronic Pancreatitis 
1.1.5.7.1 Pancreatic Cancer 
Pancreatic cancers and chronic pancreatitis can be potential differentials of pancreatic pathology 
and both can co-exist, making their differentiation challenging.88 Histological diagnosis, which would 
normally be the gold standard to confirm or refute neoplasia, can be difficult as disease may be 
patchy and absence of neoplastic, or fibrosed cells in a biopsy sample, does not necessarily rule out 
the diagnosis.87  Therefore in some cases a definitive diagnosis can only be confirmed with resection, 
with a high risk of morbidity and mortality to the patient. 
1.1.5.7.2 Minimal Change Pancreatitis and Early Chronic Pancreatitis 
A small number of individuals with a clinical diagnosis of CP have equivocal or minor abnormalities of 
the pancreas evident on imaging. This minimal change pancreatitis is more commonly identified in 
middle-aged women and alcohol excess is uncommon.89  Pancreatitics may have normal or abnormal 
pancreatic function tests.90  Due to the difficulty in obtaining objective evidence despite clinical 
symptoms, these cases may often end up being undiagnosed. 
1.1.5.7.3 Groove Pancreatitis 
Groove pancreatitis is a form of segmental chronic pancreatitis that occurs between the dorsocranial 
part of the head and the duodenum. The diagnosis is typically made in men aged 40-50 years with a 
history of alcohol excess with a relatively short history of pain (often less than one year).91 The main 
significance of groove pancreatitis is that the clinical findings can conflict with pancreatic cancer 
causing diagnostic dilemma preoperatively.91  
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1.1.6 Consequences of the Development of Chronic Pancreatitis 
Those with CP may exhibit some or all of the associated problems below. There is no classical 
pattern as to which problems develop, which adds to the difficultly of diagnosing the disease.  
Traditionally, before current investigations were available, the triad of pain, exocrine and endocrine 
insufficiency would be diagnostic of chronic pancreatitis, but now with more sensitive tests, some 
individuals may even be picked up incidentally without any suggestive clinical features. 
1.1.6.1 Chronic Pain 
The most significant consequence for the majority of individuals with CP is the chronic pain that can 
be associated with fibrosis of the pancreas.92  Once pain develops, it can be very difficult to treat and 
patients will often become opiate dependant.  Interventions which can be attempted when opiates 
are no longer effective in pain management include: EUS-guided coeliac plexus block, thoracoscopic 
splanchnicectomy or decompression procedures which can either be endoscopic or surgical but the 
outcomes are often poor, as once pain is established, even with removal of the tissue the nerve 
innovation continues.93 
1.1.6.2 Endocrine Insufficiency 
One of the two main functions of the pancreas is the endocrine release of insulin, and therefore 
chronic damage to the pancreas parenchyma often leads to the development of diabetes.94  
Diabetes purely induced by reduction of parenchyma is referred to as a distinct entity, Type 3c 
diabetes mellitus.95 This is thought to account for around 10% of all cases of diabetes, and the most 
common cause of Type 3c diabetes mellitus is CP.95 
1.1.6.3 Exocrine Insufficiency 
The second role of the pancreas is the production and excretion of digestive juices. Therefore 
damage and loss of cell function leads to exocrine insufficiency in a proportion of pancreatitics.  This 
leads predominately to a reduction in fat absorption, and therefore by default, insufficiency of the 
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fat-soluble vitamins, A, D, E and K.  Pancreatitics can end up with malnutrition related to their CP, 
but this may overlap with aetiology such as alcohol that compounds the lack of absorption with low 
dietary intake.96  Exocrine insufficiency can often be effectively treated with enzyme replacement 
therapy.97 
1.1.6.3.1 Osteoporosis 
Osteoporosis is becoming increasingly recognised as a complication of chronic pancreatitis.98 Due to 
the poor absorption of the fat-soluble vitamins as a result of the exocrine insufficiency, there is poor 
uptake of Vitamin D, leading to osteoporosis and increased fracture rate.99 There are no current 
guidelines into the management of osteoporosis risk in those with chronic pancreatitis.100 
1.1.6.4 Pancreatic Cancer 
The link between pancreatic cancer and chronic pancreatitis is complex.  One is often found to co-
exist with the other, and both can potentially be the causative agent for the other: CP can cause 
neoplasia due to dysplastic changes in the fibrosed tissues over time; tumours can cause obstruction 
of outflow from the pancreas leading to chronic pancreatitis changed in the distal pancreas.101  There 
is an increased incidence of PDAC with CP patients.101 Although at present there are no suitable 
methods for screening of pancreas cancer, lifelong surveillance maybe advisable in these individuals 
should such a test be found.102-104 
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1.1.7 Summary 
Chronic pancreatitis has a prevalence of about 30 per 100000 with the incidence rising tenfold in a 
population of those with a history of heavy drinking.  Chronic pancreatitis is caused by fibrosis of the 
pancreas leading to progressive loss of both structure and function of the gland.  There are multiple 
causes identified, of which alcoholism is the most common.  In addition, an individual’s risk can be 
increased by smoking, poor diet and genetic factors. 
Alcohol-related chronic pancreatitis may develop due to a build-up of FAEE within the pancreas, a 
breakdown of non-oxidative metabolism of alcohol and fat. Although there is the suggestion that 
different drinking patterns and different levels of fat consumption may bear some part in this 
process, it is remains unclear if there is any genetic component. 
No international consensus has been developed as to how to diagnose chronic pancreatitis.  This is 
partly contributed to by the lack of clear definition on what the disease is, and no current diagnostic 
gold standard that is suitable to compare current and future studies against.  Therefore, there would 
be benefit in systematically reviewing the available literature to assess and identify the best 
methods for the diagnosis of chronic pancreatitis. 
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 Alcohol Metabolism 1.2
As discussed, there are many reasons why individuals develop chronic pancreatitis, however, to 
quote Apte, the most obvious response to the question, why do individuals develop chronic 
pancreatitis is, “it’s the alcohol, stupid”.105 
1.2.1 Ethanol Metabolism 
Ethanol is a two-carbon alcohol and due to its small size and alcoholic hydroxyl group is soluble in 
both aqueous and lipid solutions. These factors allow ethanol to pass freely through the cells of the 
intestinal wall and travel via the portal circulation to the liver, where the majority of alcohol 
metabolism occurs.106 
Alcohol can be metabolised through several different pathways (Figure 3). 
 
Figure 3 Oxidative and non-oxidative metabolism pathways of ethanol and lipids  
Oxidation of ethanol can also occur in peroxisomes with catalase activity but this oxidation pathway 
requires hydrogen peroxide (H2O2) and therefore plays no significant role under normal physiological 
conditions.  
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1.2.1.1 Alcohol Dehydrogenase Pathway 
The main pathway responsible for the majority of ethanol metabolism is initiated by alcohol 
dehydrogenase (ADH; Table 6). ADH is commonly found in hepatocytes and requires NAD+ to oxidize 
ethanol to acetaldehyde, which upon entering the mitochondria is oxidized by aldehyde 
dehydrogenases (ALDH) to produce acetate. 
There are two primary ALDH enzymes involved in this process; ALDH1A1 and ALDH2.107 ALDH1A1 is a 
cytosolic enzyme while ALDH2 resides in the mitochondria. The majority of acetaldehyde oxidation 
utilises ALDH2 in the mitochondria, however, a small amount of oxidation occurs in the cytosol via 
ALDH1.  
1.2.1.2 Microsomal Ethanol Oxidation System  
The alternate ethanol metabolism pathway is the microsomal ethanol oxidizing system (MEOS). This 
pathway uses CYP2E1 and requires NADPH. This pathway is more commonly used in individuals with 
chronic alcohol consumption.108 
1.2.1.3 Non-oxidative Pathway 
The non-oxidative pathway is catalysed by fatty acid ethyl ester (FAEE) synthase (carboxylesterase), 
which results in the formation of FAEE and takes place primarily in the pancreas.109  Due to this 
association with fatty acids, the pathways of alcohol and lipid metabolism are interlinked. 
Alcohol can be metabolised through several different but predominately oxidative pathways.  
However it has been demonstrated that inhibition of oxidative pathways can lead to an increase in 
both hepatic and pancreatic FAEE levels, which are products of non-oxidative metabolism 
(Figure 3).110  This demonstrates that the oxidative and non-oxidative pathways are potential 
inversely linked.32 The preference towards non-oxidative metabolism appears to be stronger in the 
pancreas than in other organs.111 
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1.2.2 Metabolism of Triglycerides 
Alcohol and triglyceride metabolism are closely linked with increased alcohol intake having a J-
shaped relationship with triglyceride levels.112 
Apolipoprotein (APOB), which is related to VLDL synthesis, has been shown to reduce expression 
when alcohol is ingested.113  Acute alcohol intake has been shown to decrease the activity of 
lipoprotein lipase, therefore reducing the lipolysis of VLDL and chylomicrons, causing an increase in 
their presence with increasing alcohol consumption.114  
Chronic alcohol consumption has been demonstrated to increase free fatty acid release, mediated 
by activation of hormone sensitive lipase (LIPE) and a decrease in insulin sensitivity.113 This 
mechanism may contribute to the development of alcoholic steatosis of the liver.  
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1.2.3 Effects of Ethanol Metabolism 
The metabolic effects of inebriation mostly derive from the action of ADH and ALDH and the 
NADH/NAD+ ratio imbalance they cause.  The NADH produced during alcohol metabolism must be 
reduced back to NAD+, therefore the continued ability to metabolize ethanol is dependent upon the 
capacity of hepatocytes to reduce NADH.115 The reduction of NADH is moderated by the Krebs cycle 
in the mitochondria, which in turn is affected by the NADH produced by the ADH and ALDH 
reactions.  There is an increase of hepatic lactate production due to the effect of NADH on the 
hepatic lactate dehydrogenase (LDH) reaction leading to a decrease in the liver’s capacity to deliver 
glucose.115 
The altered NADH/NAD+ ratio also leads to a decrease in fatty acid oxidation, as this process requires 
NAD+.  An increase in fatty acid synthesis and triglyceride production by the liver are associated with 
reduced fatty acid oxidation.116  In the mitochondria, the metabolism of acetaldehyde to acetate 
leads to increased levels of acetyl-CoA, which is diverted to fatty acid synthesis.116 The reduction in 
cytosolic NAD+ leads to reduced activity of glycerol-3-phosphate dehydrogenase (GPDH) resulting in 
increased levels of glycerol 3-phosphate, which aids in the synthesis of the triglycerides. This leads to 
fatty acid deposition in the liver, causing fatty liver syndrome and hyperlipidaemia.106 
Acetaldehyde is produced as a part of alcohol metabolism.  The acetaldehyde combines with 
proteins, nucleic acids and other compounds resulting in impaired activity of the affected 
compounds. Acetaldehyde compounds are known to promote cancer development.106 
Ethanol metabolism can lead to an oxygen deficit in the liver; the metabolism of ethanol requires 
oxygen, therefore there are higher demands on oxygen from the blood.  Hepatocytes residing beside 
arteries supplying oxygenated blood to the liver will tend to take up more than their normal share of 
oxygen and therefore the perivenous hepatocyte may have depleted levels of oxygen; therefore this 
hypoxic area is normally the first to show evidence of damage from chronic alcohol consumption.117 
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The metabolism of ethanol via the CYP2E1 pathway results in increased reactive oxygen species 
(ROS) production, including superoxide, hydrogen peroxide, and hydroxyl radicals.118 ROS production 
is associated with cancer development, atherosclerosis, diabetes, inflammation, aging, and other 
harmful processes.119 Under normal conditions, a balance between ROS production and antioxidant 
removal exists in cells but this balance can be disturbed. Alcohol consumption increases ROS 
production which leads to oxidative stress, an established pathway in the development of chronic 
pancreatitis.120 
Under conditions of acute ethanol consumption, the majority of ethanol is degraded by the hepatic 
oxidative pathways, predominantly the alcohol dehydrogenase mediated pathway. However, under 
conditions of chronic ethanol consumption, hepatic MEOS activity and non-oxidative pathways are 
induced and quantitatively make a greater contribution to ethanol catabolism. 
1.2.3.1 Organ Specific Effects of Alcohol 
It remains unclear why organs other than the liver develop alcohol-induced damage, especially the 
heart, pancreas, and brain, which lack or show minimal oxidative metabolism of ethanol and 
therefore are free of substantial acetaldehyde production.31 
Alcohol encourages the collection of fat in the liver predominately through replacement of ethanol 
with fatty acids as the main hepatic fuel; the degree of fat deposition depends on the dietary supply 
of lipids.121 
A statistically significant increase of class III alcohol dehydrogenase (ADH3) isoenzymes has been 
demonstrated in serum from individuals with both acute and chronic pancreatitis. In addition the 
activity of the class I ADH isoenzyme was significantly higher in serum from ACP patients.122  
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1.2.4 Ethanol Metabolism and Alcoholism 
In addition to the predisposition of individuals to develop chronic pancreatitis in relation to their 
alcohol consumption, it must also be considered that some individuals have a greater predisposition 
for substance abuse. 
There are several different commonly described polymorphisms of both ADH and ALDH genes 
(Appendix 10.1). Several of these variations have been linked with alcohol dependence (AD).123 
ADH1A, ADH1B, ADH1C and ALDH2 all play a central role in alcohol metabolism.124 It is thought that 
genetic variability in these genes is associated with an individual’s susceptibility to developing 
alcoholism and this also has potential to mediate alcohol-related tissue damage. Common 
polymorphisms exist in both ADH1B and ADH1C genes, which are associated with varying levels of 
enzymatic activity (Table 6).125 
The ADH1B alleles occur at different frequencies in different populations. For example, the ADH1B*1 
form is found predominantly in Caucasian and Black populations, whereas ADH1B*2 is more 
common in Chinese and Japanese populations and is seen in around 25% of people with a Jewish 
background.126-128 
Although many ALDH genes have been identified, only ALDH2 and to a lesser extent ALDH1 have 
been shown to metabolise acetaldehyde.129  
Because polymorphisms of ADH and ALDH2 play an important role in determining peak blood 
acetaldehyde levels, they also influence vulnerability to alcohol dependence; polymorphisms that 
elevate acetaldehyde levels reduce the amount of alcohol drunk. As a consequence, alcohol-induced 
tissue damage is reduced in populations that harbour these polymorphisms due to the reduced 
preference for drinking.130   
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1.2.5 Summary 
Ethanol metabolism has many different pathways, which commonly produce disease-causing 
products such as acetaldehyde, reactive oxygen species, and fatty acid ethyl esters.  Oxidative 
metabolism is chosen preferentially but under some circumstances, especially within the pancreas, 
the non-oxidative pathway may be used. 
Genetic variations in genes related to alcohol metabolism have been shown to influence those who 
become dependent on alcohol.  Alcohol excess can lead to various disease processes effecting the 
liver, pancreas, heart and brain, but not all diseases seem to be directly dose-related, and some 
individuals may be more predisposed to one disease process rather than another. 
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 Alcoholic Liver Disease 1.3
This thesis examines why some individuals who abuse alcohol get pancreatitis while others do not. 
Alcohol can cause damage to other organs in the body other than the pancreas, the most prominent 
of which is the liver.  Alcoholic liver disease (ALD) arises in around 30% of heavy drinkers and liver 
cirrhosis in 10%.131,132 
1.3.1 Definition of Alcoholic Liver Disease 
ALD is a combination of different disease processes with the liver, as a result of alcohol excess, which 
include fatty liver, hepatitis and cirrhosis. 
1.3.1.1 Alcoholic Fatty Liver Disease 
Heavy alcohol consumption, even over only a few days, starts the build-up of fats within the liver 
(steatosis), which is the first step of the development of ALD.  Steatosis does not cause any systemic 
symptoms and is reversible, but if excess alcohol consumption continues the extent of the liver 
disease will progress. 
1.3.1.2 Alcoholic Hepatitis 
Alcoholic hepatitis is normally the second stage of the development of ALD. Excess alcohol intake 
over a more prolonged period of time leads to inflammation of the liver.  The liver damage 
associated with mild alcoholic hepatitis is usually reversible if alcohol consumption is stopped. 
1.3.1.3 Cirrhosis 
Cirrhosis is the final stage of ALD, when the disease is well established and the liver becomes 
significantly scarred.  Once decompensated cirrhosis is established then life expectancy at 5 years 
can be as low as 15%.133 
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1.3.2 Pathophysiology of Alcoholic Liver Disease 
In the presence of alcohol excess, liver disease is due to production of toxic metabolite acetaldehyde 
in the liver. Acetaldehyde is toxic to the mitochondria, which promotes leakage.134 
In addition, the generation of NADH, which promotes steatosis of the liver by stimulating the 
synthesis of fatty acids and opposing their oxidation. Excess dietary lipids and their replacement with 
triglycerides also promote steatosis.  
The CYP2E1 metabolism pathway releases free radicals, which cause oxidative stress and in turn can 
lead to altered enzyme activity. Oxidative stress and associated cellular injury promote inflammation 
in the liver. 
Intracellular concentration of free fatty acids may be in sufficient levels to damage membranes, 
leading to necrosis and inflammation, which can progress to fibrosis and ultimately cirrhosis.134 
1.3.3 Natural History of Alcoholic Liver Disease 
Studies of individuals with a strong history of alcohol excess suggest that 80% develop steatosis, 
which is the earliest and most common histopathological manifestation of ALD.131 Steatosis occurs in 
most people consuming alcohol in excess of 80g/day, but normally resolves within 2–4 weeks of 
abstinence; only 20–40% individuals with steatosis go on to develop alcoholic steatohepatitis (ASH) 
and of them only around 40% will go on to develop cirrhosis.135,136 In some cases the hepatitis stage 
may be bypassed but the overall figure for the development of alcoholic cirrhosis is approximately 
10% of heavy drinkers. 
There is an increased susceptibility of women as compared with men to develop alcoholic liver 
disease, however overall the disease process in more common in men, as they are more likely to 
consume alcohol to excess.137 
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1.3.4 Diagnosis of Alcoholic Liver Disease 
It can be very difficult to predict the clinical stage in ALD before the development of decompensated 
cirrhosis.131 In addition, some ALD patients may present with decompensated chronic liver disease 
without cirrhosis on biopsy. Therefore staging of ALD is most accurately performed though liver 
biopsy, which is not always available or suitable, especially for those with deranged clotting function. 
Typical laboratory findings in ALD include transaminase levels with aspartate aminotransferase (AST) 
greater than alanine aminotransferase (ALT) as well as increased mean corpuscular volume (MCV), 
and gamma-glutamyltranspeptidase (GGT). In unclear cases, the diagnosis can be supported by 
imaging and liver biopsy. The histological features of ALD can ultimately define the diagnosis 
according to the typical presence and distribution of hepatic steatosis, inflammation, and Mallory-
Denk bodies (inclusions found in the cytoplasm of liver cells).138 
1.3.5 Chronic Pancreatitis and Alcoholic Liver Disease  
There has been shown to be an inverse relationship between the risk of developing pancreatitis 
symptoms and the risk of developing liver symptoms, suggesting that the mechanism of the 
development of these disease processes is different.139  Even when histologic samples are examined 
the correlation of presence of the two disease processes is low.140 
Chronic alcoholic liver disease and chronic pancreatitis have a well-described association due to their 
common aetiology.40  Although most individuals with alcoholic pancreatitis do not have cirrhosis, 
72% of those with chronic pancreatitis have abnormal liver biopsies (12.5% have cirrhosis, and the 
remaining patients have steatosis, cholestasis, hepatitis or fibrosis).40 About 15% of individuals with 
known cirrhosis have evidence of chronic pancreatitis.40 
Several studies have looked at lifestyle factors to assess if alcohol intake or type predisposed 
patients to the develop ACP or ALD (Table 3).141 These studies show no conclusive evidence that 
specific drinking habits affect a patient’s predisposition to develop either ALD or ACP. 
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It has been shown that ACP, rather than ALD, may be more common in alcoholics who smoke.142  
Studies looking at the consumption of a high-protein and high-fat diet as a factor in the development 






Table 3 Review of published effects of drinking habits on the development of Alcohol-related Chronic Pancreatitis and Alcoholic Liver Disease 
 
Paper Year Population 
Number of participants 
(ACP vs. ALD) 
Age started drinking 
(ACP vs. ALD) 
Type of alcohol consumed 
(ACP vs. ALD) 
Daily intake 
(ACP vs. ALD) 
Wilson141 1985 Australia 20 vs. 33 No comment 
Beer (70% vs. 48%; NS) 
Spirits (25% vs. 55%; NS) 
Wine (5% vs. 27%; p = 0.07) 
No comment 
Mezey137 1988 USA 42 vs. 18 No comment 
Beer (7% vs. 33%; p = 0.01) 
Spirits (50% vs. 39%; NS) 
Wine (14% vs. 6%; NS) 
180 vs. 218g/day; NS 
Levy143 1995 France 56 vs. 50 19 vs. 19.6; NS 
Beer (77% vs. 84%; NS) 
Spirits (75% vs. 76%; NS) 
Wine (80% vs. 98%; p < 0.005)  




2004 Japan 59 vs. 17 No comment Spirits (71% vs. 53%; p = 0.05) 
>150g/day  








2012 Czech 66 vs. 80 
Started before age 15 
(29% vs. 88%; p = 0.03) 
Beer (77% vs. 56%; p = 0.02) 58 vs. 64g/day; NS 
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1.3.6 Summary 
Alcoholic liver disease is present in around 30% of all patients with a strong history of alcohol 
dependence.  Clinically, there is little overlap in patients who develop ACP and ALD, suggesting that 
it is not simply the amount of alcohol consumed leading to a disease process but in fact there may 
be genetic aspects that leads to development of one disease process over another. 
Life style and environmental factors have been compared between the two groups to try and 
account for the different disease processes, but no clear trend has been identified to explain this. 
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 Genetics 1.4
1.4.1 Characterising Genetic Differences 
Variations can be in several different forms such as Single Nucleotide Polymorphisms (SNPs), 
Insertions or Deletions (Indels), Variable Nucleotide Tandem Repeat (VNTR) and Copy Number 
Variants (CNV) as detailed below in Table 4. 






SNPs are when a single genomic position has more than one potential base. In 
non protein-coding regions may still affect transcription on gene coding, but 
often their effect cannot be clearly quantified.  These could be due to codon bias, 
enhanced binding or be at a splice site.147  
Insertion and 
Deletions (Indel) 
Insertion or the deletion of bases in DNA. If the indel is not a multiple of three 
then this will cause a frame shift in the amino acids produced, therefore, natural 
selection makes their presence uncommon in coding regions. Indels can be 
difficult to pick up accurately in some forms of genetic sequencing depending on 





The nulecotide repeats cluster together and oriented in the same direction. 
Individual repeats can be removed from (or added to) the VNTR via 
recombination or replication errors, leading to alleles with different numbers of 
repeats, commonly trinucleotide repeats.148 Due to the repetitive nature of the 
sequence, many sequencing techniques that use short amplicons to eventually 
build the genomic sequence can fail to sequence VNTRs; the fragmentation of the 




CNVs are a duplication of a gene, or a section of a gene, meaning that the copied 
area may be more active.  It is often difficult to identify CNVs as most sequencing 
techniques will only read a sequence and not quantify the proportionate amount 
of it.  
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1.4.2 Genetics of Chronic Pancreatitis 
In the majority of cases the genetics of chronic pancreatitis is poorly understood.  Only small 
numbers of patients are either classified as having hereditary or familial CP.149 The development of 
CP is complex and multifactorial with potential gene-gene interactions in addition to gene-
environmental factors.  Genetic influence can be divided into those with hereditary pancreatitis (a 
clear pattern of autosomal dominant inheritance), familial pancreatitis (those with a family 
predisposition with no clear autosomal link) and those with potential associated genetic factors. 
Genetic risk factors that link alcohol to susceptibility to CP have not been clearly defined.150 
1.4.2.1 Hereditary Pancreatitis 
Those patients classified with HP exhibit an autosomal dominant pattern of inheritance that 
accounts for around 1% of all known cases of chronic pancreatitis.151 Around 80% of hereditary 
pancreatitis cases can be attributed to known variants in the serine protease 1 (PRSS1) gene, which 
is the only identified disease-causing gene, with the remaining 20% due to an as yet unknown 
cause.152 PRSS1 codes for cationic trypsinogen and disease causing variants within this gene have a 
generally accepted penetrance of around 70%.47 Within the hereditary pancreatitis subpopulation, 
the cumulative risk of pancreatitis cancer rises from a 6-7-fold increase in sporadic CP patients to 
around 69 fold.101  
The first identified and most commonly found variant within PRSS1 is p.R122H, accounting for 
around 50-65% of known HP cases.67,153,154 The variant p.R122H results in increased trypsin stability, 
increased zymogen stability and increased autoactivation leading to increased intrapancreatic 
trypsin activity which can lead to pancreatitis.48,155 
An additional polymorphism affecting the same codon but with a different affect is p.R122C.156  This 
adds an extra cysteine leading to partial misfolding of the recombinant protein causing reduced 
activity, autolysis, and autoactivation similar to p.R122H.157 
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The p.N29I variant accounts for 20% of HP cases.47  It has no effect on trypsin or trypsinogen stability 
but increased autoactivation.158 The less common p.N29T variation exhibits a phenotype similar to 
that of p.R122H and therefore as increased autoactivation was the common factor observed within 
the previously documented variations, the conclusion was put forward that autoactivation is the 
common pathogenic mechanism of hereditary pancreatitis.155,159 
p.A16V has been identified as a less frequent variant of PRSS1 in patients with pancreatitis.50,160  
p.A16V affects the first amino acid of mature trypsinogen, residing at the start of the signal peptide, 
although not forming a part of it, and therefore it is considered to influence secretion. However, the 
low penetrance of p.A16V (44%) may suggest this is a fairly conservative substitution, and has been 
identified in idiopathic CP cases with no family history.47 
Copy number variants have also been demonstrated within PRSS1.156  A list of commonly identified 
variations is found in Table 5.  An up-to-date list of known PRSS1 variants is collated at 
http://www.pancreasgenetics.org/.  
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Table 5 Time line of identification of disease causing mutations reported in PRSS1 
(modified from Chen161) 
 
Missense mutation  
1996 p.R122H48 Increases trypsin stability and enhances trypsinogen autoactivation162 
1997 p.N29I49 Enhances trypsinogen autoactivation and increases trypsin stability155 
1999 p.A16V50 Possibly increases the rate of chymotrypsinogen C-mediated 
trypsinogen activation163 
1999 p.K23R164 Increases trypsinogen autoactivation165 
2000 p.D22G166 Increases trypsinogen autoactivation165 
2001 p.R116C167,168 Results in protein misfolding that possibly leads to endoplasmic 
reticulum stress169 
2001 p.R122C170 Increases trypsin stability and enhances trypsinogen autoactivation157 
2002 p.N29T171 Enhances trypsinogen autoactivation and increases trypsin stability155 
2003 p.D19A165 Increases trypsinogen autoactivation165 
Copy number mutation 
2006 605-kb triplication172 Gene dosage effect 
2008 605-kb duplication156 Gene dosage effect 
2010 320-kb complex CNM173 Gene dosage effect 
Double gain-of-function mutation  
2008 PRSS2/PRSS1 hybrid174 Gene dosage effect plus the effect of PRSS1 p.N29I 
Microduplication 
2011 p.K23 I24insIDK175 Increases trypsinogen autoactivation175 
PRSS1-PRSS2 loci 
2012 PRSS1-PRSS2 SNP176 Disease susceptibility by altering expression of the trypsinogen gene 
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1.4.2.2 Familial Chronic Pancreatitis 
Familial chronic pancreatitis (FCP) are cases in which there is not a clear autosomal dominant 
pattern of inheritance, but there is a familial trend.  The two genes that have been commonly 
associated with this form of pancreatitis are SPINK1 and CFTR. 
1.4.2.2.1 Serine protease inhibitor, Kazal-type 1 
SPINK1 encodes PSTI (pancreatic secretory trypsin inhibitor; one of the defensive mechanisms 
against premature trypsin activition within the acinar cells) and SPINK1 mutations are thought to be 
a disease modifying factor rather than being a disease-causing factor in chronic pancreatitis.177,178 
SPINK1 was first associated with chronic pancreatitis with the indication of p.N34S variant in 18.75% 
of idiopathic CP patients, but not present in any controls.45 However, p.N34S variant has not been 
demonstrated to result in a functional defect. By expression studies, p.L14P and p.L14R mutations 
demonstrated a markedly reduced SPINK1 expression and resulted in loss of function.179 
A few other polymorphisms have been noted in SPINK (including p.D50E, p.P55S and p.C58C), but 
their clinical significance remains unclear.180 
There is some evidence that SPINK1 may work in synergy with other variants.  It has been recently 
reported that the coinheritance of CFTR p.R75Q and SPINK1 p.N34S variants is significantly higher in 
patients with idiopathic chronic pancreatitis than in controls (8.75% vs. 0.38%).181  In addition there 
is some evidence that p.N34S variant may be more potent in a specific haplotype with other 
variations.182 
A calcium-sensing receptor (CASR) gene variant (p.L173P) has been associated with a family with the 
p.N34S SPINK1 variant, who also have a history of familial hypocalciuric hypercalcaemia.158  An 
association has also been demonstrated with the presence of the p.R990G CASR variant, with the 
common SPINK1 variant, especially in the presence of heavy alcohol consumption.183  
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p.P163R, p.I427S, p.D433H, p.V477A, all lying within CASR, have also been described as being 
associated with CP in the presence of p.N34S.184  
1.4.2.2.2 Cystic fibrosis transmembrane conductance regulator  
Cystic fibrosis transmembrane conductance regulator (CFTR) is most commonly associated with 
cystic fibrosis (CF), a disease caused by high chloride output from secretory cells, predominately in 
the lungs and the pancreas, and therefore commonly causes pancreatic dysfunction.  Symptoms of 
pancreatitis can be present in the absence of any other associated CF features.185 
CFTR disease causing variants are common in the normal population (1 in 25 patients) but normally 
these variants need to be inherited from both parents to cause CF itself.  However, some of the 
heterozygous variants can lead to chronic pancreatitis.186-188 
Initial studies into the effect of CFTR variations in CP showed 134 patients with CP for 22 mutations 
of the CFTR gene. None of the patients had a mutation on both copies of the CFTR gene.46 Eighteen 
patients (13.4%) had a CFTR mutation on a single chromosome, as compared with a frequency of 
5.3% among 600 controls (p < 0.001). A total of 10.4% (14/134) of the patients had the 5T-allele 
(intron 8), which is twice the expected frequency (p = 0.008).  The most commonly recognised CFTR 
variants are p.R75Q, p.I148T, 5T-allele and p.E528E.189 
A specific CFTR haplotype has been shown to be associated to CP compared to healthy controls 
(p=0.045).186 The haplotype contains three common synonymous SNPS, CFTR_rs213950 (p.V470M), 
CFTR_rs1042077 (p.T854T) and CFTR_rs1800136 (p.Q1463Q), none of which are known to be 
associated with CP. 
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1.4.2.2.3 Other Genes Associated with Familial Chronic Pancreatitis 
1.4.2.2.3.1 PRSS1 
Although some mutations in PRSS1 are very clearly associated with hereditary pancreatitis (Chapter 
1.4.2.1) the penetrance of some other variants is so low that they are better described as being 
associated with FCP. This could be extended to include the p.A16V variant described in the HP 
section.47 
Other non-synonymous polymorphisms, such as p.K170E and p.E79K have been shown to have an 
association with CP, but their true pathogenic nature is unclear.190 
1.4.2.2.3.2 PRSS2 
PRSS2, which encodes anionic trypsinogen, lies close to the genetic position of PRSS1.191  The variant 
p.G191R in PRSS2 has been shown to be protective against the development of chronic 
pancreatitis.192 The polymorphism was present in 3.4% controls but in only 1.3% of CP patients (OR 
0.37); these findings were confirmed in Japanese populations.
159
 p.G191R is thought to moderate 
intrapancreatic trypsin activity and thereby protects against chronic pancreatitis.191 
A PRSS1/PRSS2 hybrid, containing exon 1 and 2 from PRSS2 and exons 3 to 5 from PRSS1, has been 
demonstrated in a French family.174 This was thought to be disease causing by acting simultaneously 
as a 'quantitative' copy number mutation and a 'qualitative' missense mutation. 
There has been reported CNV associated with both duplication and triplication of a 605kb segment 
on chromosome 7q35 associated with chronic pancreatitis.  This has led to both increased copy 
number of PRSS1 as well as PRSS2.193 
  
The Role of Genetic Variation in the Predisposition to Alcohol-related Chronic Pancreatitis                             2015 
Introduction – Genetics of Alcohol Metabolism 63 
1.4.2.2.3.3 PRSS3 
Protease, serine, 3 (PRSS3) encodes a trypsinogen (mesotrypsin), a member of trypsin family. This 
enzyme is expressed in the brain and pancreas and is resistant to common trypsin inhibitors. Four 
transcript variants encoding different isoforms have been described for this gene. 
Although PRSS3 is thought to be a likely candidate gene for development for CP, several studies have 
failed to develop a clear causative relationship.194,195 There has been a possible association with 
p.E32del, a frequent polymorphic variant, but has not been demonstrated to a statistically significant 
level.195 No CNVs have not been demonstrated in PRSS3.196 
1.4.2.2.3.4 Chymotrypsin C 
Chymotrypsin C (CTRC) codes for a protein that promotes the degradation of trypsin and has been 
shown to be associated with idiopathic and alcoholic chronic pancreatitis.197 The CTRC variants are 
known to exhibit diminished secretion and/or activity.189 
One study identified two common variants and 19 rare variants in patients with idiopathic chronic 
pancreatitis.198 These rare variants, when combined, were shown to be significantly higher in ICP 
than controls (12% vs. 1.1%; OR, 11.8; p < 0.001)). 
p.R254W and p.K247_R254del were significantly overrepresented in patients with alcoholic, 
idiopathic or hereditary chronic pancreatitis (2.1% vs. 0.6% and 1.2% vs. 0.1% respectively).197 
Functional analysis of these and other associated CTRC variants showed impaired chymotrypsin C 
activity and/or reduced secretion. 
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1.4.3 The Genetics of Alcohol Metabolism 
There are several key genes associated with both the oxidative and non-oxidative pathways of 
alcohol dependence.199 Several of these genes have common polymorphisms and are linked to 
protection against the development of alcohol dependence, predominately through causing adverse 
reactions due to high acetaldehyde levels caused by the enzyme dysfunction. 
1.4.3.1 Alcohol Metabolism and Alcohol Dehydrogenase 
There are several different genes, and gene classes of alcohol dehydrogenase (Table 6).  One group 
has claimed specific expression of ALDH1A1, ALDH2, ADH1, and ADH5 in pancreas, although no 
other group has substantiated this.200 
 
Table 6 Enzymes within the Alcohol Dehydrogenase (ADH) family 
(Modified from Hurley 2012125) 
Gene Name and 
Common Haplotypes$ Gene Class Protein Name KM(mM) for Ethanol Primary Tissue 

























ADH4 II π 30 Liver, cornea 
ADH5 III χ >1000 Widely expressed 
ADH6 V ADH6 Unknown Stomach 
ADH7 IV μ or σ 30 Liver, stomach 
$Description of haplotypes is given in Appendix 10.1.  
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1.4.3.1.1 Alcohol Dehydrogenase 1A 
Two common genetic variants have been identified in ADH1A1, ADH1A1*2 (17bp deletion in the 
promoter region present in many different populations) and ADH1A1*3 (3bp insertion in the 
promoter region only described in those of African descent); both polymorphisms have been 
associated with alcohol dependence.201 
1.4.3.1.2 Alcohol Dehydrogenase 1B 
The three most studied alleles of ADH1B are referred to as ADH1B*1 (the reference allele, encoding 
β1 with arginine at both positions 48 and 370 in the amino acid chain), ADH1B*2 (encoding β2 by 
p.R48H (ADH1B_rs1229984)), and ADH1B*3 (encoding β3 p.R370C (ADH1B_rs2066702); Table 39). 
ADH1B*2 has been shown to be negatively associated with alcohol dependence, due to the 
problems of alcohol metabolism present in this population group.202  The frequency of the ADH1B*2 
carriers has not been shown to be different in ACP than other alcohol dependent populations.203 
1.4.3.1.3 Alcohol Dehydrogenase 1C 
The two most studied polymorphism ADH1C are ADH1C*1 and ADH1C*2 (Appendix 10.1, Table 40). 
These two alleles differ at two sites, resulting in two amino acid changes: the enzyme encoded by 
ADH1C*2 (γ2) has amino acid variation of p.R272Q (ADH1C_rs1693482) and p.I350V (ADH1C_rs698). 
The functional change in relation to p.I350V may be related to linkage disequilibrium with p.R48H 
within ADH1B.204 
In a study of Polish populations, those homozygous for ADH1C*2 were thought to be protected from 
chronic pancreatitis compared to other populations exposed to alcohol excess.205  Other studies 
report no association of ADH1C*1 with alcohol dependance (AD) in European samples.206 
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1.4.3.2 Alcohol metabolism and Aldehyde Dehydrogenase 
An intron identified in ALDH1A1_rs8187974 may be associated with alcohol consumption behavior, 
but needs to be replicated to prove these data.207 No other associations have been well described. 
This is more common in individuals with a polymorphism in ALDH2 (Appendix 10.1) that leads to low 
acetaldehyde oxidizing capacity, which is functionally significant even in the heterozygous form.208 
This polymorphism is prevalent in those of Chinese, Japanese, and Korean descent, leading to high 
leaves of intoxication in these populations after relatively little intake, meaning this variant is 
strongly protective against alcohol dependence. The polymorphism is not normally demonstrated in 
European or African populations.209 
Other than the well-described polymorphism of ALDH2, there have not been any other disease 
associated SNPs described within the coding gene. ALDH2*2 is common in oriental populations, 
being present in around 50% Chinese and Japanese populations.127,128 ALDH2*2 heterozygotes and 
particularly homozygotes show increased acetaldehyde levels after alcohol consumption and 
therefore experience significant negative physiological responses to alcohol.210 
1.4.3.3 Alcohol metabolism and Cytochrome P450 
There are several different polymorphisms of CYP2E1 (Appendix 10.1, Table 41) which vary between 
populations.211 
The CYP2E1*1D polymorphism is found more commonly in non-Caucasian populations, and has been 
shown to increase the risk of alcohol dependence.212 This trend was also present in Caucasian 
populations, but did not reach significance. 
There is a well described relationship with both alcohol dependence and ALD with CYP2E1*5B (also 
known as CYP2E1*c2), and to a lesser extent with CYP2E1*5A.213  
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1.4.3.4 Genes of Alcohol Metabolism Associated with Chronic Pancreatitis 
Although there is a clear association between the consumption of alcohol and chronic pancreatitis, 
the sensitivity of the pancreas to injury from alcohol is dependent on other factors (environmental, 
dietary or genetic).214 Specifically within the subgroup of patients with ACP, certain genetic 
polymorphisms have been identified within the genes commonly associated with alcohol 
metabolism that appear to predispose patients to the development of alcohol dependence and 
chronic pancreatitis. 
The frequency of the ADH1B*2 carriers has not been shown to be different in ACP than other alcohol 
dependent populations.203 
Those homozygous for ADH1C*2, in a Polish population, have been shown in one study to be 
protected from chronic pancreatitis compared to controls exposed to alcohol excess and did not 
develop chronic pancreatitis.205  
The common ALDH2*2 has been shown to be more common in ACP (71%) than in alcoholics without 
signs of the disease (48%), but was statistically lower than in the normal population (76%) which was 
replicated in a similar study.203,215 
Heterozygotes CYP2E1*5A/CYP2E1*5B were present only in patients consuming excessive amounts 
of ethanol, in 7% of patients with alcoholic cirrhosis and in 4.5% of those with ACP.216  This has not 
been demonstrated in other studies but they may be insufficiently powered to identify these rare 
polymorphisms.217,218 Carboxyl-ester lipase (CEL) has been examined previously in two different 
studies.41,219 The original work, carried out in Japan, showed an association between both the 
absence of ACP and being homozygous for the normal 16-repeat alleles and an increase incidence of 
ACP in individuals with a repeat longer than 16-repeats.219  However, when attempts were made to 
replicate this in a second Germany population, the findings were not substantiated.41 
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In addition to its established association with hypertriglyceridemia, the LPL polymorphism, p.S447X 
has been specifically linked with patients with a history of pancreatic calcification and 
steatorrhoea.220 
APOC2 deficiency is an uncommon, autosomal dominant condition that is normally identified in 
childhood and can lead to pancreatitis.221 There are individual reports of loss of function 
polymorphism such as p.V40T in APOC2 or p.T133R in APOA5 can lead to hypertriglyceridemia, 
which therefore can lead to pancreatitis.222 
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1.4.3.5 ABO Blood Group System 
The ABO blood type is well recognized to be associated with some disease processes such as gastric 
cancer.  In the case of pancreatic diseases, several studies have identified an association between 
those who developed pancreatic cancer and a SNP in linkage disequilibrium with the O blood group, 
giving a raised OR of 1.2 (95% confidence interval 1.12-1.28).223,224 
Although there is some association with pancreatic cancer, other studies have failed to show an 
association with chronic pancreatitis.153,225,226  
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1.4.4 Genetics of Alcohol Liver Disease 
Other than the established association of ADH1B*1, ADH1C*2 and ALDH2*1 with the risk of 
developing AD, there is no evidence that any of the commonly recognised enzymes involved in the 
metabolism of ethanol have any effect on the development of ALD.227 
CYP2E1*5B (intronic SNPs CYP2E1_rs3813867 and CYP2E1_rs2031920) has been shown to be an 
associated factor with the development of ALD in both an Asian, and a Caucasian population.213 
Interleukin 1B has been shown to have some association with the development of ALD in one 
study.228 The SNP IL1B_rs16944 is present significantly more often in patients with alcoholic cirrhosis 
than in those with non-cirrhotic ALD (p = 0.026), heavy drinkers without ALD (p = 0.001), and HC (p = 
0.032). The frequencies of IL1B_rs16944 (p = 0.030) and of IL1B_rs1143634 (p = 0.027) were both 
significantly higher in heavy drinkers without ALD than in patients with ALD.  The haplotype, 
IL1B_rs16944/IL1B_rs1143634 was associated with the development of alcoholic cirrhosis (p < 0.05). 
Several studies have shown a polymorphism within PNPLA3 is associated with ALD, 
PNPLA3_rs738409 (p.I148M).227  The presence of the minor SNP has been shown in four studies to 
significantly increase the OR of developing ALD.229 
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1.4.5 Methods for Assessing Genetic Variation 
When assessing different modalities of genetic sequencing for their suitability for a specific project, 
several factors need to be taken into account: the type of disease processes (germline, somatic); the 
type of variation to be assessed; area to be assessed; time scale of the project; and budget of the 
project. 
There are many different techniques that are currently available for genetic sequencing but each has 
different implications in terms of throughput, area to be sequenced, time, and cost.   This is a field 
that is constantly evolving, but below are a description of the more traditional methods used over 
the last few decades, moving into Next Generation Sequencing (NGS) options which became 
available following the first whole genome sequencing in 2002. 
1.4.5.1 Sanger Sequencing 
The classical chain-termination method requires a single-stranded DNA template, a DNA primer, 
DNA polymerase and both normal and modified di-deoxynucleotidetriphosphates (ddNTPs), the 
latter of which terminate DNA strand elongation.230  The different ddNTPs can be selectively 
fluorescently labelled. The various products are then measured and the sequence derived by 
ordering the lengths. 
This system works well when small-scale projects require long continuous sequences, of over 500bp 
reads, or when the sequence to be read is largely unknown as there is no reference sequence to 
compare sequenced fragments to; otherwise it has been mostly superseded by other techniques. 
1.4.5.2 Polymerase Chain Reaction (PCR) based approaches 
There are a variety of techniques based on the selective ability to produce a product by PCR (e.g. 
allele specific PCR) or differential sizes of products from different alleles (e.g. Small Tandem Repeat 
analysis), which can be used to distinguish known alleles. 
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1.4.5.3 Single Nucleotide Polymorphism (SNP) arrays 
SNP arrays potentially contain hundreds of thousands of probes that are designed to specifically 
hybridize with the complimentary section of DNA.  Fluorescently labelled target sequences then bind 
to the probe. The total strength of the signal depends upon the amount of target sample binding to 
the probes allowing some quantitation, as well as the identity of the target sample sequence by 
binding to a probe with a known position on the chip. 
SNP arrays are a common way of assessing SNPs over a large genetic area. Panels can be off-the-
shelf or custom made to look at specific SNPs or genetic areas.  They are commonly used for large-
scale discovery experiments such as Gene-Wide Association Studies (GWAS) where hundreds of 
thousands of SNPs can be read on a single chip. 
1.4.5.4 Next Generation Sequencing (NGS) 
Following the first human genome being sequenced in 2000, there has been a range of different 
commercial sequencing machines that have become available to re-sequence the large section of 
the genome. These are based on massively parallel sequencing: the sequencing of many single 
fragments in individual reactions.  These include products produced by Roche, Illumina, Applied 
Biosystems and Life Technologies that are described further in Table 7. 
Depending on the accuracy required and whether germline or somatic mutations are to be 
identified, the depth of coverage must be taken into account with NGS. In the case of germline 
mutation, coverage of x20-x100 would be expected and this may be over x1000 in the case of 
somatic mutations. 
1.4.5.4.1 Next Generation Sequencing Methods 
Roche 454 uses pyrosequencing techniques to sequence DNA.  It is a fast, high throughput machine, 
but is proportionally much more expensive to run than other similar products. 
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Both the HiSeq and MiSeq from Illumina use polymerase-based reactions to sequence.  HiSeq 
processing time is over a week per run.  It is good for sequencing a large amount of DNA from a 
limited number of samples, but is poor at multiplexing many samples.  The MiSeq is the smaller 
quicker, benchtop version of the same technique. 
Applied Biosystems SOLID has high throughput but long sequencing times and has the advantage of 
a low error rate. 
The Ion Torrent™ uses a semi-conductor chip that detects hydrogen ions that are released during 
polymerization of DNA.  Hydrogen ions are released when the appropriate next sequential base is 
incorporated, leading to a peak in amplitude; when two or more matching bases are incorporated 
sequentially, then the amplitude in increase proportionately. 
The system has the advantages that it is relatively inexpensive to buy the machine and is quick to 
run.  Its accuracy at detecting SNPs is much better than those of Indels or homopolymers (a 








Table 7 Comparison of the different properties of different Next Generation Sequence platforms 
Data taken from manufactures websites and in correct as of 5
th
 September 2014 
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200-400 bp 2 hrs 100-200 
Mb 
0.99 $1.00 USD Low cost, speed Difficulty with 
reading 
homopolymers 
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1.4.5.5 Sequence Capture 
Whichever NGS method might be adopted, there needs to be some method of selection of the DNA 
to be sequenced, as whole genome sequencing is costly, time consuming and makes data analysis 
very challenging.  In the case of small sections (up to 1000bp) traditional PCR may be appropriate, 
however, in most cases this will be too limited to cover the required area, and therefore sequence 
capture techniques should be used. These are commercially available, and can be used to isolate the 
necessary genes. 
Two of the main modalities to achieve this are Haloplex and SureSelect.  Both methods use similar 
processes.  Haloplex works by first denaturing or shearing the DNA, then hybridizing with specific 
probes and barcodes for multiplexing. These specific regions are then captured using magnetic 
beads and a PCR amplification is undertaken to prepare the samples for downstream NGS. 
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1.4.6 Summary 
A common type of variation in the human genome, accounting for phenotypical differences, are 
SNPs.  At the current time there is a wide array of different techniques to obtain specific subsets of 
genetic data; whole genome sequencing is unfeasible, due to time, cost and difficulty with data 
analysis.   Therefore a more focused approach is required.  This can either be in the form of sampling 
of different SNPs throughout the genome (GWAS), targeting SNPs in specific areas such as in custom 
arrays or targeted sequencing of specific genetic areas (focused NGS). In addition other areas such as 
VNTR cannot be sequenced by these common methods and in these cases specific PCR techniques 
can be used with either Sanger sequencing or frequent analysis performed to assess the product. 
When concentrating on specific areas of investigation, this can been done by analysis of a wide 
range of SNPs regardless of disease type (GWAS), a focus on SNPs thought to be associated with that 
disease processes, or a similar mechanism through custom arrays or selection of areas of interest 
based on a hypothesis of the mechanism of disease.  The use of a variety of different but 
complimentary methods will give the most inclusive approach to identifying the role of genetic 
variations in predisposition to alcohol-related chronic pancreatitis. 
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 To determine the factors required to classify a chronic pancreatic population and 




 Systematically review methods of diagnosis of chronic pancreatitis to assess the 
most effected method of diagnosing the disease and defining a disease population.  
 To identify polymorphisms in selected genes associated with lipid and ethanol 
metabolism. 
 To identify polymorphisms in selected genes associated with trypsinogen activation. 
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3 Chapter 3: Systematic Review of the Diagnosis of Chronic 
Pancreatitis 
While clinical features can be indicative, consensus is lacking as to which diagnostic tests reliably 
confirm the presence or absence of CP.12 Many tests have been used either individually or in 
combination, but no single gold standard has emerged. The most widely used reference tests have 
been the identification of ductal changes viewed by ERCP, now considered too high risk to perform 
as a diagnostic procedure, and histology that is usually only available in those with severe disease 
undergoing surgery.62,231-233 
 Materials and Methods 3.1
3.1.1 Data Sources and Search Strategy 
The systematic review was carried out in reference to the Cochrane Handbook for Diagnostic Test 
Accuracy.234 The author (MJ) and James Nicholson (JACN) independently performed searches of 
databases for publications from 1980 to 2012: MEDLINE (PubMed), Web of Science, and Cochrane 
Central Register of Controlled Trials & Database of Systematic Reviews (CENTRAL). The following 
terms were used to search the databases (where * is a wildcard): “chronic pancreatitis”[Title] AND 
((“imaging” OR “etiolog*” OR “aetiolog*” OR “clinical” OR “history” OR “abdominal x-ray” OR “tube” 
OR “tubeless” OR “CCK” OR “CT” OR “topography” OR “tomography” OR “ultrasound*” OR “US” OR 
“USS” OR “endoscop*” OR “EUS” OR “ERCP” OR “magnetic” OR “MR” OR “MRI” OR “MR” OR 
“function” OR “PFT” OR “faecal elast*” OR “fecal elast*” OR “secretin” OR “Ca199” OR “Ca-199” OR 
“Ca19.9” OR “biomarker*” OR “guideline*”) AND (“diagnose*” OR “diagnostic*” OR “diagnosi*”)). 
Only full text articles in English were included.  Abstracts were reviewed and potentially relevant 
papers were obtained and evaluated in detail by two independent authors; where there was failure 
of consensus, a third author adjudicated (Thomas Hanna, TH). Once the papers were selected a 
detailed review of referenced papers was carried out to obtain any studies that may have been 
missed in the original search. 
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3.1.2 Study Selection 
Studies assessing the specificity and sensitivity of diagnostic tests in a population of patients with 
suspected chronic pancreatitis (classed as cohort), or in a group of known pancreatitis patients 
compared with either healthy controls or individuals with other gastrointestinal diseases (classed as 
case control) were eligible for inclusion.235 
Exclusion criteria included: abstracts, reviews, letters and case reports; studies only including 
animals; studies in which the aim was not the diagnosis of chronic pancreatitis; studies aiming to 
differentiate mass forming CP from cancer; studies that did not attempt to measure diagnostic value 
of a test; studies not stating how the diagnosis of CP was arrived at and studies for which data could 
not be successfully extracted either from the presented data or following correspondence with the 
authors. 
3.1.3 Data Extraction 
MJ and TH independently extracted data using a predesigned form, and any discrepancies in data 
extraction were resolved by consensus (JACN). In studies where a cohort of patients with suspected 
CP were compared to a group of normal controls, data on normal controls was excluded and the 
study was classified as a cohort study. 
3.1.4 Data Synthesis and Analysis 
Data provided from different diagnostic tests were considered separately.  When it was not possible 
to extract data from the paper, the source data was requested from the authors for use in the 
systematic review. In cases where data were presented giving both the pre-determined cut-off level 
for diagnosis and the optimum level for that study, only data using the pre-determined cut-off levels 
were used. 
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3.1.5 Quality Assessment 
The quality of included studies was assessed using factors that would influence the outcome of 
diagnostic studies (Figure 5).  Size of study was not included as this was taken into account by 
weighting of the studies in the model. 
3.1.6 Statistical Analysis 
Data are extracted from each study in terms of true positive (TP), false negative (FN), false positive 
(FP) and true negative (TN) frequencies by MJ and TH.  Each study is summarised in the form of 
sensitivities and specificities with associated 95% confidence intervals.  Meta-analyses techniques 
were carried out by Richard Jackson using a Bayesian Hierarchical Summary Receiver Operating 
Characteristic (HSROC) technique.236 This approach calculates the position and shapes of the receiver 
operator curve for each diagnostic test and allows for variability both within and between 
studies.  Diagnostic test is included as a covariate in the model as opposed to using different models 
for each test.  This ensures that model summaries are accounted for within study variability as many 
studies report on more than one test.  For the analysis of the full dataset, a two-step approach is 
carried out to account for study quality within the analysis. Here, studies with a quality score of one 
or two are considered as low quality studies and those with a score of three or greater as high 
quality studies.  Low score studies are initially analysed with vague uninformative priors.  The 
posterior results of the first stage are used to inform the analysis of the high quality studies through 
the prior distributions.  In this second step, the results from the low quality study are penalised by 
increasing the posterior variances by a factor of two. This approach is equivalent to a power priors 
approach and ensures that higher quality studies have a larger effect upon the analysis.237 For 
subgroup analysis, a simpler single step analysis is carried out due to the lack of data available.  For 
the subgroup analyses of endoscopic data, cut-off values were included as covariates in the analysis. 
Model summaries are presented in terms of summary sensitivity and specificity estimates with 
associated 95% credibility intervals for each summary statistic individually.  The shape of the 
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credibility interval is determined by the observed correlation between model parameters and the 
size set to contain 95% of the observed posterior estimates.  The diagnostic odds ratio, given by 
(sensitivity x specificity) / ((1-sensitivity) * (1-specificity)) is also presented as a summary measure. 
Publication bias due to sample size is investigated by plotting the log diagnostic odds ratio against 
the effective sample size (ESS).238 Analyses are carried out using the statistical packages WinBUGS 
and results compiled using R (version 3.01).239,240 Parameter estimates are obtained via a Monte 
Carlo Markov Chain (MCMC) procedure (10000 draws with a thin of 20 following burn in and 
convergence). 
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Figure 4 Flow diagram of studies considered in the systematic review 
  
Potentially relevant citations 
identified after screening of the 
electronic libraries (n = 1382) Citations excluded after title 
review (n = 956) 
Cancer 163 




Not diagnostic 480 
Studies retrieved for more detailed 
evaluation (n = 190) 
Manual review of reference in 
selected studies 6 
  
Synthesis of all studies included in 
systematic review (n = 54)  
 
Abstracts reviewed (n = 426) 
Citations excluded after abstract 
review (n = 236) 
Cancer 9 
Case report/series 10 
Letter 10 
Not in English 2 
Review 131 
Not diagnostic 74 
  
Studies excluded after evaluation 
of full text due to (n = 150) 
Multiple reasons may apply 
  
Not assessing diagnosis 78 
No gold standard 7  
No comparison group 14 
Unextractable data 28  
Compared with cancer cases 5 
Other 9  
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Figure 5 Method used for assigning quality of evidence for systematic review 
 
One point for each quality factor; maximum score 5 
 Prospectively recruited patients  
 Taken from a population of patients with suspected chronic pancreatitis  
 Blinded reviewers of diagnostic tests 
 Pre-defined cut-off for diagnosis  
 Uniform gold standard  
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 Results 3.2
3.2.1 Population 
Using the search criteria 1373 studies were identified, of which 190 were retrieved for detailed 
review; 47 of these met the inclusion/exclusion criteria (Figure 4).  A further six studies were 
identified from papers cited within the references of the selected papers and one further study was 
added after the authors provided data that was previously unextractable.241 In total, 54 studies were 
identified which assessed the use of a diagnostic tests against defined criteria (Table 8). For the 
diagnosis of CP in a population of individuals with and without CP this gave a total of 5287 
individuals tested, of which 2298 (43%) had chronic pancreatitis.  Of these studies 35 were cohort-
type and 19 were case-control. In the cohort studies the pooled prevalence of chronic pancreatitis 
was 45% (95% CI, 40-50%); individual studies ranged from a prevalence of CP of 12% to 94%. 
3.2.2 Gold Standards 
Histology was used as the gold standard in nine of the published studies (two as the sole gold 
standard and seven in combination with other factors); and in all studies describing histology, tissue 
was obtained from resected pancreatic specimens.  In those studies where the classification of 
histology was specifically stated, the Ammann fibrosis classification was used.37 
ERCP was used as the gold standard in 40 (74%) of the studies and was either applied to all patients 
(19) or in a proportion of patients (21).  Criteria for ERCP diagnosis of CP included the Marseille 
criteria, and criteria described by Kasugai; following the development of the Cambridge classification 
in 1984, the majority of studies use this classification (25).61,242,243 
A mixed diagnostic standard was used to identify CP patients in 25 (46%) studies. Calcification was 
used as one of multiple factors in 8 (32%) of these studies. 
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3.2.3 Index Tests 
Data are presented by modality of test in Table 9, with sensitivities and specificities for each 
individual tested provided.  Investigations were broadly classified into pancreatic function tests (PFT; 
direct, serum, or faecal) or imaging (conventional or endoscopic). This saw ten, eight, two, four and 
two different diagnostic modalities being analysed respectively, with the addition of one study using 
FNA with EUS, which was the only study using pathology as the evaluated diagnostic method.  
Table 10 shows those tests with three or more values, which could be pooled to provide combined 
sensitivities, specificities and diagnostic odds ratios (DOR; Figure 6).   
3.2.4 Variation Over Time 
Figures 7 and 8 show the variation of the examination of different diagnostic tests and gold 
standards over the decades. This demonstrates the decline of ERCP being used as a gold standard for 
the diagnosis of CP, with an increase in the use of EUS and MR as a suitable diagnostic modality. 
3.2.5 Comparison of Specific Test 
Several studies compared the utility of faecal elastase and faecal chymotrypsin in the diagnosis of 
CP.  Both sensitivity and specificity were higher in pooled elastase results (Table 10 and Figure 6). 
Five studies examined the use of MR, and most also assessed the effect of secretin in improving its 
diagnostic performance.  Although secretin improved the specificity, it reduced the sensitivity of the 
test (Table 10 and Figure 6). 
Endoscopic ultrasound was the most assessed diagnostic modality, although the diagnostic criteria 
varied between studies (Table 11).  When the number of criteria required for a diagnosis was 
considered the sensitivity decreased, but the specificity increased with each extra criterion required 
(Figure 9 and Table 12).   
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3.2.6 Publication bias 
Publication bias was assessed by both study size and quality score of each publication.  There was no 
publication bias demonstrated in smaller studies (Figure 10, p=0.15), but poor quality studies 






















 UK P CC 297 27 (9) Serum Immunoreactive Trypsin Lundh test
245
 No Unclear Set in paper 2 
Stern 1981
246
 Australia P CC 83 50 (60) Serum Pancreatic Polypeptide PFT/Calc/ERCP/Op No Unclear Pre-set 2 
Valentini 1981
247
 Italy P Co 59 7 (12) Duodenal Bicarbonate ERCP No No Set in paper 3 
Noda 1983
248
 Japan P CC 262 79 (49) Secretin-Pancreozymin test, 
Duodenal Dimethadione 
Calc/Histology No Unclear Set in paper 1 
Enselv 1984
249
 Denmark P Co 80 25 (31) Serum Immunoreactive Trypsin, 
Pancreatic Polypeptide, Isoamylase 
PI/Calc/Previous AP Yes Unclear Pre-set 3 
Tait 1984
250
 Australia P CC 76 38 (50) Serum Amylase, Pancreatic Isoamylase ERCP/Calc/Histology No Unclear Pre-set 2 
Gaia 1985
251
 Italy P CC 98 40 (41) Duodenal Lactoferrin ERCP/Calc Unclear Unclear Set in paper 1 
Hamilton 1986
252
 UK P Co 18 6 (33) Duodenal Bicarbonate, Trypsin ERCP Unclear Yes Pre-set 5 
Heij 1987
253





Denmark P Co 105 36 (34) Serum Trypsin Immunoreactivity, 
Lipase, Pancreatic Isoamylase 
ERCP/CT/AUS Yes Yes Optimised 3 
Bolondi 1989
255
 Italy P CC 33 15 (45) Secretin AUS History + PI Yes No Not defined 1 
Riedel 1991
256





Germany P Co 296 167 (56)  Serum Amylase, Lipase, 
Immunoreactive Trypsin 
ERCP/CT/ PFT Yes Unclear Optimised 2 
Dominguez-Munoz
258
 Germany P CC 144 90 (63) Serum Pancreolauryl test ERCP/CT/Clinical No Yes Pre-set 3 
Natterman 1993
77
 Germany P CC 94 51 (54) EUS ERCP Unclear Unclear Not defined 2 
Wiersema 1993
75
 USA P Co 69 (67) 19 (28) EUS, Duodenal Bicarbonate ERCP Unclear Yes Pre-set 5 
Bozkurt 1994
259
 Germany P Co 48 38 (79) Duodenal Lipase, Amylase, Bicarbonate 
CT, AUS 
ERCP No Yes Pre-set 4 
Buscail 1995
260





Germany P CC 69 20 (29) Serum Pancreolauryl ERCP/CT/Clinical No Unclear Pre-set 2 
Lankisch 1996
261
 Germany R Co 202 110 (54) Secretin-Pancreozymin test ERCP Unclear Unclear Not defined 2 
Glasbrenner 1996
262
 Germany P CC 188 63 (34) Serum Pancreolauryl test, 
Faecal Elastase, Chymotrypsin 
ERCP No Unclear Pre-set 3 
Amann 1996
263
 USA P CC 36 14 (39) Faecal Elastase ERCP/Calc/Op/PI No Unclear Pre-set 2 
Kitagawa 1997
264
 Japan P Co 424(324 197 (61) Secretin test AUS/CT/ERP No Unclear Set in paper 2 
Katischinski 1997
265
 Germany P CC 33 11 (33) Faecal Elastase, Chymotrypsin AUS/CT/ERCP No Unclear Pre-set 2 
Lock 1997
266
 Germany R Co 60 40 (67) Serum Pancreolauryl test ERCP Unclear Unclear Optimised 2 
Sahai 1998
76





Germany P Co 271 127 (47) Serum Pancreolauryl test AUS/CT/ERCP Yes Yes Pre-set 4 
Catalano 1998
268





 Italy P CC 140 44 (31) Faecal Elastase, Chymotrypsin History/ERCP/AUS No Unclear Optimised 2 
Hastier 1999
269
 France P CC 104 14 (13) EUS ERCP Yes Unclear Not defined 2 
Pezzilli 2000
270
 Italy P CC 81 50 (62) Serum Amylase, Trypsinogen, Lipase, 
Pancreatic Isoamylase, Elastase-1 
ERCP/Calc/Histology/ 
Clinical 
Unclear Unclear Pre-set 2 
Hollerbach 2001
86
 Germany P Co 37 31 (84) EUS with FNA ERCP No  Yes Optimised 5 
Hardt 2002
271
 Germany P Co 251(213 201 (94) Faecal Elastase ERCP Yes Yes Pre-set 5 
Kahl 2002
74
 Germany P Co 130 92 (71) EUS ERCP No Unclear Pre-set 3 
Keim 2003
272
 Germany P Co 212 45 (21) Faecal Elastase ERCP Yes Yes Pre-set 5 
Conwell 2003
273
 USA P Co 18 6 (33) Duodenal bicarbonate ERCP Yes Yes Pre-set 4 
Chowdhury 2005
274
 USA R Co 74 28 (38) EUS Duodenal Bicarbonate Unclear Yes Optimised 2 
Draganov 2005
275
 USA P Co 23 (19) 9 (47) Standard secretin stimulation test, 
Intraductal secretin stimulation test 
ERCP No Unclear Optimised 3 
Conwell 2007
276
 USA R Co 56 23 (41) EUS Duodenal Bicarbonate Unclear Yes Pre-set 4 
Conwell 2007
276
 USA R Co 36 17 (47) Duodenal Bicarbonate ERCP No No Pre-set 4 
Miyakawa 2007
277
 Japan R Co 106 41 (39) EUS ERCP/MR/CT/PFT Unclear Unclear Not defined 2 
Pungpapong 2007
278
 USA P Co 79 38 (48) Duodenal Interleukin-8, EUS ERCP/CT/MR/Histology No Yes Pre-set 5 
Pungpapong 2007
279
 USA P Co 99 40 (40) MR, EUS ERCP/Histology/Clinical Yes No Pre-set 3 
Varadarajulu 2007
280
 USA P Co 42 21 (50) EUS Histology Yes Yes Optimised 4 
Bilgin 2008
281
 Germany R Co 81 25 (31) MR Faecal Elastase Yes No Not defined 2 
Parsi 2008
282
 USA P Co 35 24 (69) Duodenal Lipase ERCP/MR/Histology/PI Yes Yes Pre-set 4 
Schlaudaff 2008
283
 Germany P Co 62 9 (15) sMR AUS/CT/ERCP Yes Yes Not defined 3 
Akisik 2009
284
 USA R Co 89 52 (58) MR, sMR ERCP/CT/Clinical No Yes Optimised 2 
Akisik 2009
285
 USA P CC 28 12 (43) MR ERCP Unclear Yes Optimised 3 
Stevens 2009
286
 USA P CC 84 (50) 14 (28) Duodenal Lipase, EUS CT Yes Yes Optimised 3 
Stevens 2009
287
 USA P Co 100 41 (41) EUS (Radial/Linear) Duodenal Bicarbonate Yes Yes Optimised 4 
Balci 2010
288
 USA R Co 36 12 (33) MR, sMR Duodenal Bicarbonate No No Not defined 2 
Albashir 2010
289
 USA R Co 25 21 (84) EUS, Duodenal Bicarbonate Histology No Yes Pre-set 4 
Law 2012
241
 USA P Co 69 16 (23) Duodenal Lipase, Amylase, Bicarbonate EUS No Unclear Not defined 3 
& - Values in brackets are the actual number of patients included in the results. 
P – Prospective; R – Retrospective 
CC – Case control; Co - cohort 
PEI - (%6hr urinary PABA in 1st day)/(%6hr urinary PABA in 2nd day); PABA - Para-aminobenzoic acid 
Calc – Calcifications 
Q – Quality score as calculated from factors in Figure 5. 
Op – underwent operation for chronic pancreatitis; AP – Acute pancreatitis 
ERCP – Endoscopic retrograde cholangiopancreatography; AUS – Abdominal Ultrasound; MR – Magnetic resonance; sMR – Secretin enhanced Magnetic resonance; CT – Computer 
Tomography; EUS – Endoscopic Ultrasound; PFT – Pancreatic function test; PI – Pancreatic insufficiency  
 
 
Table 9 Individual tests separately extracted from each study, grouped by modality with sensitivity and specificity with 95% confidence intervals 




























 ≥5 >5000 IU/L 8 8 10 43 0.50 [0.26, 0.74] 0.81 [0.68, 0.90] 
Lactoferrin (LF) 
     LF/Chymotrypsin 





 - 29 11 5 53 0.73 [0.56, 0.85] 0.91 [0.80, 0.97] 
- 34 6 5 53 0.86 [0.71, 0.94] 0.91 [0.80, 0.97] 
- 38 2 3 55 0.95 [0.82, 0.99] 0.95 [0.85, 0.99] 
Dimethadione Noda 1983
248
 Histology/Calc Japan 1971
290










 <50 mg/h 2 4 0 12 0.33 [0.06, 0.76] 1.00 [0.70, 1.00] 
Bicarbonate Valentini 1981
247

























 SST <80 mEq/L 5 4 4 6 0.56 [0.23, 0.85] 0.60 [0.27, 0.86] 





 <80 mEq/L 16 1 4 15 0.94 [0.69, 1.00] 0.79 [0.54, 0.93] 
Stevens 2009
286










 ≥5 <80 mM
286










 <800 IU/mL 23 1 7 4 0.96 [0.77, 1.00] 0.36 [0.12, 0.68] 
Stevens 2009
286





 ≥5 <300000 IU/L
286
 16 0 48 5 1.00 [0.76, 1.00] 0.09 [0.03, 0.21] 




 Z score 30 6 2 20 0.83 [0.67, 0.93] 0.91 [0.69, 0.98] 
Secretin test~ Kitagawa 1997
264









 Histology/Calc Japan 1971
290





















 >240 IU/L 37 130 8 121 0.22 [0.16, 0.29] 0.94 [0.88, 0.97] 
Pezzilli 2000
270
 ERCP/Calc/Histology - >392 IU/L 13 37 4 26 0.26 [0.15, 0.41] 0.87 [0.68, 0.96] 
Elastase-1 Pezzilli 2000
270
 ERCP/Calc/Histology - >343 ng/dl 25 25 6 24 0.50 [0.36, 0.64] 0.80 [0.61, 0.92] 
Trypsinogen Pezzilli 2000
270
 ERCP/Calc/Histology - <15 ng/ml 14 36 0 30 0.28 [0.17, 0.43] 1.00 [0.86, 1.00] 





+/ml/min <117 µg/l 7 20 11 259 0.26 [0.12, 0.47] 0.96 [0.93, 0.98] 
Enselv 1984
249
 PI/Calc/Previous AP Marseille
293
























 <8 ng/ml 54 113 10 119 0.32 [0.25, 0.40] 0.92 [0.86, 0.96] 
Pezzilli 2000
270
 ERCP/Calc/Histology - <8IU/L 7 43 1 29 0.14 [0.06, 0.27] 0.97 [0.81, 1.00] 
Pancreatic polypeptide Stern 1981
246
 PFT/ERCP/Calc/Op - Peak/basal ratio<5 45 5 3 30 0.90 [0.77, 0.96] 0.91 [0.75, 0.98] 
Enselv 1984
249
 PI/Calc/Previous AP Marseille
293
 <50 pg/ml 11 14 3 52 0.44 [0.24, 0.65] 0.95 [0.84, 0.99] 
Isoamylase Enselv 1984
249
 PI/Calc/Previous AP Marseille
293















 <40 U/L 45 122 5 124 0.27 [0.20, 0.34] 0.96 [0.91, 0.99] 
Pezzilli 2000
270


































 <200 mcg/g 14 6 6 41 0.70 [0.46, 0.87] 0.87 [0.74, 0.95] 
Amann 1996
263
 History/ERCP/PFT/Calc/Op - <200 mcg/g 10 4 4 18 0.71 [0.42, 0.90] 0.82 [0.59, 0.94] 
Glasbrenner 1996
262
 ERCP - <200 mcg/g 50 13 28 97 0.79 [0.67, 0.88] 0.78 [0.69, 0.84] 
Katischinski 1997
265



























0.69 [0.53, 0.81] 
0.78 [0.63, 0.88] 
0.77 [0.70, 0.83] 
0.76 [0.69, 0.82] 
Chymotrypsin Riedel 1991
256





 >3 U/g 8 12 3 33 0.40 [0.20, 0.64] 0.92 [0.76, 0.98] 
Glasbrenner 1996
262
 ERCP - >3 U/g 30 33 22 103 0.48 [0.35, 0.60] 0.82 [0.74, 0.88] 
Katischinski 1997
265



















 Any changes 33 5 5 5 0.87 [0.71, 0.95] 0.50 [0.20, 0.80] 
Buscail1995
260
 Calc/Histology/PI - Any changes 25 5 19 13 0.83 [0.65, 0.94] 0.41 [0.24, 0.59] 
sAUS Bolondi 1989
255
£ History + PI Gullo
296





 Any changes 33 5 4 6 0.87 [0.71, 0.95] 0.60 [0.27, 0.86] 
Buscail 1995
260





 ERCP/Histology/Clinical  Cambridge
61
 Paper specific 37 3 4 55 0.93 [0.79, 0.98] 0.93 [0.83, 0.98] 
Schlaudraff 2008
283
 AUS/CT/ERCP - 
&
 6 3 4 49 0.67 [0.31, 0.91] 0.92 [0.81, 0.98] 
Bilgin 2008
281
 Faecal elastase <200mcg/g Cambridge
61









/s 37 13 13 24 0.74 [0.60, 0.85] 0.65 [0.47, 0.79] 
Balci 2010
288
 Bicarbonate <80mEq/L Cambridge
61
 7 5 9 15 0.58 [0.29, 0.84] 0.63 [0.41, 0.80] 
 
 
~ The total volume, total amylase output, and maximal bicarbonate concentration were measured in each sample during a 60-min period after injection of secretin. 
* Calcification/PD dilation/atrophy 
$ 
Main pancreatic duct dilation in the absence of structural obstruction, dilated side branches, intraductal stones, ductal irregularity, reduced T1-signal intensity, atrophy 
& pancreatic duct stenosis or dilatation, dilatation of the ductal side branches, presence of pseudocysts, and extrapancreatic abscess formation. 
# 1- slight, output of only one or more enzymes impaired; 2 - moderate, bicarbonate concentration and enzyme output reduced, stool fat excretion still normal; and 3 - severe, abnormal SPT 
result plus steatorrhoea 
£ - MCP – Minimal change pancreatitis 
IDST - Intraductal secretin stimulation test; SPT - Secretin-pancreozymin test 
CCK – Cholecystokinin; PEI - PABA excretion index; PABA - Para-aminobenzoic acid 
PI – Pancreatic insufficiency 
ERCP – Endoscopic retrograde cholangiopancreatography; AUS – Abdominal Ultrasound; sAUS – Secretin Abdominal Ultrasound; MR – Magnetic resonance; sMR – Secretin Magnetic 
resonance; CT – Computer Tomography; EUS – Endoscopic Ultrasound; PFT – Pancreatic function test; PI – Pancreatic insufficiency 
ADC - Apparent Diffusion Coefficient; FNA – Fine needle aspiration; PI – Pancreatic insufficiency;  ST – standard secretin test;  PPJ – pure pancreatic juice test
sMR Schlaudraff 2008
283
 AUS/CT/ERCP - 
&


















/s 13 0 4 11 1.00 [0.72, 1.00] 0.73 [0.45, 0.91] 
Balci 2010
288
 Bicarbonate <80mEq/L Duodenal filling 12 0 0 24 1.00 [0.70, 1.00] 1.00 [0.83, 1.00] 
ERCP Buscail 1995
260
 Histology/Calc/PI - Any changes
295














 19 0 10 38 1.00 [0.79, 1.00] 0.79 [0.65, 0.89] 
Buscail 1995
260
 Calc/Histology/PI - ≥1
260

















0.63 [0.52, 0.72] 
0.38 [0.28, 0.48] 
0.70 [0.50, 0.85] 




























 92 0 36 6 1.00 [0.95, 1.00] 0.14 [0.06, 0.29] 
Chowdhury 2005
274
 IDST <80 mEq/L ≥4
274
 16 12 16 30 0.57 [0.37, 0.75] 0.65 [0.50, 0.78] 
Pungpapong 2007
279
 ERCP/Histology/Clinical  Cambridge
61
 ≥4
279 26 14 6 53 0.65 [0.48, 0.79] 0.90 [0.79, 0.96] 
Conwell 2007
298
 Bicarbonate <80 mEq/L ≥6
298
 12 34 0 10 0.26 [0.15, 0.41] 1.00 [0.66, 1.00] 
Miyakawa 2007
277





















0.90 [0.68, 0.98] 
0.43 [0.23, 0.66] 
0.86 [0.63, 0.96] 
1.00 [0.81, 1.00] 
Stevens 2009
286
 CT * Radial≥4
76
 14 0 5 31 1.00 [0.73, 1.00] 0.86 [0.70, 0.95] 
Stevens 2009
287






















0.68 [0.52, 0.81] 
 0.41 [0.27, 0.58] 
0.44 [0.29, 0.60] 
0.32 [0.19, 0.48] 
0.95 [0.85, 0.99] 
1.00 [0.91, 1.00] 
0.95 [0.85, 0.99] 







 16 3 0 4 0.84 [0.60, 0.96] 1.00 [0.40, 1.00] 






 24  0 1 2 1.00 [0.83, 1.00] 0.67 [0.13, 0.98] 
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Table 10 Pooled sensitivity and specificity of tests to diagnose chronic pancreatitis where at least 
three studies were available  
Study type Pooled sensitivity (95% CI) Pooled specificity (95% CI) 
Duodenal bicarbonate 0.78  (0.61, 0.90) 0.72  (0.59, 0.87) 
Lipase 0.96  (0.76, 1.00) 0.57  (0.23, 0.90) 
Serum Amylase 0.40  (0.16, 0.80) 0.93  (0.74, 0.99) 
Serum Trypsin Immunoreactivity 0.33  (0.20, 0.57) 0.97  (0.88, 0.99) 
Serum Lipase 0.28  (0.13, 0.63) 0.95  (0.80, 0.99) 
Serum Isoamylase    0.35  (0.22, 0.62) 0.96  (0.92, 0.98) 
Serum Pancreolauryl 0.75 (0.60, 0.86) 0.78 (0.58, 0.89) 
Faecal Elastase 0.69  (0.55, 0.81) 0.85  (0.75, 0.91) 
Faecal Chymotrypsin 0.54  (0.20, 0.85) 0.78  (0.51, 0.95) 
MR 0.79  (0.47, 0.92) 0.77  (0.51, 0.94) 
sMR 0.87  (0.47, 0.99) 0.88  (0.58, 0.98) 













Figure 6 Forest plot showing pooled diagnostic odds rations for individual tests where at least 




Table 11 Evaluation of the variation of EUS criteria employed between different studies 
 
 
Number of Criteria 
 













Dilation of  
MPD 





Nattermann 199377 ≥1 Yes Yes Yes Yes No No Yes Yes Yes Yes Yes No No 
Wiersema 199375 ≥3 Yes >3 mm >3mm Yes No No Yes Irregular 
contour 
Yes Yes Yes Yes No 
Buscail 1995260  ≥1 Hetero- 
geneous 
>3 mm Yes No No No No No No No Yes No No 
Sahai 199876 - No 1-2mm >2mm 2-5mm 
lobules 





Yes No No 
Catalano 1998268 ≥3 Hetero- 
geneous 
Yes > 5 mm No No Septa Yes Yes >3mm Side-branch 
ectasia 
Yes No No 









Hollerbach 200186 ≥1 No Yes Pseudocysts Yes Yes No No ? Yes No Yes Yes No 
Chowdhury 2005274 - Yes Yes Yes Yes No Yes Yes Yes Yes Viable side 
braches 
No No No 
Conwell 2007298 ≥6 No Yes Yes Yes No Yes Yes Yes Yes Yes Yes No No 
Miyakawa 2007277 ≥1 No Yes No Yes No Yes No Yes No No No No No 
Pungpapong 2007279 ≥4 No Yes Yes Yes No Yes Yes Yes Yes Yes Yes No No 
Rosemont  
Criteria 200978 




Minor MajorB (HnC); 
Minor (w/o 
HnC) 
No Minor Minor Minor Minor Minor 
(≥1mm) 
Major A No No 
§Rosemont criteria - Consistent -1 MajorA + ≥3 Minor; 1 MajorA + MajorB; or 2 MajorA. Suggestive 1 MajorA + <3 Minor; 1 MajorB ≥3 Minor; ≥5 minor.  Indeterminate 3-4 Minor; MajorB +<3 Minor 
HnC – Honeycombing 
~ Other complications - Microcyst formation; Vascular thrombosis; Biliary stenosis 
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Year study published in 5 year blocks 
Variation of the type diagnostic test assessed in studies 
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Figure 8 Variation of gold standard used for diagnosing chronic pancreatitis over time 










































Year study published in 5 year blocks 
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Figure 9 Pooled studies for EUS including sensitivity and specificity by cut-off point 
Circle diameter represents sample size and colour represented the minimum number of EUS criteria 
needed to diagnosis chronic pancreatitis. ROC curve developed from pooled sensitivities and 
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Table 12 Variation of sensitivity and specificity using different numbers of EUS diagnostic criteria  
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Figure 10 Funnel plot demonstrating publication bias on the basis of study sample size 
ESS: Effective sample size. Technique taken from Deeks et al.238  
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Figure 11 Box plot demonstrating study bias between low quality studies and high quality studies  
There was a statistically significant difference between the diagnostic odds ratio between the lowest 
quality studies (score 1) and the highest (score 5; p=0.019). 
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 Discussion 3.3
This is the first systematic review of tests used to diagnose CP and provides a comprehensive 
analysis of all tests evaluated over four decades. Despite the lack of standardisation and the 
possibility to undertake meta-analyses on only 12 of 27 tests, we found clear evidence to support 
the use of EUS and MRI, the latter preferably with secretin. These two tests were found to have the 
highest pooled sensitivities and specificities, each in excess of 0.80, making them the most accurate 
tests evaluated to establish a diagnosis of CP. Either or both would therefore be appropriate as first 
line tests when there is a strong suspicion of CP.  
None of the nine function tests performed as well as EUS or secretin MRI, although some were 
found to have either pooled sensitivities or pooled specificities that were comparable, such as the 
pooled sensitivity of duodenal lipase or pooled specificity of faecal elastase. This is likely in part 
because deficiency is apparent only after very marked parenchymal loss;299 also, loss of function may 
be secondary to other diseases.300 Where faecal tests are deemed appropriate, the data supports 
the use of faecal elastase over faecal chymotrypsin. Poor sensitivity and specificity of pancreatic 
function tests mean, however, that it is likely to be more appropriate to confirm structural changes 
either in the form of imaging or histology to make a diagnosis. Simple function testing may be useful 
as a screening tool, provided the relatively low pooled sensitivity (e.g. of faecal elastase) is 
recognised, thus when clinical suspicion remains despite normal function testing, EUS or secretin 
MRI would be preferable. Furthermore, the addition of endoscopic pancreatic function testing, 
digital image analysis and/or elastography to EUS may increase sensitivity and/or specificity, but we 
have not been able to assess these or other combinations. 
Tools commonly used for quality assessment of diagnostic tests include STARD, which does not 
evaluate study design, and QUADAS2, which does not give an objective value to compare the quality 
of one study against another.301,302 In our review the quality of studies was assessed using a newly 
defined composite measure that included prospective design, individuals with the suspected 
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disease, blinding, pre-defined diagnostic criteria and uniform application of the chosen gold 
standard (Figure 5). This quantifiable score allowed for appropriate weighting of the studies in the 
pooled analysis, to reduce bias in the calculation of accuracy. Consistent with this, the quality score 
demonstrated higher diagnostic ORs in lower quality studies (Figure 11). 
Pre-defined diagnostic criteria are necessary to evaluate any test that has been developed for 
general application, but in several studies diagnostic thresholds were selected after testing to 
optimise diagnostic efficiency (13); in a further 12 it was not stated what the diagnostic cut-off was 
or how it was obtained.234  Post hoc selection of diagnostic cut-off levels will tend to inflate 
diagnostic sensitivity and specificity, unlikely to be reproduced by subsequent validation.303 Well-
established diagnostic criteria are available for a minority of tests e.g. faecal elastase at 200 µg/g, 
duodenal bicarbonate at 80 mEq/L and ERCP using the Cambridge criteria.61,81,304 Some studies used 
the same scoring systems for EUS, but in the main these varied (Table 11). Increasing the number of 
EUS criteria increased specificity while decreasing sensitivity (Table 12); four diagnostic criteria gave 
the highest accuracy. No study has yet evaluated the Rosemont criteria, developed in the search for 
consensus in scoring EUS; randomised studies using predefined criteria are needed, preferably with 
long-term follow up. 78 
We excluded studies evaluating the diagnosis of CP in the context of suspected pancreatic cancer. In 
such studies the suspicion of neoplasm is the diagnostic priority and affects the nature of diagnostic 
tests chosen, such as CT and positron emission tomography.305 The number of studies included in 
this review that examined the efficiency of CT in the primary diagnosis of CP was small. None of the 
studies used contemporary CT technology, which can more readily identify calcification, duct dilation 
and atrophy indicative of CP.306,307 Therefore, assessment of the utility of CT in the diagnosis of CP 
requires further evaluation. 
Three studies specifically addressed the detection of early CP, but not surprisingly either sensitivity 
or specificity was low; complicating factors include fibrosis and atrophy that are more frequent in 
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elderly, asymptomatic individuals.74,252,255 Accurate identification of minimal change CP could 
significantly improve patient management by avoiding extensive diagnostic delay, which can 
otherwise result in pursuit of alternative diagnostic pathways and inappropriate treatment. Both 
EUS and secretin MRI are capable of identifying modest changes, e.g. when functional assessment 
and CT imaging is normal. Notably, EUS has been shown to be more sensitive than ERCP in the 
identification of early changes.74 Nevertheless treatment decisions require substantial confidence in 
results, essential in the planning of surgical treatment of CP. When available, histology remains the 
final arbiter in the identification of CP. While wide bore needle sampling can provide sufficient 
pancreatic tissue to identify CP at an early stage, sampling may be misleading, not representative of 
the whole pancreas and itself carries additional risk.37,233 Further studies are needed to determine 
the clinical utility of these and more recently developed technologies in suspected minimal change 
CP, both singly and in combination, preferably in randomised studies that also address outcomes. 
This will minimise bias inherent in comparisons made between those with a normal or highly 
abnormal pancreas, as in the 19 diagnostic case-control studies evaluated in retrospective studies.308 
Accordingly here the quality score was weighted towards prospective cohort studies. 
We made the basis for the assessment of diagnostic tests comparison with a gold standard. Ductal 
changes on ERCP were the most commonly used gold standard, but recommendations that it should 
only be used as a therapeutic intervention mean that diagnostic ERCP is no longer appropriate.62 
Histology was used as the gold standard in a minority of studies, most frequently from resected 
specimens. This approach is likely to have introduced bias, as those individuals who undergo 
resection tend to be those with the most severe disease or those in whom there is a strong suspicion 
of cancer. In addition, scoring of histology can be subjective and is aligned to that found in alcoholic 
CP.37 Composite gold standards were used in 25 (46%) of the 54 studies examined, but lacked 
uniformity. In practice CP requires a combination of all diagnostic approaches, including clinical 
features, functional assessment, imaging and histology. As with most diseases some criteria may not 
need to be positive for the diagnosis to be made, e.g. CP can be painless or there may be no evident 
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loss of function, but the priority is to identify CP in the presence of either so that appropriate advice 
and treatment can be given promptly. Further work is required to develop consensus, incorporating 
all informative components in the diagnosis of CP. 
Studies that analyse the diagnosis of CP are wide ranging in both modality and study design.  The 
most analysed test of EUS shows good overall sensitivity and specificity, and should be 
recommended for diagnosis of CP, either in addition to, or in place of secretin MRI which shows 
promising results but requires further evaluation. 
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4 Chapter 4: Genome-wide Association Study 
Although alcohol has long been known to be of the primary causative agents of chronic pancreatitis, 
it has also been recognised that genetic contributions are relevant since the identification of PRSS1, 
CFTR and SPINK1 variants as associated factors with pancreatitis risk. This idea was explored further 
with a genome wide approach to identify further genes that may have an association with the 
development of chronic pancreatitis. 
As part of this thesis samples from well-characterised patients with chronic pancreatitis were 
selected, DNA extracted and the DNA sent along with anonymised clinical data by myself to a 
collaborative project in Pittsburgh combining samples from USA, Germany and Spain. This work has 
been published by Whitcomb et al, and contains the materials and methods and results for the 
study.176 
 Discussion 4.1
The GWAS carried out in collaboration with the Pittsburgh group, was the first GWAS to be carried 
out in chronic pancreatitis.  Collaboration between many groups was required to obtain the large 
number of samples needed to run a GWAS. Over 300 samples were provided from the biobanks held 
in the Liverpool Pancreas Biomedical Research Unit. 
Through discovery and validation stages, two highly significant and reproducable SNPs were 
identified one in the region of PRSS1 and the other in the not previously associated Claudin-2 gene; 
PRSS1-PRSS2_rs10273639 and CLDN_rs12688220. These produced an odds ratio (OR) of 0.734 (p = 
2.0 × 10−14) and 1.385 (p = 2.3 x 10-27) respectively. 
Overall, the when assessing patients with established alcohol-related pancreatitis the estimated 
odds ratio (OR) were greater for both PRSS1-PRSS2_rs10273639 and CLDN_rs12688220 than those 
produced for cases with pancreatitis of other etiology. This suggests that the effects of both loci may 
be increased in the presence of alcohol consumption.  
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The GWAS study used a combination of different patient populations including those with recurrent 
acute pancreatitis (RAP).  This is due to the theory that there is a progression of disease from acute, 
through to recurrent acute and then on to chronic pancreatitis, but not all individuals will necessarily 
go through all stages, or some patients may no as of yet developed chronic pancreatitis, although 
with time this will occur.49 However, this has not been unequivocally proven, and therefore the 
pathophysiology of the RAP group may not exactly mirror that of CP. Nonetheless, in this study there 
is the same distribution of PRSS1-PRSS2_rs10273639 between the RAP and the CP cohorts 
suggesting that the polymorphism has a similar effect on the two populations.  In contrast the 
CLDN2 polymorphism was more strongly associated with CP than RAP, suggesting that it may act to 
accelerate the transition from RAP to CP.  
The major allele at the PRSS1-PRSS2 locus has been shown to be associated with reduced PRSS1 
expression. This effect is independent of the previously reported rare gain-of-function PRSS1 
variants that increase susceptibility to both RAP and chronic pancreatitis.48  As this allele occurs 
commonly, there would need to be a combination of other factors present in association with this 
polymorphism for chronic pancreatitis to develop. 
Claudin-2 acts as a tight junction protein, forming cation-selective ion and water channels between 
endothelial cells. It is normally expressed at low levels in the tight junction between pancreatic ducts 
and in pancreatic islets.309-311 Although it has been infrequently examined in humans, in a porcine 
model Claudin-2 has been identified in higher levels in acinar cells under stress.312 As calcium levels 
have previously been shown to be associated with the development of acute pancreatitis, poor 
regulation of this in association with the CLDN2 haplotype may explain the association with chronic 
pancreatitis. 
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5 Chapter 5: Next Generation Sequencing 
As the break down products of fat and alcohol metabolism have been shown to have a clear 
association with the development of chronic pancreatitis, it was hypothesised that variations in 
genes involved in these pathways may impact on the risk of developing chronic pacnreatitis.110  
Therefore full deep sequencing was undertaken of the exons of the selected genes to identify 
potential loci of interest. 
 Materials and Methods 5.1
5.1.1 Patients and samples 
To assess for genetic polymorphisms clinical samples were required from both disease and control 
populations. Table 13 details the different ways samples were obtained. 
5.1.1.1 Existing Resectional Sample Biobank 
There is an existing biobank of samples from pancreatic patients at RLBUHT; these samples have 
predominately been collected from patients undergoing operative procedures on the pancreas, with 
samples of blood (stored as serum, plasma and cell pellets) and urine, being taken alongside 
operative specimens including pancreatic juice, trucut biopsies of the pancreas and histological 
specimens of diseased and normal pancreas, bile duct and duodenum.  This work has been on-going 
since 1997, meaning within the larger bank there is a collection of over 100 samples from patients 
with histologically confirmed CP that was available before the start of this specific project. 
In most cases these previously recruited individuals had the most severe phenotype of the disease, 
i.e. requiring surgical intervention; the only exceptions to this being those patients with mass 
forming pancreatitis who may have undergone resection for suspicion of cancer, rather than in 
relation to symptoms of CP.  The CP samples were also derived from a range of different aetiologies, 
but patients’ more commonly had the idiopathic form of this disease. 
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5.1.1.2 Chronic Pancreatitis Biobank 
Therefore, at the start of this body of work, ethical approval was sought for a chronic pancreatitis 
biobank that would allow the attainment of samples of blood from patients with suspected or 
confirmed CP (10/WN003/46). 
To identify the patients with CP, clinic lists for the four weekly pancreato-biliary clinics were 
screened prior to clinic by cross-referencing with a list of patients who had previously been 
identified as having CP through clinic letter review, EUS results or through the pancreas resection 
database. 
Patients were approached in accordance with the ethical approval, given the appropriate patient 
information sheet (PIS) and fully consented. After the consent form was completed, the blood was 
collected as per standard operating procedures (SOP) of the GCLP facility (GCLPTSS055/2 and 
GCLPTSS040/1). 
Samples were processed into serum, plasma and cell pellets and stored in the PBRU -80oC freezers 
until they were required for further use in the project.  
5.1.1.3 Control Biobank 
In conjunction with this, a mirrored group of patients required recruitment to be used as a control 
group, and a separate ethical approval for blood samples for this group was obtained (11/NW/0347). 
Control patients with a history of alcohol excess were identified patients within the “Lifestyles” clinic 
(for alcohol dependence) or through the hepatology weekly clinic. Once collected they were 
processed using the same methods as the CP samples, and stored for further use. 
Additional healthy controls (HC) were collect through local donors at the University of Liverpool who 
volunteered for involvement in the research project (08/H1017/19). 
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5.1.1.4 Liver Transplant Tissue Samples 
Additional samples were obtained for the NIHR Birmingham Liver Biomedical Research Unit.  These 
were samples of liver tissue collected from patients undergoing liver transplants due to alcohol 
related cirrhosis in line with NREC approval (09/H1010/75). These samples were kept at -80oC for 
long-term storage.  
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5.1.1.5 Discovery Phase 
5.1.1.5.1 Chronic Pancreatitis 
Participants included in the CEL study had to meet the following criteria 
- symptoms typical of chronic pancreatitis 
- alcohol excess of greater than 35u/wk (equivalent of >40g/day)43 for at least 5 years 
- radiological evidence of chronic pancreatitis (CT/MRI/EUS) 
- cell pellet available for DNA extraction 
- patient consented to take part in research projects 
5.1.1.5.2 Alcoholic Control  
For patients to be included in the discovery phase on the NGS section they had to meet the following 
criteria 
- no personal or family history of chronic pancreatitis 
- alcohol excess of greater than 35u/wk (equivalent of >40g/day)43 for at least 5 years 
- radiological evidence of a morphologically normal pancreatitis (CT/MRI/EUS) 
- cell pellet available for DNA extraction 
- patient consented to take part in research projects 
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5.1.1.6 Validation 
5.1.1.6.1 Chronic Pancreatitis 
Patients included in the validation phase on the NGS section had met the following criteria 
- symptoms typical of chronic pancreatitis 
- alcohol excess of greater than 35u/wk (equivalent of >40g/day)43 for at least 5 years 
- cell pellet available for DNA extraction 
- patient consented to take part in research projects 
5.1.1.6.2 Alcoholic Control  
Patients included in the validation phase on the NGS section had met the following criteria 
- no personal or family history of chronic pancreatitis 
- alcohol excess of greater than 35u/wk (equivalent of >40g/day)43 for at least 5 years 
- cell pellet available for DNA extraction 
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5.1.2 DNA Preparation 
5.1.2.1 Cell Pellets 
DNA was extracted from the previously stored red cell pellets, using MagnaPure System as per SOP 
of the GCLP facility (GCLPEQU020/3). 
The red cell pellet stored in 2ml Eppendorf tube was diluted with 0.6ml of PBS.  0.4ml of the 
resuspended cell pellet was used per sample for DNA extraction using the 100-400 DNA extraction 
protocol, to elute 0.1ml of DNA.  All extracted DNA was stored at -20oC until further use. All details 
relating to each elution was recorded on Matrix LIMS (Autoscribe, Reading) and on a MagnaPure 
machine (Roche Diagnostics, UK). 
5.1.2.2 Liver Tissue 
A Cryostat (Thermo Scientific, UK) was used to keep the liver tissue frozen while slicing thin sections 
of liver tissue before DNA was extracted.  QIAamp DNA Micro Kit (Qiagen, Baltimore USA) was used 
to extract DNA from the liver tissue going through the processes of lysis, binding, washing and 
elution as detailed in the May 2010 handbook. 
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5.1.3 DNA Quality Control 
DNA extracted by both methods was quality controlled and quantified using three methods as 
detailed below.  If standards were not met in any of the three methods, then the sample was not 
used in any further experiments and a new sample was eluted from the stock of cell pellets. 
Once DNA samples had satisfied all three quality control tests, the 225ng of DNA was diluted in 45l 
of nuclease-free water to make a concentration of 5ng/l ready for use in the sequence capture. 
5.1.3.1 Gel Electrophoresis 
2l of the stock DNA solution was added to 2l of nuclease-free water, and 1l of loading buffer.  
This was loaded on to a 100ml 1% agarose gel containing Gelred™ (Biotium, California) with a 1kb 
ladder.  The gel was run at 75v for 90 minutes before photographing under UV light.  The DNA run 
on the gel was deemed acceptable if there was a smear of product greater than 2.5 KB with no 
evidence of a smear of degraded DNA below this. 
5.1.3.2 NanoDrop Spectrophotometry 
Before any readings were taken, the NanoDrop Spectrophotometer (Thermo Scientific, Delaware 
USA) was cleaned with nuclease-free water, and a blank reading was carried out using 1l of a 
“blank” created by running a sample of nuclease-free water through the MagnaPure protocol.  Then 
1l of each sample ware run through the machine and the DNA concentration and the 260/280 
ratios were recorded.  Sample with a 260/280 ratio outside 1.8 to 2.0 were excluded from further 
processing as per SOP of the GCLP facility (GCLPEQU029/1). 
5.1.3.3 Qubit® dsDNA HS Assay 
Concentration on the DNA was quantified using Qubit® dsDNA HS Assay (Life Technologies, Paisley).  
Samples were processed in batches of 8 or less.  Before quantification of any samples the machine 
was calibrated using two standards provided in the kits following the manufacturer’s instructions. 
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5.1.4 Selection of Genes of Interest 
An extensive review of the literature in relation to genes known to be involved in the lipid and 
alcohol metabolism pathways was undertaken (http://geneontology.org//).  This gave the list shown 
in Appendix 10.2 Table 42.   Many of these genes were considered as too peripheral to the main 
metabolism pathways describe in Chapter 1.1, while others were eliminated from further 
consideration because there was no literature reference to significant impacts on the overall 
pathway in deletion studies. After eliminating genes of less interest, a final list of potential candidate 
genes was formed. These were inputted into a gene ontology program (Ingenuity pathway analysis, 
IPA 6, Qiagen Redwood city, USA), to establish the pathways between the potential genes, and to 
identify if there were other key genes within the pathway that had not yet been identified.  
Given previous literature in relation to alcohol-related chronic pancreatitis, the main interest was 
the genetics of lipid and alcohol metabolism, and therefore the majority of genes included related 
directly to these processes.  However, as PRSS1, SPINK1 and CFTR have an established associated 
with chronic pancreatitis, it was felt to be beneficial to include them in the sequencing to allow any 
interaction with variants in these genes, and the genes of alcohol metabolism to be assessed. 
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5.1.5 Sequence Capture (Haloplex) 
The specific design for the sequence capture was created using the Haloplex design tool (Life 
Technologies, Paisley, UK), selecting the exonic regions from the candidate genes; the resulting 
design coverage is shown in Appendix 10.2, Table 43. 
For each batch of sequence capture performed, 15 clinical samples were run with one control 
sample provided with the kit. During the process, individual barcodes were added to each amplicon 
to allow multiplexing of up to 16 different samples on one NGS reaction.  Samples were processed in 
accordance with Protocol Version D.1, November 2012.  21 cycles were used in the PCR step. 
5.1.5.1 Bioanalyzer 
The 2100 Bioanalyzer instrument (Agilent, Santa Clara, California) was used with Agilent High 
Sensitivity DNA Kit to quantify the product produced by each Haloplex reaction to allow multiplexing 
of the samples with equal distribution.  Samples with insufficient product (defined as less than 
300pg/l, and variation from expected trace; see example in Figure 12) were deemed unsuitable for 
NGS, and therefore additional DNA from the same patient was run through the Haloplex, before 
being quantified by the Bioanalyzer again to confirm its suitability.  Samples were processed in 
accordance with Protocol Agilent High Sensitivity DNA Kit Guide, Version 5/09. 
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Figure 12 Typical output of the Haloplex capture product read with the Bioanalyzer 
Peaks at 35bp and 10380bp are the ladder markers.  The peak at 125bp indicated the PCR primers 
than have failed to bind to DNA. If this equated to greater than 10% of the overall product then the 
sample would need to be washed (this was not required for any of our samples). The majority of 
product from the Haloplex, including barcodes was between 200bp to 550bp as demonstrated on 
the graph. 
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5.1.6 Ion Torrent™ 
5.1.6.1 Ion OneTouch™ 
Following the quality and quantification measurements of each of the Haloplex products with the 
Bioanalyzer, the samples were multiplexed (15 or 16 samples with different Haloplex barcodes) with 
equivalent quantities of amplicons to give 20l of product with 0.01328nM of multiplexed amplicons. 
The sample preparation of the sequencing on the Ion Torrent™ was carried out using the Ion 
OneTouch™ (Life Technologies, Paisley, UK) system with the Protocol Ion OneTouch™ 200 Template 
Kit v2 DL (Cat Number 4480285, Publication Number MAN0006957, Revision 5). During this process, 
there is clonal amplification of the individual amplicons, and then each of the individual amplicons is 
combined with a bead within a detergent bubble to create an Isolate Positive Ion Sphere™.   
5.1.6.2 Ion Torrent™ 
The prepared samples from the Ion OneTouch™ were then loaded onto a 318 chip following the 
protocol Simplified Ion PGMTM
 
Chip Loading with the Ion PGMTM
 
Weighted Chip Bucket, Publication 
Number MAN0007517 Revision 1.0. 
The Ion Torrent PGM machine was then set up following the Ion PGMTM Sequencing 200 Kit v2 Ion 
316TM
 
Chip v2 Publication Number MAN0007273 Revision 3.0. Two chips were run in sequential pairs 
over a 24hour period to maximize the efficiency of the machine 
5.1.7 Data Output from Ion Torrent™  
The data produced from each chip run was stored on a specific server, and data was initially out 
putted from the Torrent Suite™. Basic data was provided on the number of read, length of reads and 
quality of reads (Figure 13).  The fingerprint of the chip loading was provided to show the efficiency 
of live beads loaded onto the chip (Figure 13). Overall run results for each chip are presented in 
Appendix 10.3; by chip in Table 45 and by sample in Table 46. 
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Figure 13 Sample of summary statistics from Torrent Suite™ 
The figure shows the total number of bases read, the percentage of beads loaded onto the chip 
which contained a single amplicons sequence, the total number of individual usable reads, the mean 
read length and a histogram of the variation in read lengths.  This is for 16 multiplexed samples run 
on an individual chip. The image shows the evenness of loading with red indicating high levels of 
leading, green/yellow poorly levels of loading and blue is out with the loading area of the chip. 
 
5.1.8 Data Analysis from Ion Torrent™ 
The reads for each sample were downloaded from the Ion Torrent™ PGM in Fastq format. With the 
assistance of Roy Chaudhuri (Centre for Genenomic Research, University of Liverpool) the reads 
were mapped to the human reference genome version hg19 using Bowtie2 version 2.1.0, using the 
option "-very-sensitive-local". Reads which mapped ambiguously, defined as those with a mapping 
quality score below 10, were excluded from further analysis.313 Reads containing indels were 
realigned using IndelRealigner from GATK version 2.0, and variants were called using the GATK 
UnifiedGenotyper.314  
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5.1.8.1 Calling individual SNPs 
All genetic variation from the base line reads were produced per run in individual .csv files. All 
potential SNP positions were identified, and where the number of reads at that position for each run 
was <6, then this was called as not read.  Where no variant was called at greater than 6 reads, this 
was considered as no variant called. For any sample that called a variant, but less than 25%, this was 
also classed as not read. All variant read at between 25-75% of the reads were classed as 
heterozygous, and variant reads of >75% were classed as homozygous. 
5.1.8.2 SNPs of Interest 
The SNPs of Interest, selected for further validation of their significance, where selected by 
performing a χ2 analysis of both the heterozygous and homozygous frequency of each SNP between 
the ACP and ACtrl groups. A p value of less than 0.05 was considered significant. 
This long-list of potential SNPs were then individually examined to confirm that the polymorphism 
had been read in both directions, and did not follow a homopolymer, approximate insertions or 
deletions which may lead to a misread of the data.  Only SNPs that had been found to have a 
significant difference between the groups, and appeared to be genuine calls were included in the 
final list of SNPs of Interest, which were then validated, in a second population. 
These SNPs were assessed for their previous inclusion in reports of disease association in the 
literature.  
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5.1.9 Linkage Disequilibrium  
Deviation (D) is the difference between the observed and expected frequency of each haplotype 
where 0 indicates complete linkage equilibrium.   
Equation 1 Standard measure of Linkage Disequilibrium 
D = (x11)(x22) – (x12)(x21) 
Standardisation of D (which can range from -0.25 to 0.25) can be performed based on the theoretical 
maximum and minimum relative to D (Figure 14). 
Equation 2 Normalisation of deviation 
D’ =   |D| 
          Dmax 
Figure 14 Relationship between allele frequencies and deviation from expected values 
 A1 A2 Total 
B1 x11 = p1q1 + D x21 = p2q1 - D q1 
B2 x12 = p1q2 - D x22 = p2q2 + D q2 
Total p1 p2  
Correlation (r2) between a pair of loci is calculated using the following formula 
Equation 3 Correlation between loci  
r2=         D2     
             p1p2q1q2 
 
As data was only available to pairs of alleles, and due to the short reads produced by the Ion 
Torrent™ the probability of each haplotype occurring had to be imputed from the source data. 
5.1.9.1.1 Tagging SNPs 
To identify if the SNPs of Interest had been previously reported, tagging SNP were identified using 
data taken for 1000 genomes website (http://browser.1000genomes.org/index.html) included SNPs 
with r2>0.8 and D’ >0.9, and the tagging SNPs were then investigated in the literature. 
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5.1.10 Concordance of Results between Modalities 
The Liverpool subsection of the data produced by the GWAS was compared to identify comparable 
SNPs analysed and overlap of patient samples.  Results from the two methods were directly 
compared to calculate the correlation between the two techniques, and specifically between 
different SNPs.  
5.1.11 Sequenom Validation 
The MassARRAY® System (Agena, San Diego, California) using MALDI-TOF based technology was 
utilized to run the selected SNPs in Stage 1 for the Stage 2 analysis.  This work was carried out with 
the assistance of Daniel Carr from the Wolfson Centre for Personalised Medicine, University of 
Liverpool. 
Where the Sequenom was unable to assess the SNPs, then TaqMan PCR was designed to assess the 
SNPs.  This data was compared to the original Ion Torrent™ results to calculate a correlation 
between the two techniques. 
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5.1.12 Haplotype Analysis  
To assess for disease haplotypes in the most strongly associated SNPs, the other SNPs read on the 
same chromosome were compared to the reference SNP, and those SNPs that correlated with the 
reference SNP in either the ACP or the ACtrl population (as tested by χ2 with a p value of less than 
0.05), were then included in the haplotype design. Each of these loci were combined in location 
order to form an allelotype (e.g. 0/0 0/1 0/1 1/1 0/0); OR were calculated with a 95% confidence 
interval. 
To assess for a haplotype association, considering all the possible alternative haplotypes from each 
allelotype, the counts were based on the total number of haplotypes possible per allelotype and 
these haplotypes were tabulate as the most likely imputed haplotype for each group. A χ2 test was 
run to give a measure of the significance of disease association OR. Where there were no patients in 
one group (making computation of the OR impossible), 0.5 is added to all groups.315 
Once the significance of each OR was identified, the least significant factors were removed in a 
stepwise fashion to see if this affected the model, until the most significant model was identified. 
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 Results 5.2
5.2.1 Patients 
A total of 203 patients (102 for ACP and 101 ACtrl) successfully went through Haloplex sequence 
capture successfully and were sequenced on the Ion Torrent™.  The demographics of the patients 
sequenced are given in Table 14. 
 
Table 14 Patient demographics of Alcohol-related Chronic Pancreatitis and Alcohol Control groups  
 
 Alcohol-related  
Chronic Pancreatitis (102) 
Alcohol Controls  
(101) 
Age Median (range) 44 years (26-77) 50 years (25-89) 
































































The Role of Genetic Variation in the Predisposition to Alcohol-related Chronic Pancreatitis                             2015 
Next Generation Sequencing - Results 124 
5.2.2 Next Generation Sequencing Analysis 
Within the sequenced area 2776 different SNPs were identified within at least one of the samples, of 
which only 1484 (53.5%) were known to be SNPs, as demonstrated by possession of an rs or a CM 
identifier. 
SNPs were identified in all of the sequenced genes.  The variation of each SNP between the ACP and 
the ACtrl group is demonstrated in Figure 15. Those SNPs that either demonstrated significant 
difference between the groups for either presence of the SNP either as a heterozygote or a 
homozygote SNP were identified for further validation (Table 23), and will be referred to as the SNPs 










Figure 15 Manhattan plot of Next Generation Sequencing data presented by gene 
Width of gene on base access represents the number of SNPs identified within that gene, and not the overall size of that gene.  
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5.2.3 Known Chronic Pancreatitis Associated Variant Analysis 
5.2.3.1 PRSS1 
No patients exhibited variants in the most common recognised PRSS1 mutations of p.R122H or 
p.N29I.  Two individuals appeared to show p.A16V variant from the Ion Torrent™ alignment 
(Table 15).  Analysis of these patients is documented below. 
p.D162D and p.N246N are common polymorphisms in linkage disequilibrium and were thought to 
have no pathogenic consequences. p.K170E has only been described in four separate reports, and it 
is unclear if there is any pathologic consequence.190 
There were significantly more patients exhibiting the p.D162D polymorphism in the ACP group than 
in the ACtrl group (OR 1.80, 1.2-2.7; p = 0.004).  This is discussed further in Chapter 5.3.2.8.1. 
 
Table 15 Genotypes of commonly known PRSS1 SNPs  
 
   Alcohol-related 
Chronic Pancreatitis Alcoholic Controls 
  Pub MAF Major Hetero Minor Major Hetero Minor 
PRSS1_rs20200380550 p.A16V - 102 0 0 97 2 0 
PRSS1_rs6666164 p.D162D 0.3966 26 41 29 40 42 15 
PRSS1_rs201550522190 p.K170E 0.0016 87 9 1 87 8 0 
PRSS1_rs6667164 p.N246N 0.3938 8 47 45 17 42 37 
MAF – Published minor allele frequency; Major – Homozygous for major allele; Hetero – Major and 
minor allele; Minor – Homozygous for minor allele frequency.  
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5.2.3.1.1 p.A16V 
To confirm the p.A16V variants identified in the two control patients, Sanger sequencing of the 
genetic area was carried out using the primers and methods described by Threadgold et al.177  The 
sequences from both the patients’ samples are as show in Figure 16, with no clear G to A base 
transition at point 183. On further analysis of the surrounding sequence, the isoform of cationic 
trypsin, mesotrypsin, has Valine rather than Alanine at codon position 16 (Figure 1), and it is 
therefore likely that both the sequence capture and alignment tool lead to mesotrypsin being 
misread as cationic trypsin at this point. 
 
Figure 16 Sanger sequencing trace showing the area of potential p.A16V polymorphism 
The potential polymorphism lies at point 180, where GA was read in this sample with the Ion 
Torrent. 
 
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5.2.3.2 SPINK1 
Table 16 Genotypes of commonly recognised SPINK1 polymorphisms  
  Alcohol-related 
Chronic Pancreatitis Alcoholic Controls 
Pub MAF Major Hetero Minor Major Hetero Minor 
SPINK1_rs1710731545 p.N34S 0.006 67 6 0 58 1 0 
SPINK1_rs111966833180 p.P55S 0.003 89 2 0 78 2 0 
Pub MAF – Published minor allele frequency; Major – Homozygous for major allele; Hetero – Major 
and minor allele; Minor – Homozygous for minor allele frequency 
 
The commonly known SNPs in relation to SPINK1 are presented in Table 16. 
Due to the small numbers there was no difference in the prevalence of p.N34S between the ACP 
group and the ACtrl group, although there was a trend towards more of the polymorphisms in the 
ACP group (Fisher’s exact p = 0.13).  However, the frequencies demonstrated are representative of 
those that would be expected to be found in an ACP population.178 
There was no difference in the presence of p.P55S, and none of the other variants were identified in 
any of the samples tested.  
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5.2.3.3 Cystic Fibrosis Transmembrane Conductance Regulator 
Table 17  Genotypes of commonly reported CFTR SNPs 
Pathogenic polymorphisms are identified in bold 
The result for the common CFTR SNPs are presented in Table 17; underlining indicates SNP thought 
to have a pathogenic consequence.  Although there were high number of CFTR variants identified in 
the ACP group compared to ACtrl, none of the variants were significantly associated with ACP and 
when either the presence of the disease causing variants or all variants were taken into account, 




Chronic Pancreatitis Alcoholic Controls 
MAF Major Hetero Minor Major Hetero Minor 
CFTR_rs1800076189 p.R75Q 0.0064 87 11 0 83 5 1 
CFTR_rs78655421316 p.R117H 0.0005 98 4 0 97 2 0 
CFTR_rs35516286189 p.I148T 0.0014 102 0 0 96 1 0 
CFTR_rs143486492317 p.R297Q 0.002 99 1 0 89 0 0 
CFTR_rs121908753316 p.R352Q rare 64 5 1 53 5 1 
CFTR_rs213950318 p.V470M 0.4179 32 52 15 35 43 12 
CFTR_rs1801178189 p.I507V rare 69 1 0 62 0 0 
CFTR_rs1800095189 p.E528D 0.0106 63 5 0 58 0 0 
CFTR_rs1800098319 p.G576A 0.0024 91 3 0 82 1 0 
CFTR_rs1800100320 p.R668C 0.0041 99 3 0 96 1 0 
CFTR_rs1800103321 p.I807M 0.001 88 1 0 85 0 0 
CFTR_rs1042077322 p.T854T 0.4792 39 51 10 39 39 12 
CFTR_rs1800109323 p.T966T 0.0062 100 1 0 96 1 0 
CFTR_rs1800118 p.T1095T 0.0018 100 0 0 94 2 0 
CFTR_rs1800121324 p.Q1186Q 0.002 91 1 0 80 0 0 
CFTR_rs34911792189 p.S1235R 0.0037 90 0 0 80 1 0 
CFTR_rs1800130325 p.P1290P 0.0647 89 9 0 92 4 0 
CFTR_rs1800135 p.Y1424Y 0.0042 98 3 1 95 1 0 
CFTR_rs1800136326 p.Q1463Q 0.1861 73 25 0 70 23 1 
         
 Alcohol-related 
Chronic Pancreatitis Alcoholic Controls 







Total Pathogenic  13 89 8 93 
Total  82 20 70 31 
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The previously described CFTR haplotype was examined in this population (CFTR_rs213950, 
CFTR_rs1042077 and CFTR_rs1800136).186 The haplotypes were imputed using the method 
described in Chapter 6.1.12. The results are presented in Table 18.  Unlike previous reports, there 
were no differences identified in any of the most common haplotypes between those with alcohol-
related chronic pancreatitis and those with a history of alcohol excess. We see more A-G-G and less 
A-G-A than in previous reports, which could be potentially due to different populations used, or 
different control type. 
Table 18 CFTR risk haplotype assessed by Next Generation Sequencing data 
 
 Allele frequency  
CFTR Haplotype ACP ACtrl OR (95%CI) p value 
G-T-G 0.46 0.48 0.944 (0.485-1.835) NS 
G-T-A 0.03 0.05 0.734 (0.133-4.069) NS 
A-T-G 0.13 0.09 1.518 (0.517-4.451) NS 
A-G-G 0.15 0.18 0.807 (0.331-1.967) NS 
A-G-A 0.05 0.05 1.200 (0.258-5.571) NS 
Other 0.17 0.16 1.049 (0.426-2.580) NS 
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5.2.4 Known Variants in Genes of Alcohol Metabolism 
Below is a review of the previously reported polymorphisms in the genes of alcohol metabolism. 
5.2.4.1 Alcohol Dehydrogenase 
Previously described SNPs ADH1B_rs2066702, ADH1B_rs2018417 and ADH1B_rs1041969 were 
covered but no variants were identified in the population samples; the sequencing did not cover 
ADH1B_rs1789882. Results are presented in Table 19. 
 
Table 19 Distribution of recognised polymorphisms in the exons of ADH1B, ADH1C and ADH4 
  Alcohol-related 
Chronic Pancreatitis Alcoholic Controls 
Pub MAF Major Hetero Minor Major Hetero Minor 
ADH1B_rs1229983207 p.K20K 0.0289 75 6 1 66 2 1 
ADH1B_rs1229984202 p.R48H 0.2117 92 4 4 92 2 2 
ADH1B_rs6413413327 p.T60S 0.0078 98 3 0 91 5 0 
ADH1C_rs698202 p.I350V 0.2143 25 36 17 22 38 15 
ADH1C_rs1693482202 p.R272Q 0.2143 67 21 10 81 8 7 
ADH1C_rs1693425328 p.V158V 0.2145 60 13 10 50 15 10 
ADH1C_rs2241894328 p.T151T 0.4716 76 17 3 65 18 2 
ADH1C_rs1789915328 p.C104C 0.1502 60 14 8 48 16 6 
ADH4_rs1126670329 p.P255P 0.1528 77 12 11 70 18 9 
ADH4_rs1126671329 p.I309V 0.1530 18 24 9 23 24 8 
ADH4_rs1126672329 p.L351L 0.1172 52 32 13 54 23 13 
MAF – Minor allele frequency; Major – Homozygous for major allele; Hetero – Major and minor 
allele; Minor – Homozygous for minor allele frequency). 
 
 
All previously reported exonic SNPs in Alcohol Dehydrogenase 1C were covered, and their 
distribution between the groups is demonstrated in Table 19. 
The Role of Genetic Variation in the Predisposition to Alcohol-related Chronic Pancreatitis                             2015 
Next Generation Sequencing - Results 132 
The only one of these SNPs which shows a significant difference between the groups is 
ADH1C_rs1693482 (OR 2.04, 1.17-3.59; p = 0.017), which has been previously associated with 
alcohol dependence. 
Those SNPs which have been previously been assessed in relation to pancreatitis and had variants 
called in our population are presented in Table 19.  In addition, the sequencing covered SNP 
ADH4_rs139053416 and ADH1B_rs143067434, but no polymorphisms were identified within our 
study population. 
The previously reported SNP, ADH6_rs3857224, lies within the intronic region, and therefore was 
not covered by the Next Generation Sequencing. 
The previously reported area of ADH7 associated with alcohol dependence, ADH7_rs2654849, was 
not read as it lies outside of the exonic region.330 The polymorphism ADH7_rs971074 was within the 
sequence data but no polymorphisms were identified.   
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5.2.4.2 Aldehyde Dehydrogenase 
The commonly recognized variant ALDH2_rs671, known as ALDH2*2 was covered by the analysis, 
but no variations were identified, which is in keeping with its preponderance in Asian populations. 
5.2.4.3 Cytochrome P450 
There have been several different haplotypes described in the literature; a summary is given in 
Appendix 10.1. 
Of the different polymorphisms previously described within CYP2E1, CYP2E1*2 was covered but no 
polymorphism was identified in any of the samples, and CYP2E1*5B was not read as the 
polymorphisms lie within the intronic region. Results of CYP2E1*3 and CYP2E1*4 are given in 
Table 20. 
Table 20 Distribution of recognised polymorphisms in the exons of CYP2E1  
 
  Alcohol-related 
Chronic Pancreatitis Alcoholic Controls 
Pub MAF Major Hetero Minor Major Hetero Minor 
CYP2E1_rs55897648209 p.I389V 0.0004 95 0 0 92 1 0 
CYP2E1_rs6413419211 p.V179I 0.0778 92 5 0 92 5 0 
CYP2E1_rs915909211 p.I321I 0.027 101 1 0 100 0 0 
CYP2E1_rs2515641211 p.P421P 0.2991 73 26 0 72 22 0 
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5.2.4.4 Genes of Lipid Metabolism 
5.2.4.4.1 Lipoprotein Lipase 
The previous described SNPs in relation to LPL are presented in Table 21.  There were no differences 
between groups. 
Table 21 Previously identifed polymorphisms in the exons of LPL, APOA5 and APOE 
 
  Alcohol-related 
Chronic Pancreatitis Alcoholic Controls 
Pub MAF Major Hetero Minor Major Hetero Minor 
LPL_rs328220 p.S474X 0.0925 85 14 1 75 18 1 
LPL_rs1801177114 p.D36N 0.0176 98 4 0 94 2 0 
LPL_rs268114 p.N318S 0.0052 98 3 0 95 2 0 
APOA5_rs3135506114 p.S19W 0.0557 86 5 0 78 7 0 
APOE_rs429358114 p.C130R 0.1506 69 13 2 61 20 3 
APOE_rs7412114 p.R176C 0.0751 73 9 3 74 11 3 
 
Only one previously significant SNP was reported in APOA5, and this had no difference between 
groups.  The previously described SNPs in APOE, with no significant difference between groups, and 
no deviation from the published MAF. 
5.2.4.5 ABO Blood System 
The SNP ABO_rs505922 commonly used to establish the ABO group of an individual was not 
sequenced as it lies in an intronic region.  The SNPs that were sequenced are presented in Table 22; 
there was no difference between groups. 
Table 22 Genotypes of previously identified SNPs in ABO 
  Alcohol-related 
Chronic Pancreatitis Alcoholic Controls 
Pub MAF Major Hetero Minor Major Hetero Minor 
ABO_rs8176746225 p.L266M 0.1528 80 12 3 73 10 0 
ABO_rs8176747226 p.G268A 0.0106 81 12 2 73 9 0 
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5.2.5 Next Generation Sequencing SNPs of Interest 
The key SNPs of Interest, which were shown to have statistically significant results between the 
groups, are presented in Table 23. SNP MGLL_rs116367069, did show significance with initial 
analysis, without correction factors, but has lost significance when reanalysed with χ2 using Yate’s 
correction factor.  A comparison is made of the OR by allele frequency for each of these significant 








Table 23 Next Generation Sequencing significant results from SNPs of Interest 
     Alcohol-related 
Chronic Pancreatitis Alcoholic Controls 
 
P values 
SNP  Chr,position  Amino Pub MAF Major Hetero Minor Major Hetero Minor Hetero Minor 
ACACB_rs17848835 12,109692053 C/T p.T2027I 0.0757 88 10 0 68 23 6 0.0006 0.0140 
ADH1C_rs1693482 4,100263965 C/T p.R272Q 0.2143 67 21 10 81 8 7 0.0111 0.6131 
ADH5_rs116010022 4,99997409 C/A Intron 0.0052 100 1 0 91 7 0 0.0332 - 
ADH6_rs4147545 4,100128753 T/C Intron 0.4307 39 39 13 47 37 3 0.1768 0.0326 
APOB_novel 2,21228282 A/G p.L3820L - 42 34 4 16 46 1 0.0012 0.3841 
APOB_rs72653066 2,21246382 C/G Intron 0.0042 89 7 0 90 0 0 0.0142 - 
APOC3_rs4520 11,116701535 T/C p.G34G 0.4030 4 56 40 9 67 21 0.1598 0.0058 
CES5A_rs7500040 16,55897519 G/A Intron 0.2742 50 14 8 46 13 1 0.4335 0.0395 
CES5A_rs200911306 16,55983724 C/T p.V45I 0.0002 27 15 3 22 3 0 0.0159 0.5479 
FABP1_rs2241883 2,88424066 T/C p.T94A 0.2232 41 30 15 53 26 5 0.0466 0.0303 
FABP3_rs11578034 1,31842153 C/T Intron 0.0172 97 1 0 86 8 0 0.0168 - 
FABP6_rs10056214 5,159665485 G/C Intron 0.1188 33 18 49 48 17 29 0.0133 0.0127 
IL1B_rs1143633 2,113590467 C/G Intron 0.3109 34 46 9 49 28 3 0.0034 0.1385 
LDLR_rs1003723 19,11224181 C/T Intron 0.2768 33 51 13 22 48 27 0.1107 0.0203 
LIPA_rs1051338 10,91007360 T/G p.T16P 0.2861 49 16 3 51 4 1 0.0111 0.6260 
LIPC_rs690 15,58834741 G/T p.V155V 0.4780 20 38 40 26 44 22 0.2373 0.0139 
LIPC_rs3751542 15,58856033 T/C Intron 0.3992 57 35 8 55 35 1 0.6610 0.0182 
LPL_novel 8,19809449 C/T p.N120S - 35 35 3 18 62 2 0.001 0.58 
MGLL_rs116367069 3,127411206 A/G Intron 0.0146 88 7 2 89 2 0 0.0592 0.4978 
PRSS1_rs6666 7,142460313 T/C p.D162D 0.3966 26 41 29 40 42 15 0.0484 0.0167 
PTPRR_rs10506608 12,71155380 A/G p.F166F 0.0475 79 16 2 86 7 0 0.0313 0.4976 
Column 3 – reference allele/allele change; Pub MAF – Published Minor allele frequency; Major – Homozygous for major allele; Hetero – Major and minor 








Table 24 Next Generation Sequencing SNPs of Interest odds ratio in ACP group compared to ACtrl  
 
SNP Amino OR Lower CI Upper CI p value 
ACACB_rs17848835 p.T2027I 4.094 1.965 8.530 0.002 
ADH1C_rs1693482 p.R272Q 0.489 0.279 0.858 0.013 
ADH5_rs116010022 Intron 7.444 0.907 61.080 0.051 
ADH6_rs4147545 Intron 0.591 0.373 0.935 0.025 
APOB_novel p.L3820L 1.729 1.045 2.860 0.033 
APOB_rs72653066 Intron 0.073 0.004 1.303 0.067 
APOC3_rs4520 p.G34G 0.603 0.400 0.910 0.016 
CES5A_rs7500040 Intron 0.543 0.277 1.065 0.076 
CES5A_rs200911306 p.V45I 0.210 0.059 0.743 0.016 
FABP1_rs2241883 p.T94A 0.509 0.314 0.826 0.006 
FABP3_rs11578034 Intron 8.667 1.073 69.981 0.043 
FABP6_rs10056214 Intron 0.481 0.321 0.721 <0.001 
IL1B_rs1143633 Intron 0.481 0.295 0.782 0.003 
LDLR_rs1003723 Intron 1.685 1.126 2.520 0.011 
LIPA_rs1051338 p.T16P 0.293 0.115 0.751 0.011 
LIPC_rs690 p.V155V 0.606 0.403 0.910 0.016 
LIPC_rs3751542 Intron 0.746 0.461 1.206 0.232 
LPL_novel p.N140S 1.725 1.070 2.780 0.025 
MGLL_rs116367069 Intron 0.185 0.040 0.846 0.030 
PRSS1_rs6666 p.D162D 0.554 0.369 0.832 0.004 
PTPRR_rs10506608 p.F166F 0.340 0.140 0.825 0.017 
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5.2.6 Biological Effects of SNPs of Interest 
The potential effect of the SNPs of Interest was evaluated using commonly used web based tools 
(http://sift.jcvi.org and http://genetics.bwh.harvard.edu/pph2/).  The data from these tools is 
presented in Table 25. 
Table 25 Analysis of predicted effects of the SNPs of Interest 
Predicted effects were assessed using SIFT and Polyphen web based tools. 
Gene Chr,position Amino SIFT Orthologues SIFT Homologues Polyphen 
ACACB_rs17848835 12,109692053 p.T2027I 0.22 TOLERATED 0.01 DAMAGING BENIGN 
ADH1C_rs1693482 4,100263965 p.R272Q 0.05 DAMAGING  0.11 BENIGN 
ADH5_rs116010022 4,99997409 Intron - - - 
ADH6_rs4147545 4,100128753 Intron - - - 
APOB_novel 2,21228282 p.L3820L TOLERATED   
APOB_rs72653066 2,21246382 Intron - - - 
APOC3_rs4520 11,116701535 p.G34G TOLERATED  1 
CES5A_rs7500040 16,55897519 Intron - - - 
CES5A_rs200911306 16,55983724 p.V45I TOLERATED  BENIGN 
FABP1_rs2241883 2,88424066 p.T94A 0.52 TOLERATED 0.35 TOLERATED 0.68 
FABP3_rs11578034 1,31842153 Intron - - - 
FABP6_rs10056214 5,159665485 Intron - - - 
IL1B_rs1143633 2,113590467 Intron - - - 
LDLR_rs1003723 19,11224181 Intron - - - 
LIPA_rs1051338 10,91007360 p.T16P 0.23 TOLERATED 0.10 TOLERATED 0.21 
LIPC_rs690 15,58834741 p.V155V TOLERATED  0.58 
LIPC_rs3751542 15,58856033 Intron - - - 
LPL_novel 8,19809449 p.N140S   BENIGN 
MGLL_rs116367069 3,127411206 Intron - - - 
PRSS1_rs6666 7,142460313 p.D162D TOLERATED  1 
PTPRR_rs10506608 12,71155380 p.F166F TOLERATED  1 
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5.2.7 Linkage Disequilibrium 
Linkage disequilibrium could not be calculated between the majority of the SNPs of Interest as they 
did not lie on the same chromosome. Among those SNPs that were lying on the same gene, then 
linkage analysis was undertaken as described in the methods. 
There was no linkage disequilibrium demonstrated between any of the SNPs of Interest (Table 26). 
5.2.8 Tagging SNPs 
A list of tagging SNPs associated with the 21 SNPs of Interest is available in Appendix 10.3. Fifteen 
tagging SNPs were also mapped by the NGS sequencing covering five of the SNPs of Interest 
(Table 27). The correlation between the pairs of SNPs was assessed from the available NGS data.  















Chronic Pancreatitis Alcoholic Controls 
Chr 1st SNP 2nd SNP  r2 D' r2 D' 
2 APOB_novel APOB_rs72653066 18100 0.8691 0.7624 0.1101 0.0767 
APOB_novel FABP1_rs2241883 67195784 0.0979 0.1993 0.0106 0.0235 
APOB_novel IL1B_rs1143633 92362185 0.0556 0.0409 0.0008 0.0029 
APOB_rs72653066 FABP1_rs22418831 67177684 0.2743 0.7194 0.0214 0.3913 
APOB_rs72653066 IL1B_rs1143633 92344085 0.0505 0.0174 0.0594 0.0001 
FABP1_rs2241883 IL1B_rs1143633 25166401 0.0754 0.1612 0.0036 0.0198 
4 ADH5_rs116010022 ADH6_rs4147545 135212 0.0253 0.1487 - 0.0019 
ADH5_rs116010022 ADH1C_rs1693482 266556 0.0366 0.3188 - 0.0238 
ADH6_rs4147545 ADH1C_rs1693482 131344 0.0045 0.2167 - 0.0034 
12 PTPRR_rs10506608 ACACB_rs17848835 38536673 0.1889 0.1900 0.0313 0.0262 







Table 27 Correlation of tagging SNPs within the Next Generation Sequencing data  
The SNPs of Interest were assessed for any tagging SNPs that had been identified and for which sequencing data was available from the Next Generation 
Sequencing results. 
Reference SNP Tagging SNPs r2 D' 
Actual correlation 
ACP ACtrl 
PTPRR_rs10506608 PTPRR_rs11178399 1 1 0.977 0.976 
LDLR_rs1003723 LDLR_rs12710260 1 1 0.912 0.716 
LDLR_rs688 0.889 0.976 0.364 0.225 
LDLR_rs5925 0.889 0.976 0.821 0.747 
IL1B_rs1143633 IL1B_rs1143643 0.971 1 0.857 0.759 
ADH1C_rs1693482 
 
ADH1C_rs1612735 1 1 0.670 0.426 
ADH1C_rs698 1 1 0.658 0.474 
ADH1C_rs1693471 1 1 0.692 0.636 
ADH1C_rs1789912 1 1 0.779 0.897 
ADH1C_rs1693425 1 1 0.716 0.720 
ADH1C_rs1693426 1 1 0.682 0.608 
ADH1C_rs1693431 1 1 0.690 0.500 
PRSS1_rs6666 PRSS1_rs6667 1 1 0.680 0.606 
PRSS1_rs4726576 1 1 0.618 0.561 
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5.2.9 Sensitivity Sub-analysis of Next Generation Sequencing Samples 
5.2.9.1 Quality control 
In cases where the initial NGS run was believed to be of poor quality (less than 90% converge at 6 
bases), then the samples were either re-run from the same Haloplex extraction, or if the quality of 
the Haloplex samples was called into question, the DNA was re-run from the start of the Haloplex 
phase and then re-run on the Ion Torrent™.  In those cases where the second run had good 
coverage, this run was used exclusively for analysis; in those run where there was also concern to 
the coverage of the second run of sequencing results, the first and second runs results were 
concatenated, and if the overall reads at the position of the previously identified SNPs was greater 
than 90% at x6 depth, the concatenated data was used, otherwise that patient was discarded 
(occurred in one ACtrl case).  When these “pure” datasets were compared with the “concatenated” 
data sets, there were significant differences in the number of SNP variant calls made (Table 28).  
Those samples that had poor coverage of more than 50% of the SNPs read in the dataset (less than 6 
reads per SNP) were removed from the analysis.  This included 10 samples (two ACP, eight ACtrl).  
There were no statistically difference in the results between the original and sub-analysis (Table 47). 
5.2.9.2 Alcoholic Liver Disease compared to Disease-free Alcoholic Controls 
Of the 101 original ACtrl samples run on NGS, only 91 had a clear diagnosis of ALD.  There was no 
statistical difference determined between the groups, but the numbers were very small in the 
disease free alcoholic control group (AHC). 
5.2.9.3 Control Blood Samples compared to Control Liver Samples  
Twelve of the control DNA samples were extracted from liver tissue using Qiagen kits, as opposed to 
MagNA Pure extracted samples from peripheral blood.  Differences in the number of SNPs called and 
overall coverage was analysed and no difference was demonstrated between either sample groups. 
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5.2.9.4 Disease Status According to History of Alcohol Consumption 
Sub-analysis was attempted to identify and compare heavy drinkers to lighter drinkers within the 
study groups (based on frequency of alcohol consumption).  However, over 50% of data were 
missing for both ACP and ACtrl groups due to different sample collection methods and difficulty in 
obtaining meaningful histories from patients. We had sufficient data to confirm that there was high 
alcohol consumption, but did not have information on the exact quantities of consumption, 
especially from the Birmingham liver samples. Therefore this sub-analysis could not be undertaken. 
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Table 28 Comparison on the frequency of call types between individual samples, or those where 
samples were concatenated from two runs 
 
 
Individual Samples Concatenated Samples 
 Mean calls SEM Mean calls SEM p value 
Not called 1033.60 56.31 1270.44 117.01 0.149 
No variant 2878.39 50.72 2642.13 101.16 0.109 
Heterozygous for variant 208.80 5.12 153.30 20.65 0.001 
Homozygous for variant 105.76 2.24 160.13 30.68 <0.001 
 
A sub-analysis of the whole dataset was performed excluding those patients who did not have a 
good enough quality score in their own right. The sensitivity analysis led to 6 of the SNPs no longer 
being of significance.  For most there was a minor change in the numbers, and changes in 
significance were likely due to the reduced number of reads.  However, in the case of 
IL1B_rs1143633, there was a significant shift in both OR and p value, suggesting this original 
difference may have been purely an artefact. The data are available in Appendix 10.2. 
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5.2.10 Internal Validation - Next Generation Sequencing compared with Genome-
wide Association Study 
Forty-six of the ACP samples were analysed by both the GWAS method and NGS.  A total of 219 SNPs 
were covered by both modalities, giving over 10,000 comparable SNPs.  Due to drop out of reads 
from some areas of the NGS results, there were 9300 points that were comparable, of which 8916 
were concordant.  This gave an overall accuracy of the dataset of 96%.  126 of the 219 SNPs analysis 
were 100% concordant.  Of the remaining 97 SNPs with some element of discordance, there was a 
range of 44% to 98%. 
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5.2.11 Next Generation Sequencing Validation with Sequenom (Stage 1) 
Of the initial batch of 203 samples, 170 were rerun to confirm the results using the Sequenom array.  
Details of the demographics of the samples used are presented in Table 31.  An example of the 













Figure 17 Example SNP genotype clusters on Sequenom for PTPRR_rs10506608 
Red and blue indicate called homozygotes, green indicates heterozygotes, and black is non-called 
(missing) genotypes.  This graph shows the distinct separation between the different groups. 
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5.2.12 Next Generation Sequencing Validation with Sequenom (Stage 2) 
The validation set were then run through the same Sequenom chip, using a second set of patient 
samples as described in Table 31.  Results are presented in Table 32 and concordance of samples is 
presented in Table 30. 
In addition to the ACP groups and ALD groups, 49 HC who had a history of alcohol excess with no 
evidence of ACP or ALD, were also sequenced with the Sequenom.  The results are presented in 
Table 33, in comparison with the combined ACP and ALD groups. 
An assessment was made of the correlation of SNPs read between the two sequencing modalities, 
comparing exact matches, those that had 50% discordance (on matching allele) and 100% 
(complete) discordance (neither allele matching); Table 29. 








discordant % Correlation % Discordant 
ACACB_rs17848835 147 18 19 89.09 22.62 
ADH1C_rs1693482 76 87 0 46.63 0 
ADH5_rs116010022 165 3 0 98.21 0 
ADH6_rs4147545 120 27 2 81.63 1.24 
APOB_rs72653066 157 0 12 100 12.77 
APOC3_rs4520 118 48 10 71.08 11.11 
CES5A_rs7500040 91 16 8 85.05 8.6 
FABP1_rs2241883 124 15 0 89.21 0 
FABP3_rs11578034 153 3 5 98.08 4.2 
FABP6_rs10056214 81 81 63 50 41.72 
IL1B_rs1143633 95 49 6 65.97 6.82 
LDLR_rs1003723 129 35 3 78.66 3 
LIPA_rs1051338 65 34 11 65.66 11 
LIPC_rs3751542 122 38 1 76.25 0.89 
LIPC_rs690 130 28 2 82.28 2 
MGLL_rs116367069 154 4 0 97.47 0 
PRSS1_rs6666 89 73 2 54.94 2.15 








Table 30 Comparison of additional validation step between using Sanger sequencing in comparison to Next Generation Sequencing and Sequenom 
results 
 
  Sanger results 
 Number that are 
discordant 
Agrees with NGS Agrees with Sequenom Agrees with neither Misread 
ACACB_rs17848835 18 6 (33%) 12 (67%) 0 0 
ADH1C_rs1693482 88 6 (7%) 6 (7%) 16 (18%) 60 (68%) 
ADH5_rs116010022 3 1 (33%) 2 (67%) 0 0 
FABP1_rs2241883 15 2 (13%) 13 (87%) 0 0 
FABP3_rs11578034 3 0 (0%) 3 (100%) 0 0 
IL1B_rs1143633 49 4 (8%) 44 (90%) 1 (2%) 0 
LIPA_rs1051338 34 3 (9%) 31 (91%) 0 0 
LIPC_rs690 28 4 (14%) 24 (86%) 0 0 
LIPC_rs3751542 37 4 (11%) 33 (89%) 0 0 
MGLL_rs116367069 4 1 (25%) 3 (75%) 0 0 
PRSS1_rs6666 71 4 (6%) 53 (75%) 1 (1%) 13 (18%) 









Table 31 Characterisation of the demographics of the samples used in the Sequenom validation  
 
 Stage 1 Stage 2 Combined 
ACP (114) ACtrl (87) ACP (80) ACtrl (85) ACP (194) ACtrl (172) 
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Table 32 Sequenom results from the Stage 1, Stage 2 and both stages combined comparing Alcohol-related Chronic Pancreatitis and Alcoholic Controls  
 
  













OR p value OR p value OR p value OR p value OR p value OR p value 
ACACB rs17848835 0.412 0.039 0.134 0.082 1.541 0.291 3.960 0.210 0.930 0.499 0.492 0.437 
ADH1C_rs1693482 0.604 0.214 0.833 0.865 0.655 0.844 0.320 - 0.667 0.035 0.715 0.344 
ADH5_rs116010022 0.215 0.194 1.125 - 0.640 0.448 - - 0.362 0.140 - - 
ADH6_rs4147545 1.435 0.386 3.428 0.093 0.740 0.470 1.535 0.228 0.967 0.970 1.989 0.033 
APOB rs72653066 4.684 0.040 - - 2.527 0.594 - - 3.106 0.066 - - 
APOC3_rs4520 0.994 0.945 1.743 0.405 1.213 0.434 0.632 0.464 1.058 0.660 0.994 0.930 
CES5A_rs7500040 0.419 0.080 0.522 0.078 0.198 0.174 0.783 0.321 0.369 0.044 0.660 0.045 
FABP1_rs2241883 0.620 0.159 0.745 0.454 1.407 0.292 0.977 0.790 0.882 0.779 0.854 0.477 
FABP3_rs11578034 0.845 0.123 - - 1.939 0.210 - - 0.637 0.657 - - 
FABP6_rs10056214 2.104 0.217 - - 1.381 0.407 - - 1.788 0.106 - - 
IL1B_rs1143633 0.718 0.648 0.659 0.119 1.035 0.774 0.912 0.907 0.873 0.654 0.802 0.269 
LDLR_rs1003723 0.879 0.609 0.635 0.282 1.048 0.781 0.690 0.221 0.961 0.872 0.658 0.106 
LIPA_rs1051338 1.793 0.058 1.141 0.810 0.676 0.089 0.413 0.067 1.033 0.775 0.649 0.275 
LIPC_rs3751542 0.576 0.043 0.933 0.761 0.676 0.313 1.087 0.822 0.616 0.027 1.071 0.914 
LIPC_rs690 0.789 0.153 1.284 0.535 0.893 0.591 0.957 0.984 0.859 0.546 1.107 0.689 
MGLL_rs116367069 1.775 0.347 2.278 0.241 1.589 0.300 - - 2.112 0.164 0.970 0.307 
PRSS1_rs6666 3.529 0.004 1.421 0.131 5.930 <0.001 2.534 0.011 4.432 <0.001 1.840 0.003 








Table 33 Combined results of Stage 1 and Stage 2 of Sequenom validation comparing allele frequencies between Alcohol-related Chronic Pancreatitis, 
Alcoholic Liver Disease and Alcoholic Healthy Controls 
 
    Allele frequency  ACP compared to ALD ACP compared to AHC ALD compared to AHC 
  Alleles ACP ALD AHC  OR p value OR p value OR p value 
ACACB rs17848835 C T 0.11 0.13 0.102   0.93 0.623 0.816 0.539 0.878 0.792 
ADH1C_rs1693482 C T 0.251 0.321 0.143   0.734 0.057 1.410 0.141 1.921 0.007 
ADH5_rs116010022 C A 0.008 0.021 0.01   0.362 0.126 0.944 0.961 2.605 0.359 
ADH6_rs4147545 A G 0.331 0.298 0.327   0.967 0.407 0.906 0.627 0.937 0.932 
APOB rs72653066 G C 0.025 0.008 0   3.106 0.081 - 0.087 - 0.327 
APOC3_rs4520 C T 0.262 0.25 0.224   1.058 0.833 1.409 0.264 1.331 0.330 
CES5A_rs7500040 G A 0.251 0.178 0.163   0.652 0.021 0.582 0.038 0.893 0.579 
FABP1_rs2241883 T C 0.29 0.267 0.316   0.882 0.46 1.135 0.600 1.286 0.295 
FABP3_rs11578034 C T 0.006 0.008 0   0.637 0.622 - 0.425 - 0.319 
FABP6_rs10056214 C G 0.083 0.054 0.056   1.788 0.084 1.314 0.564 0.735 0.532 
IL1B_rs1143633 G A 0.395 0.359 0.357   0.873 0.347 0.573 0.398 0.656 0.843 
LDLR_rs1003723 C T 0.406 0.444 0.52   0.961 0.297 0.637 0.053 0.663 0.230 
LIPA_rs1051338 A C 0.312 0.322 0.357   1.033 0.653 1.063 0.672 1.029 0.912 
LIPC_rs3751542 A G 0.285 0.34 0.245   0.616 0.098 1.211 0.531 1.965 0.082 
LIPC_rs690 G T 0.428 0.426 0.490   0.859 1 1.398 0.389 1.628 0.389 
MGLL_rs116367069 A G 0.058 0.035 0.051   2.187 0.045 0.761 0.636 0.360 0.039 
PRSS1_rs6666 T C 0.702 0.539 0.488   1.991 <0.001 3.063 <0.001 1.538 0.020 
PTPRR_rs10506608 A G 0.072 0.079 0.102   0.924 0.596 0.771 0.626 0.834 0.905 
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5.2.13 Next Generation Sequencing Haplotype Analysis 
The most consistent polymorphism throughout the NGS analysis was PRSS1_rs6666.  This SNP has 
been previously described, but is believed to be benign in nature and is common within both 
populations, therefore, it was felt it could in fact be a marker for a haplotype, which holds the 
disease causing polymorphism.  Therefore, all other SNPs on Chromosome 7, where PRSS1_rs6666 
lies, were examined to look at their association with PRSS1_rs6666 using χ2 in both the disease and 
control populations.  Those SNPs which showed significance at the <0.05 level were included in the 
haplotype analysis.  The OR was calculated for the common haplotypes in both the disease group 
and the control group.  If there was no effect on the model exhibited by the presence of a SNP, it 
was dropped from the haplotype and the new, smaller haplotype were analysed.  This was done 
sequentially until the most significant haplotype was formed.  The results of this analysis are shown 
in Table 34. No haplotype was produced that gave better OR than simply using the polymorphism 
PRSS1_rs6666 as a factor.  
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Table 34 Comparison of different haplotypes and the association with Alcohol-related Chronic 
Pancreatitis in relation to Alcoholic Controls 
 
CFTR PRSS1     
rs1042077 rs1800136 rs6666 rs201550522     
p.T854T p.Q1463Q p.D162D p.K170E OR Upper CI Lower CI p value 
T G T A 0.516 0.305 0.873 0.01 
T G T G 1.942 0.178 21.159 NS 
T G C A 1.947 1.147 3.306 0.013 
T G C G 2.051 0.073 57.828 NS 
T A T A 1.177 0.256 5.411 NS 
T A T G -   NS 
T A C A 1.273 0.316 5.127 NS 
T A C G -   NS 
G G T A 0.728 0.399 1.329 NS 
G G T G 0.281 0.016 4.852 NS 
G G C A 1.294 0.624 2.684 NS 
G G C G 0.075 0.000 24.121 NS 
G A T A 1.110 0.290 4.251 NS 
G A T G -   NS 
G A C A 1.299 0.380 4.441 NS 
G A C G -   NS 
        
T G T  0.542 0.323 0.911 0.020 
T G C  1.969 1.163 3.333 0.013 
T A T  1.373 0.313 6.028 NS 
T A C  1.307 0.327 5.226 NS 
G G T  0.688 0.381 1.243 NS 
G G C  1.163 0.571 2.368 NS 
G A T  1.139 0.300 4.332 NS 
G A C  1.325 0.389 4.510 NS 
        
T  T  0.581 0.351 0.961 0.035 
T  C  1.963 1.179 3.269 0.009 
G  T  0.733 0.420 1.280 NS 
G  C  1.217 0.645 2.297 NS 
        
  T  0.554 0.369 0.832 0.004 
  C  1.804 1.202 2.707 0.004 
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 Discussion 5.3
5.3.1 Previous Identified Variants 
5.3.1.1 Protease, Serine, 1 (Trypsin 1) 
The most well-known disease causing variants within PRSS1 are autosomal dominant in expression, 
and therefore would not be expected to be represented within this population of patients with no 
familial history of pancreatic disease.  Initially results of the NGS work suggested some patients were 
exhibiting the p.A16V polymorphism, but on further investigation this was shown to be a misread.  
This is not unexpected within the trypsin coding genes as there are many genetic similarities 
between them (Figure 1) which may lead to either cleavage of the wrong amplicons initially or 
misalignment of amplicons within the Ion Torrent™ leading to apparent polymorphisms.  In the case 
of p.A16V, this variant mirrors the natural variation within PRSS3, leading to misreading of this 
region in a few of the samples. 
The previously reported, but believed to not be disease related, polymorphisms p.D162D and 
p.N264N will be addressed in Chapter 6.3.2.8.1. 
5.3.1.2 Serine Protease Inhibitor Kazal Type I 
p.N34S SPINK1 was first identified as an associated factor in 2000 at which time it was thought to be 
a clearly causative factor with 23% of tested CP patients having the variant, and none of the 
controls.45  However, subsequent studies have shown the variant could be present in healthy 
controls, but the frequency was still higher in patients with CP (most commonly those who 
developed idiopathic CP from childhood).  Therefore it is unsurprising that both ACP and ACtrl 
groups showed the presence of p.N34S, and although the prevalence was higher in the ACP group, 
this did not reach significance in the small sample size used. 
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5.3.1.3 Cystic Fibrosis Transmembrane Conductance Regulator 
There has been a previously reported risk haplotype within CFTR associated with chronic 
pancreatitis, which includes two of the significant CFTR SNPS identified. The haplotypes were 
imputed using three SNPs in the haplotype (CFTR_rs213950, CFTR_rs1042077 and 
CFTR_rs1800136).186 The previously described CFTR haplotype was reconfirmed by the SNP array 
data (Table 18).186  Both these populations used a mix of ACP and ICP patients compared to the 
normal population. When we examined the NGS results of an ACP population compared to an ACtrl 
group for these polymorphisms, no difference was shown (Table 34).  It may be that this association 
is only exhibited within the ICP group, but this theory will need to be tested in further in an ICP 
population.  
In all cases the haplotype analysis has been carried out using software based on probabilistic models 
to create the likely haplotypes, therefore it is likely that some haplotypes will be over, or under 
called in frequency.331  The best way to create haplotypes is using points that can be sequencing on 
the same strand with long distance sequencing, but this was not possible within our study 
populations and therefore imputation was the only method of analysis available. 
The Whitcomb group recently reported that the coinheritance of CFTR p.R75Q and SPINK1 p.N34S 
variants is significantly higher in patients with idiopathic chronic pancreatitis than in controls (8.75% 
vs. 0.38%).181 In our population, none of the participants were found to have both the p.R75Q and 
p.N34S variation in either subgroup.  
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5.3.2 Significant SNPs identified in the NGS analysis 
5.3.2.1 Alcohol Dehydrogenase 
The polymorphism, ADH1C_rs1693482 (p.R272Q), has been frequently described in the literature in 
relation to alcohol dependence, and has also been associated with other alcohol risk diseases such 
as gastric cancer.202,332 
It has been shown that the duodenal and jejunal activity of ADH1C is reduced in the presence of the 
ADH1C_rs1693482.6 
Many different populations have shown to have a strong association with this polymorphism and 
alcoholism.123,127 Analysis of a Korean GWAS has showed an association of ADH1C_rs1693482 to 
alcohol dependence but it was felt that this association might be driven through linkage 
disequilibrium with ADH1B_rs1229984 (p.R48H), rather than be a pathogenic polymorphism in its 
own right.123 Similar results have been reported in a British and Irish population although the level of 
linkage disequilibrium was not as strong.202 
Some other studies have been less sure of the AD risk of ADH1C_rs1693482 in Europeans.206,333,334 
However it is felt that there is some independent effect of both ADH1B and ADH1C on the drinking 
habits of European populations.334,335 
One paper has suggested that there is also an association of this polymorphism with the 
development of ALD in combination with ADH1C_rs698 (p.I350V) and ADH1B_rs1229984 
(p.R48H).336 p.R272Q and p.I350V were shown to be in almost complete linkage disequilibrium 
(Appendix 10.4, Table 48). The 272Q/350V allele increased the risk of alcohol dependence in the 
homozygous form (OR 1.78, 1.11-2.85; p = 0.016). When ADH1B 48H was combined with the wild 
type ADH1C R272/I350 allele, it was protective against ALD (OR 0.37, 0.16-0.85; p = 0.019). 
The significance of ADH1C_rs1693482 was maintained following the validation stage, but only 
between the ALD group and the AHC (OR 4.44, 1.71-11.52); ACP and AHC approached but did not 
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reach significance.  Both these finding are supported by the previous findings in relation to alcohol 
dependence which is likely to be the genuine significance from this polymorphism. 
A meta-analysis of 6796 cases and 6938 controls including samples of Asian, European, African, and 
Native American origins showed strong evidence of association between ADH1C_rs698 (p.I350V) and 
alcohol dependence (OR 1.51, 1.31-1.73; p = 1 × 10-8)337 with Asian population demonstrating a 
stronger association (OR 2.14, 1.89-2.43; p = 4 × 10-33). The findings support that ADH1C_rs698 may 
increase the risk of AD as well as alcohol-related cirrhosis in pooled populations, with the most 
consistent effects in Asians.337  There was no difference demonstrated between ACP and ACtrl in our 
population (Table 33). 
The common polymorphism ADH1B*2 has been well described to be heavily associated with alcohol 
dependence.123 As all patients used in this analysis had a history of alcohol dependence, there was 
no association shown between the groups (8/100 vs. 4/96). 
It has been shown that ADH1C_rs698 (p.I350V) substitution is in linkage disequilibrium with the 
ADH1B_rs1229984 (p.R48H) substitution, and that the ADH1B_rs1229984 polymorphism is 
responsible for differences in ethanol metabolism and alcoholism among Taiwanese populations, 
with the ADH1C_rs698 variant showing association only because of linkage disequilibrium.204 
ADH5_rs116010022 is a previously identified intronic SNP, which has not been reported as being 
involved in any disease processes before.  This SNP has been shown to be in complete linkage 
disequilibrium with 6 other intronic SNPs (Appendix 10.4, Table 48), none of which have been 
identified in the literature. 
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5.3.2.2 Lipase and Lipoprotein 
The SNP LDLR_rs1003723 lies in the intronic region.  It has been reported in two different studies by 
the same group to have an association with an increased risk of bile duct cancer and also has been 
show to raise total cholesterol (p = 0.002) and LDL (p = 0.01).338,339 
There are several tagging SNPs associated with LDLR_rs1003723, two of which lie within coding 
regions of LDLR, but both are synonymous variations. 
The closely associated tagging SNP, LDLR_rs688, is non-synonymous and codes for p.N591N.  In 
previous work, despite its non-synonymous nature, it has been shown to exhibit functional changes 
to LDLR, leading to increased plasma total and LDL cholesterol.340  This is thought to be due to an 
association with increased exon 12 alternative splicing.341,342 
The associated SNP LDLR_rs5925 leads to the synonymous variant, p.V653V.  A meta-analysis of 
studies assessing the role of LDLR in cerebral infarction showed that LDLR_rs5925 had been shown in 
three studies to be associated with an increased risk.342 
LDLR_rs2738446 and LDLR_rs2738450 are both closely linked intronic SNPs, which have been 
examined in relation to modification of stroke presentation. In one study, a significant overall 
association between small vessel occlusion and the CC genotype was observed when compared to 
non-small vessel occlusion (OR 2.0, 1.08-3.70; p = 0.025).343   
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LIPA_rs1051338 lies within exon 2 and causes an amino acid change (p.T16P).  It has previously been 
reported in a study related to obesity that, after adjustments for the effect of age, sex, diabetes, and 
medication, the C allele of SNP LIPA_rs1051338 was associated with lower blood pressure (systolic p 
= 0.004; diastolic p = 0.006).344  It has also been shown to cause a significant reduction in 24S-
hydroxycholesterol/cholesterol in one study.345 
A previous GWAS examining coronary artery disease showed a tagging SNP, LIPA_rs1412444 was 
strongly associated with expression of the LIPA transcript itself but was not associated with 
hyperlipidemia.346 This was supported by a separate GWAS.347 
Another tagging SNP, LIPA_rs2246942, within the LIPA gene was associated with an increased risk of 
coronary heart disease (cases vs. HC: OR 1.63 (1.02-2.60), p = 0.04).348 
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LIPC_rs690 is a  common synonymous SNP (p.V155V), which is only reported in one previous 
publication in relation to cleft lip, where it was found to have a weak association with the 
development of both cleft palate and dental abnormalities.  However, when multiple testing is 
taking into account, the significance is lost.349  There have been no recognised tagging SNPs in 
association with this variation. 
MGLL_rs116367069 is a SNP that codes for an intronic region of monoglyceride lipase.  This SNP has 
not been noted in the literature, nor does it have any associated tagging SNPs.  
Following the validation process, MGLL was shown to be significantly different between ACP and 
ALD groups (OR 2.19, 0.01-4.64) and ALD and AHC groups (OR 0.38, 0.15-0.98). There was no 
difference between the ACP and AHC suggesting that the association may be with ALD rather than 
with ACP.  
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5.3.2.3 Trypsin 
5.3.2.3.1 PRSS1_rs6666 
This SNP codes for a common synonymous variant in PRSS1_rs666 (p.D162D).164 Previous reports on 
this SNP are listed in Table 35.  The normally reported allele frequencies for different populations are 
given in Table 36.  It is reported to be in complete linkage disequilibrium with PRSS1_rs6667 
(p.N246N).168 
The majority of reports have suggested that there is no difference between with ACP or ICP 
populations.350,351 However, there have been two studies (one published and one in abstract) 
suggesting there may be a relationship. One small study showed that the frequency of the C allele 
was higher in ACP group compared to HC (OR 8.44, 2.39-29.79).352  The study presented in abstract 
also suggested that the C allele was in higher frequency in the ACP and ICP patients compared to 
healthy controls.353 
These two studies support our findings produced by the NGS and the validation with Sequenom of 
PRSS1_rs6666.352,353  Of note, these studies are both carried out within European populations. 
Table36 shows that there is a great variation in the frequency of this SNP within different 
populations, and this may account for the absence of a difference being identified in some other 
studies. 
As this is a synonymous SNP, there is no clear reason why it could be causative, therefore it was 
postulated that it may be a marker for a disease haplotype.  Using the technique described in the 
methods, several potential haplotypes were devised using other SNP identified within chromosome 
7, however, the attrition of other potential SNPs did not increase the OR or the probity of the effect 
of PRSS1_rs6666.  As only the exons of PRSS1 and CFTR were specifically sequenced as part of NGS, 
we cannot rule out other significant variants within non-coding regions, which could be important in 








Table 35 Previous published reports of PRSS1_rs6666 
Paper Year Country 
Nomenclature 
used by paper 
Population group Frequency of polymorphism 
Gorry49 1997 USA Asp162 HP families Not stated 
Teich354 1998 Germany nt 133807 (C/T) HP vs. relatives of HP  7/7 (100%) vs. 3/14 (21%) 
Ferec164 1999 France D162D HP families  No comment  
Nishimori355 1999 Japan 162Asp HP families No comment 
*Gomez Lira356 2001 Italy 133807 C/T  NHNST 13/50 (26%) NHNST 
O’Reilly352 2001 UK C133807T ACP vs. HC 9/29 (31%) vs. 19/24 (79%); p < 0.001 
Tautermann168 2001 Germany D162D ICP 34/109 (31%) 
Chandak357 2002 India D162D TCP vs. HC 58/68 (85%) vs. 90/100 (90%); p = 0.5 
*Patuzzo357 2002 Italy 133807 C/T NHNST 21/50 (24%) 
Guarner353 2003 Spain D162D 5.3.2.3.2 44 ACP vs. 22 ICP vs. 34 HC 23/44 (52%) vs. 12/22 (55%) vs. 28/34 (82%) 
Bernardino351 2003 Brazil N264N (64 ACP, 16 ICP, 2 HP) vs. 200 HC 47/164 (29%) vs. 85/300 (28%) p = 1 
Chandak358 2004 India 162Asp (37 HP, 120 ICP, 41 ACP) vs. 290 HC 88% vs. 90% 
Tzetis350 2007 Greece p.D162D ICP/RAP vs. HC 9/25 (36%) vs. 10/25 (40%); p = 1 
Liu359 2009 China 133807 C/T (22 ACP, 16 ICP, 30 TG, 35 HP, 150 GS) 27/253 (11%) 
Johnstone 2014 UK p.D162D ACP vs. ALD vs. AHC 105/352 (30%) vs. 155/342 (45%) vs. 54/102 
(53%) 
NHNST – Neonatal Hypertrypsinaemia with normal sweat chloride tests.  
*Gomez Lira 2001 and Patuzzo 2002 may be using the same population. 
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Table 36 MAF of PRSS1_rs6666 in different populations 
Region C T 
Africa 0.41 0.59 
American 0.53 0.47 
Asian 
Han Chinese, Beijing 




























All 0.4 0.6 
Data taken from 1000 genomes database 4th Nov 2014. 
The T allele polymorphism is reported to have a lower frequency in Europeans (0.4), whereas it is 
more frequent in subjects of Asian origin (0.75) or subjects from those from India (0.9).360 
To assess what the functional significance of rs666 may be, we examined codon usage, which 
showed no bias to either codon, there was no splice site at the region of the variant and in a search 
for micro RNA that bound to PRSS1, only has-miR-185 was shown to be associated.  There was no 
association with the sequence in exon 4.  When assessing for enhancer binding, one potential 
transcription factor that would bind preferentially to the T variant was identified.  This gave an 18% 
increase in function, but this is unlikely to be the main promoter of this gene.  
5.3.2.3.2.1 PRSS1_rs6667 
The most common tagging SNP is p.N246N, which has been reported alongside PRSS1_rs6666 in 
most papers, the only exception being Bernardino et al.351  In this paper there was no difference in 
frequency of PRSS1_rs6667 in either CP or control groups in a Brazilian population. 
In this study there was no significance found in PRSS1_rs6667.  Where PRSS1_rs66667 was 
compared to PRSS1_rs6666 there was only between a 60-68% correlation in reads, accounting for 
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the difference in significance. The difference in reads may be related to the difficultly in sequencing 
the trypsin regions, due to the multiple isoforms, which can lead to misalignment and misreading of 
these readings as demonstrated in Figure 1. 
PRSS1_rs6667 was examined in a similar way to assess for codon bias, splice sites, micro RNA and 
binding enhancers, but nothing of significance was found. 
Other tagging SNPs are reported in Appendix 10.4, Table 48.  None lie within exonic regions or have 
been previously reported on in the literature. 
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5.3.3 Quality of Next Generation Sequencing Results 
Sub-analysis was performed removing the ten samples that had insufficient coverage to produce 
50% on the SNPs analysed, and this had no effect on outcome.  This cut off may have been fairly 
conservative, 28 samples lay beneath 70% covered and 69 samples had less than 90% coverage, but 
due to the small sample size used, such a large reduction in number would be likely to remove any 
true significance from the results. 
Quality control of the Next Generation Sequencing results showed that results were less reliable 
from samples where the results from two chips had been concatenated and including these results 
may have given false positive readings.  These samples were excluded from sub-analysis, and 
showed better consistency of results (Table 47).  As a consequence, the sub-analysis has reduced 
down the number of samples that can be analysed, and therefore some samples may lose 
significance simply due to the reduced numbers. 
5.3.3.1 Calling of Variants 
The appropriate calling of variants by the Ion Torrent™ first required correct alignment of the 
amplicons to the reference structure, and also requires the appropriate criteria to identify whether 
there is truly a variant at this point, or simply a misread in the DNA.  As with all tests there is a 
balance between sensitivity and the specificity that must be achieved.  We selected a custom 
designed approach to both the alignment and the SNP calls to try and optimise the sensitivity and 
specificity of the test.  The identification of false reads is less common in the case of germline 
mutations, and a fairly high threshold (>25% calls) is required to ensure this.  It is more probable that 
some true variants may be missed due to exclusion of individuals with any reads under 25%.  There 
may also be miscalling between homozygous and heterozygous calls, which lie at a cut-off of above 
and below 75% of all calls, respectively.  This system may lead to bias towards the calling of SNPs, 
rather than the normal variant.361 
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5.3.3.2 Nature of Variants 
The most commonly recognised reading errors, specific to the Ion Torrent™ system are 
homopolymers.362  Due to the nature of the reading system the number of bases in homopolymers is 
calculated by the amplitude of the pH change, which has more variability with the more consecutive 
reads at this point.  As a result of this, when the potential SNPs of Interest were examined, many 
were discarded as they were related to a long homopolymer, and all variant reads appeared to be in 
relation to this.  As a result any variants either directly related to the homopolymers or which 
immediately juxtapose a homopolymer, are likely to be assumed to be this common read error. 
5.3.3.3 Phenotypic Significance of Variants 
To assess the potential phenotypic sequelae of some of the variants expresses, different online tools 
(SIFT and Polyphen) were used to assess the potential likelihood of an effect by looking at 
homologues and orthologues of the sequence.363   These tools are only useful in the case of non-
synonymous SNPs, and only give a predication related to other species, or similar polymorphism 
identified within the same species, which may not be related to the genuine significance of the SNP 
in question. 
5.3.3.4 Tagging SNPs 
The use of Tagging SNPs to identify the true area of genetic interest is a common approach, and 
relies on close LD between the SNPs selected.364  In the NGS work, there were some unexpected 
inconsistencies between the calls of pairs of tagging SNPs, making the validity of this difficult to 
assess.  
5.3.3.5 Next Generation Sequencing Validation 
The NGS data was independently validated in part by cross over with the GWAS data and Sequenom 
sequencing and with Sanger sequencing in the case of p.A16V.  There were some SNPs with poor 
concordance between the different modalities. The individual SNP analysis performed as part of the 
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GWAS and Sequenom sequencing, exhibit similar sequencing techniques, and this may explain 
consistent errors between different modalities.  The NGS uses different technology, but relies on 
good use of alignment and calling tools to produce an accurate result.  
Due to the discrepancies in some SNPs between the NGS and Sequenom validation data, further 
Sanger sequencing was undertaken as a second stage of validation, to determine which of the 
modalities are more consistent, or whether any differences are just natural variation in the reads 
between different modalities.  This showed that for the most part that the Sequenom provided more 
reliable reads than the analysis of the NGS data.  This may have been in part due to the analysis 
pipeline used to interpret the ion torrent data that may have been due to difficulties with alignment 
or with call thresholds in relation to the interpretation of the data. 
These steps of validation have allowed us to hone the analysis to identify a few key SNPs that have 
been replicated in two populations with more than one modality of analysis.  Further work can be 
done to reassess the original NGS output to identify if there are other key SNPs that may be been 
overlooked with the original analysis. In addition the key SNPs, which have been shown to be 
significant in this work need to be further, assess in similar and different populations to confirm the 
validity of results.  Once a clear association is established, further research will need to be conducted 
to confirm what the physiological process is that leads to disease predisposition.  
5.3.4 Statistical Analysis 
Due to the large amount of data create by the Next Generation Sequencing, there is potential risk of 
identifying false positive results due to multiple testing.  In larger studies such as GWAS, there is 
commonly alteration to the p value using Bonferroni correction.365 However it was not felt 
appropriate in this study due to the small sample size in the discovery set, and the specific selection 
of the genetic areas for study. 
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6 Chapter 6: Variable Nuculeotide Tandam Repeat in Carboxyl-
ester Lipase  
FAEEs are a product of the non-oxidative metabolism of ethanol and fatty acids; carboxyl-ester 
lipase (CEL) is a key enzyme involved in this metabolic pathway.29,366,367 
There is a 33bp Variable Number Tandem Repeat (VNTR) in exon 11 (the final exon) of CEL.368 This 
VNTR sits in a functional domain of the gene and is most commonly represented by a 16–repeat 
variant, but between 3 and 23 repeats have been reported, with segment duplication also present in 
up to 5% of individuals.369  
Due to the lack of consistency in the literature, we sought to further investigate potential 
associations between this polymorphism and ACP using a combined strategy with both a matched 
control cohort of alcoholic liver disease patients and a group of healthy controls from a British 
population. 
 Materials and Methods 6.1
6.1.1 Patients 
6.1.1.1 Chronic Pancreatitis 
Participants included in the CEL study had to meet the following criteria 
- symptoms typical of chronic pancreatitis 
- alcohol excess of greater than 35u/wk (equivalent of >40g/day)43 for at least 5 years 
- radiological evidence of chronic pancreatitis (CT/MRI/EUS) 
- cell pellet available for DNA extraction 
- patient consented to take part in research projects 
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6.1.1.2 Alcoholic Liver Disease 
Participants included in the CEL study had to meet the following criteria 
- no personal or family history of chronic pancreatitis 
- reviewed by the hepatology clinic with a diagnosis of alcoholic liver disease or having 
undergone a liver transplant for alcoholic cirrhosis 
- alcohol excess of greater than 35u/wk (equivalent of >40g/day)43 for at least 5 years 
- radiological evidence of a morphologically normal pancreatitis (CT/MRI/EUS) 
- cell pellet available for DNA extraction 
- patient consented to take part in research projects 
6.1.1.3 Healthy Controls 
Participants included in the CEL study had to meet the following criteria 
- no personal or family history of chronic pancreatitis 
- no personal or family history of alcoholic liver disease 
- no history of alcohol excess 
- DNA available 
- patient consented to take part in research projects 
 
These criteria parallel the type of patient samples used for the NGS project, but the actual groups 
used had some overlap, were not the same.  
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6.1.2 Association of Carboxyl-Ester Lipase Variable Nucleotide Tandem Repeat  
6.1.2.1 Polymerase Chain Reaction  
PCR was performed using minor modifications on methodology previously described by Torsvik et 
al.369 A PCR reaction volume of 10µl was used, containing 1 x GC buffer I, 0.34mM dNTPs, 0.2U LaTaq 
Polymerase (TaKaRa, Japan RR02AG), 1.0M betaine (Sigma-Aldrich, USA), 0.2µM CEL_VNTR_F primer 
(5’-ACCGACCAGGAGGCCACCC-3’), 0.2µM CEL-VNTR_R2 primer (5’-CCTGGGGTCCCACTCTTGT-3’; 
labelled with HEX) and 20ng template DNA.  The PCR cycle was 94oC for 1min 30s; then 94oC for 30s, 
61oC for 30s and 72oC for 1min 10s for 40 cycles, followed by 72oC for 5min, and cooling to 4oC. 
6.1.2.2 Fragment Analysis 
The PCR product (2μl) was mixed with 10 μl of Hi-Di™ Formamide and 0.5 μl GeneScan™ 1000 ROX 
Size Standard (both Life Technologies, Paisley) heated at 95oC for 2 min and snap chilled on ice prior 
to loading on a 3130 Genetic Analyser (Life Technologies, Paisley).  Electrophoretic separation 
utilised a 36cm capillary array and POP7 polymer.  The GeneMapper software v2.0 (Life 
Technologies, Paisley) was used to analyse the detected peaks. 
6.1.2.3 Statistical Analysis 
Haplotypes were subdivided into short (S), normal (N) or long (L) VNTR alleles; the most common 
number of repeats (16) was classified as normal, those with less than 16 repeats as short, and those 
with more than 16, as long.219  Data were presented using medians (interquartile range).  Differences 
between cohorts were examined using χ2 or Fisher’s exact test for categorical data and Mann-
Whitney-U for continuous data (SPSS 20.0, Chicago, Illinois). 
To test whether there was selection for or against homozygotes and whether populations were 
representative, Hardy Weinberg equilibrium was used (p2 + 2pq + q2 = 1). This was tested using the χ2 
test of expected numbers of homozygote and heterozygote based on allele frequency, taking the 16-
repeat VNTR as the major allelotype (p) and any variation from this as the minor allelotype (q).
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 Results  6.2
In total 284 samples were analysed, 102 ACP, 91 ALD, and 91 HC: median age ACP 42 (37-49) years, 
ALD 57 years (50-63; p < 0.001).  Male distribution between the groups was 86 ACP (84%), 60 ALD 
(66%) and 36 HC (40%; Table 37). 
Results were assessed using both gel electrophoresis (Figure 19) and capillary electrophoresis 
(Figure 20). 
Data on individual allele frequencies by group are presented in Table 38.  The overall frequency of 
the normal, 16-repeat allele was statistically different between ACP (56%) and ALD (67%; p = 0.020).  
There was no significant difference between ACP and the HC (58%) groups (p = 0.729) and the 
difference between ALD and the HC groups tended towards, but did not reach statistical significance 
(p = 0.062).  The long allele was more common in patients with ACP (6%) than ALD (2%; p = 0.036), 
but there was no significant difference in either group from HC (4%; p > 0.1). 
Genotypes of patients by cohort group are presented in Table 39.  Again there was a significant 
difference between the number of individuals homozygous for the normal 16-repeat (NN) between 
ACP (33%) and ALD (47%; p = 0.034).  This difference was upheld between the ALD and HC (33%) 
groups (p = 0.049) but not between ACP and HC (p = 0.928).  There was also a greater representation 
of NL genotype in the ACP patients (9%) compared to both HC (2%) and ALD patients (0%; ACP vs. 
ALD, p = 0.004). Duplicates of the CEL VNTR were identified in 8 (3%) patients with no variation 
between groups. 
The level of selection of the different groups for or against the normal allele was tested using the 
Hardy-Weinberg equation.  For all groups, there was no selection for or against homozygotes.  
There was no significant difference between the distribution of alleles between males and females 
(S, 36% vs. 37%; N, 60% vs. 62%; L, 5% vs. 3%; p>0.1).  
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Age (years)     Median (range) 43 (20-72) 57 (34-80) 
Sex                   Male 





Smoking          Never 
                         Former 
                         Current 









Alcohol            Former 





Diabetes         Yes 
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Figure 18 Electrophoresis gel showing CEL PCR product for different combinations of Variable 
Tandem Repeats 
Different samples are represented: NN, homozygous for the normal 16 repeat at 617bp; SN, 
heterozygous for normal (16 repeats) and the shorter 10, 14 or 15 repeat VNTR; and NL, 
heterozygous for the normal 16-repeat and the longer 17 repeat. 
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Figure 19 Capillary electrophoresis output for a) short/normal and b) homozygous normal VNTR  
Red -ROX1000 ladder; Blue/green - marked PCR product showing a double peak at 518bp (13 
repeats) and 617bp (16 repeats) in trace a, and only a single peak at 617bp for trace b. 
  
a)        262   293 317                        439                    557                  692 
b)        262   293 317                       439                           557                      692 
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Table 38 Total allele frequencies of the CEL VNTR by cohort 
 
Number of VNTR repeats ACP (%) ALD (%) HC (%) ACP vs. ALD p value 
7 2 (1.0) 0 (0) 0 (0) 0.501 
10 0 (0) 1 (0.5) 0 (0) 0.472 
11 1 (0.5) 0 (0) 0 (0) 1.000 
12 8 (3.9) 2 (1.1) 1 (0.5) 0.110 
13 12 (5.8) 8 (4.3) 14 (7.6) 0.508 
14 29 (14.0) 19 (10.3) 29 (15.8) 0.260 
15 28 (13.5) 28 (15.1) 27 (14.7) 0.650 
16 115 (55.6) 124 (67.0) 106 (57.6) 0.020 
17 10 (4.8) 3 (1.6) 7 (3.8) 0.094 
18 2 (1.0) 0 (0) 0 (0) 0.501 
Total 207 185 184  
p value was calculated using χ2 or Fisher’s exact test as appropriate.  
p < 0.05 was considered significant and is highlighted in bold. 
 
Table 39 Frequency of genotypes by groups of VNTR repeats 
 
Genotypes ACP (%) ALD (%) HC (%) ACP vs. ALD p value 
SS 18 (17.6) 8 (8.8) 11 (12.1) 0.072 
SN 37 (36.3) 35 (38.5) 41 (45.0) 0.754 
SSN 2 (2.0) 2 (2.2) 2 (2.2) 0.908 
SL 2 (2.0) 2 (2.2) 4 (4.4) 0.908 
NN 33 (32.6) 43 (47.3) 30 (33.0) 0.034 
SNL 1 (1.0) 1 (1.1) 0 (0)  0.935 
NL 9 (8.8) 0 (0) 3 (3.3) 0.004 
LL 0 (0) 0 (0) 0 (0) 1.000 
Total 102 91 91  
S – short (15 repeats or fewer); N – normal (16 repeats); L – long (17 or 18 repeats) 
p value was calculated using χ2 or Fisher’s exact test as appropriate.  
p < 0.05 was considered significant and is highlighted in bold. 
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 Discussion 6.3
This work corroborates the original findings of a Japanese study, which reported a reduced number 
of homozygous normal (16-repeat, NN) genotype in ACP populations and an increased frequency of 
NL genotype as compared to a non-pancreatic disease alcoholic population.219 This study did not 
establish an association of VNTR length with ACP compared to healthy controls, consistent with the 
subsequent European study.41  Therefore, although the results of the two original studies appear to 
be conflicting, it has been shown the difference in results could be explained by the difference in the 
control groups selected rather than any difference in ethnicity or other confounding factor. 
In this study, ALD patients were exclusively used rather than individuals defined as simply alcoholic 
without pancreatitis.  This was due to the availability of individuals; those individuals who attended 
hospital with alcohol dependence normally did so as they had some pathological process, which in 
most cases was either liver disease or pancreatic disease.  The majority of individuals presenting to 
hospital with problems related to alcohol have either liver or pancreatic disease. The alcoholic 
controls used by Miyasaka et al were only expressly stated as being free from pancreatic disease; 
liver disease can be assumed but was not mentioned.219  Therefore, a difference in distribution 
between VNTR length in ALD and other groups could have been the true effect seen in the original 
Japanese paper, but the association was missed due to lack of classification of the ALD population. 
Ragvin et al did not use any individuals with a history of alcohol excess, other than those with 
confirmed ACP.41 The lack of any association with length of VNTR is therefore consistent with the 
hypothesis that the true difference in VNTR length is associated with ALD.  
The present study includes an ALD group with VNTR length in Hardy Weinberg equilibrium, but with 
NN group over-represented compared to other groups (ACP or HC).  
There is ambiguity in relation to the association of ACP and ALD.  It has been reported that clinical 
ACP and ALD occur concurrently in around 16-20% of ACP/ALD cases, but the prevalence may be 
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higher at a histological level.140,370,371 However it is generally agreed that there is some unknown 
factor(s) that predispose individuals to one or other disease process.139,144  We appreciate there is a 
risk that members of either ALD group or the ACP group could subsequently develop the opposite 
disease process.  The median age of patient within the ALD group was significantly higher than those 
with ACP, reducing the possibility of including individuals at high risk of ACP in the ALD group. The 
difference in age and gender distribution is typical of other studies.137,141 
Further work needs to be done on how CEL variants may protect those with problems of alcohol 
abuse from ALD. 
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7 Chapter 7: Overall Discussion 
 Patients 7.1
7.1.1 Definition of Alcohol Excess 
There is no clear consensus as to how much alcohol is required to classify a patient as having alcohol 
induced chronic pancreatitis.  Due to the difficulty in obtaining and recording a clear alcohol history 
and the difficult groups of patients included in the study there was no clear way of comparing the 
volumes or types of alcohol consumed in our patient group. This problem is further augmented by 
the fact that different countries classify their alcohol consumption in different units, making 
extrapolation of results more challenging. Alcohol units, which are the usual method of 
quantification in the UK, equate to 10g of alcohol.372  However most studies arising from the USA 
utilise “drinks” which contain 8g grams, and therefore this can make superficial interpretation of 
studies confusing.43 
Previous studies have not shown that the differential outcome (ACP or ALD) is determined by the 
relative volume or type of consumption (Table 3). Therefore, although the lack of adequate 
classification remains a concern it is unlikely to impact on the final conclusions of this thesis. 
7.1.2 Defining the Presence or Absence of Pancreatitis 
The majority of genome wide studies such as the GWAS project, which require large populations, 
normally from multiple different institutes, inevitably have to rely on the appropriate diagnosis of CP 
by the local investigators.176 This poses a problem because there is a lack of international consensus 
on the diagnosis of CP.17,18,24 Therefore, in all such studies there is a risk of some individuals being 
included in either disease or control groups inappropriately. 
The systematic review of the diagnosis of chronic pancreatitis showed that the best diagnostic 
modalities were EUS or MR to confirm or refute the diagnosis of pancreatitis; in the NGS study we 
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used CT scan to predominately diagnose the presence or absence of chronic pancreatitis. Where 
other modalities were available they were also used in the diagnosis of pancreatitis.  
Although CT has been poorly examined as a specific modality for the diagnosis of CP, in clinical 
practice it is commonly use to both diagnosis CP and to rule out other pathology.  The APA has now 
recommended CT as the first line diagnostic tool.24 
This study was not carried out on the basis of a clinical trial and so no systematic use of imaging was 
applied to the patients without pancreatitis. There is therefore reliance on the clinical interpretation 
of the clinicians who managed and reported on these patients. This is not ideal but is in line with 
most other studies of this type.24,373 
7.1.3 Control Groups 
Several different control groups were used for different parts of the analysis.  For the GWAS a 
different control cohort was utilised.374,375 This meant inclusion of both an unselected cohort group 
and groups specifically selected to balance against a different disease process.375 The prevalence of 
CP is low so it is unlikely that many (if any) CP patients would have been inadvertently included 
within the control groups. If any had been included this would reduce the power to identify risk 
genotypes and would not have led to false associations.  
In the NGS section of the study, two different control populations were obtained: participants with a 
strong history of alcohol excess and no history of any alcohol related disease; and participants with a 
strong history of alcohol excess and a history of ALD.  In most cases it was possible to review recent 
CT scans to eliminate the possibility of CP although clearly otherwise healthy controls would not 
routinely have imaging of the pancreas. Individuals with ALD were an exception to this as they were 
being scanned as part of their management.  Therefore this well characterised group was selected as 
the main comparator for the ACP group. 
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Comparison of genetic differences in patients with ACP and ALD could identify polymorphisms 
related to ACP or ALD (or potentially to both in opposite directions). To determine if features were 
related to alcohol rather than disease process a second analysis was done using the alcohol excess 
healthy controls (AHC), to indicate how the frequency mediated from the population base line.  The 
AHC group was chosen rather than a traditional HC group as several polymorphisms have been 
described in relation to alcohol dependence, and these may have falsely been shown to be related 
to either ACP or ALD, when in fact it is related to the increased consumption of alcohol, inherent in 
these patient groups.123 
7.1.4 Heterogeneity between Groups 
Although it would be preferable to have been able to use direct standardisation for all factors other 
than the presence or absence of ACP, this was not possible as there are natural differences between 
groups, such as higher rates of diabetes within ACP patients.95 There was a higher ratio of men in the 
ACP group than the ALD group. Men are more likely to be alcoholics than women, but there has 
been a purported increased susceptibility to ALD in women,137,376 but ACP is more common in men6. 
It was difficult to assess differences between drinking patter in in our groups due to missing data. 
Various studies have shown difference between alcohol drinking patterns in AP and ALD, but these 
findings have not been replicated across different studies (Table 3). 
The pattern of smoking was different between the two groups with more ACP patients smoking. 
Smoking is a known risk factor for ACP, but this may also be true for ALD.43,377 
7.1.5 Bias in Sample Source 
All different sample groups will have inherent sources of bias, which may affect the final results 
produced.  One such example is the chronic pancreatitis samples obtained for the NGS work.  The 
original source available were all from operative samples, and these would have been derived from 
two distinct groups of individuals: either end-stage chronic pancreatitis making it an extreme 
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phenotype; or individuals who may have been resected as their disease was presumed to be cancer, 
but only found to be CP on histology. The first group would not give a representative picture of all 
chronic pancreatitics, and may skew findings towards a sub group, which may either augment, or 
hide the true genetic results.  The second group are not a typical CP group and again would likely 
hide any true finding.  To attempt to mitigate for this, additional criteria were added including the 
need for a clear clinical history of pancreatitis, and samples were collected from less severe cases of 
chronic pancreatitis, where they were not yet requiring surgical intervention. 
 Synonymous SNPs 7.2
Synonymous SNPs are normally classified as polymorphisms, which are considered to be neutral in 
nature; however, this may not always be the case. Through analysis of the mRNA produced from 
variant alleles, there is evidence that many human disease genes contain exonic variants that affect 
pre-mRNA splicing therefore inactivating genes by inducing the splicing machinery to skip mutant 
exons.147 Alternative splicing is a regulated process during gene expression that can result in a single 
gene coding for multiple proteins.341 It has been shown at least 74% of human multi-exon genes are 
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8 Chapter 8: Conclusion 
This thesis sought to establish the role of genetic variation in the predisposition of alcohol-related 
chronic pancreatitis.  Initially, the patient group of patients with clinically proven diagnosis of CP had 
to be defined. Assessment of the literature has suggested that either EUS or MR scanning may be 
the most sensitive way of identifying patient with a good clinical history, however in current practice 
CT scanning is the most commonly used modality, diagnosis is specific to CP and does allow 
appropriate characterisation of the group. 
In terms of the genetic disposition, this was explored in several ways, including GWAS assessing an 
array of predefined loci, and exploring previously identified role of fatty acid ethyl esters by looking 
at CEL VNTR and Next Generation Sequencing of targeted genes. 
GWAS revealed two associations with CP (identified and replicated) at PRSS1-PRSS2_rs10273639 (OR 
0.73, 95% CI 0.68-0.79) and X-linked CLDN2_rs12688220 (OR 1.39, 1.28-1.49) and the association 
was more pronounced in the ACP group (OR 0.56, 0.48-0.64 and OR 2.11, 1.84-2.42). CLDN 
polymorphism has been shown to produce a difference in phenotypes; its role in chronic pancreatitis 
may be related to calcium transport, and this needs to be explored further. 
The previously identified VNTR in CEL was shown to have a lower frequency of the normal repeat in 
ACP than ALD (OR 0.61, 0.41-0.93).  Homozygosity of the normal variant was more common in ALD 
than ACP (OR 0.53, 0.3-0.96) or Healthy Controls (OR 0.55, 0.3-1.00)). The variations in the results 
identified in this work are most likely to be related to differences in the control groups used.  This 
may be most useful in explaining difference between development of one pathology or the other.  
The NGS discovery phase led on to validation of the 21 most significant SNPs with Sequenom array. 
This showed a significance difference between ACP and ALD in allele frequency of the synonymous 
SNP, PRSS1_rs6666, (OR 1.99, 1.46-2.72) and between presence or absence of a polymorphism in 
ADH1C_rs1693482 (OR 1.49, 1.11-2.01).   
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p.D162D lies within PRSS1, which is a gene of known significance in chronic pancreatitis, but the 
direct significance of the polymorphisms itself in unknown. This needs to be explored further in 
larger groups to identify if the association is held out in all populations, and if this SNP holds the true 
relationship, or is a marker for a disease associated variant. 
The polymorphisms identified within this thesis are linked with their roles in metabolism of alcohol 
in the development of pancreatitis, which is a cascade of calcium influx, leading to activation of 
trypsinogen. Where we have identified significant differences the mechanism is not always clear, 
and this may represent linkage of genotype or subtitle difference that may impact only in specific 
tissues. 
This work has identified a range of potential exonic and intronic sites associated with a 
predisposition of developing chronic pancreatitis on a background of alcohol excess.  Further work 
needs to be done on how these factors interact, and assess their presence in further populations. 
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10 Chapter 10: Appendices 
 Common Alleles of Genes of Alcohol Metabolism 10.1
10.1.1 Alcohol Dehydrogenase 1B 
Table 40 Table demonstrating the amino acid difference between the different ADH1B alleles 
 
  Amino acid position 48  
ADH1B_rs1229984 
Amino acid position 370  
ADH1B_rs2066702 
ADH1B*1 β1 R R 
ADH1B*2 β2 H R 
ADH1B*3 β3 R C 
 
10.1.2 Alcohol Dehydrogenase 1C 
Table 41 Table demonstrating the amino acid difference between the different ADH1C alleles 
 
 Amino acid position 272  
ADH1C_rs1693482 
Amino acid position 350  
ADH1C_rs698 
ADH1C*1 γ1 R I 
ADH1C*2 γ2 Q V 
 
10.1.3 Aldehyde Dehydrogenase 2 







10.1.4 Cytochrome P450 






















CYP2E1*1A           
CYP2E1*1B  x         
CYP2E1*1C Six          
CYP2E1*1D Eight          
CYP2E1*2   x        
CYP2E1*3    x       
CYP2E1*4     x      
CYP2E1*5A      x x x   
CYP2E1*5B      x  x   
CYP2E1*6       x    
CYP2E1*7A         x  
CYP2E1*7B        x   
CYP2E1*7C         x x 
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  Genes of Interest 10.2
10.2.1 Genes of Alcohol Metabolism 
Table 43 Long list of genes known to be related to alcohol metabolism  
 
Gene symbol Gene name 
ABCA1 ATP-binding cassette sub-family A member 1 
ABCG1 ATP-binding cassette sub-family G member 1 
ACAA2 3-ketoacyl-CoA thiolase, mitochondrial 
ACACA Acetyl-CoA carboxylase alpha 
ACACB Acetyl-CoA carboxylase beta 
ACADL Long-chain specific acyl-CoA dehydrogenase, mitochondrial 
ACADVL Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 
ACER1 Alkaline ceramidase 1 
ACER2 Alkaline ceramidase 2 
ACER3 Alkaline ceramidase 3 
ACHE Acetyl cholinesterase 
ACSL3 Long-chain-fatty-acid--CoA ligase 3 
ACSS1 Acetyl-coenzyme A synthetase 2-like, mitochondrial 
ACSS2 Acetyl-coenzyme A synthetase, cytoplasmic 
ADH1A Alcohol dehydrogenase 1A 
ADH1B Alcohol dehydrogenase 1B 
ADH1C Alcohol dehydrogenase 1C 
ADH4 Alcohol dehydrogenase 4 
ADH5 Alcohol dehydrogenase class-3 
ADH6 Alcohol dehydrogenase 6 
ADH7 Alcohol dehydrogenase class 4 mu/sigma chain 
AGPAT6 Glycerol-3-phosphate acyltransferase 4 
AKR1B10 Aldo-keto reductase family 1 member B10 
AKR1C3 Aldo-keto reductase family 1 member C3 
AKR1D1 3-oxo-5-beta-steroid 4-dehydrogenase 
ALDH18A1 Aldehyde dehydrogenase 18 family, member A1 
ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 
ALDH1A2 Aldehyde dehydrogenase 1 family, member A2 
ALDH1A3 Aldehyde dehydrogenase family 1 member A3 
ALDH1B1 Aldehyde dehydrogenase X, mitochondrial 
ALDH1L1 Aldehyde dehydrogenase 1 family, member L1 
ALDH1L2 Aldehyde dehydrogenase 1 family, member L2 
ALDH2 Aldehyde dehydrogenase 2, mitochondrial 
ALDH3A2 Fatty aldehyde dehydrogenase 
ALDH3B1 Aldehyde dehydrogenase family 3 member B1 
ALDH3B2 Aldehyde dehydrogenase family 3 member B2 
ALDH5A1 Aldehyde dehydrogenase 5 family, member A1 
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ALDH6A1 Aldehyde dehydrogenase 6 family, member A1 
ALDH7A1 Alpha-aminoadipic semialdehyde dehydrogenase 
ANGPTL3 Angiopoietin-related protein 3 
APLP2 Amyloid-like protein 2 
APOA1 Apolipoprotein A-I 
APOA2 Apolipoprotein A-II 
APOA4 Apolipoprotein A-IV 
APOA5 Apolipoprotein A-V 
APOB Apolipoprotein B 
APOC1 Truncated apolipoprotein C-I 
APOC3 Apolipoprotein C-III 
APOE Apolipoprotein E 
APOF Apolipoprotein F 
APOL1 Apolipoprotein L1 
APOL2 Apolipoprotein L2 
APP Amyloid beta A4 protein 
ASM Acid sphingomyelinase 
AWAT2 Acyl-CoA wax alcohol acyltransferase 2 
BCHE Butyrylcholinesterase, isoform CRA_a 
BCMO1 Beta, beta-carotene 15,15'-monooxygenase 
BMP2 Bone morphogenetic protein 2 
BMP5 Bone morphogenetic protein 5 
BMP6 Bone morphogenetic protein 6 
CACNA1H Voltage-dependent T-type calcium channel subunit alpha-1H 
CALM1 Calmodulin 
CAT Catalase 
CDS1 Phosphatide cytidylyltransferase 1 
CEBPA CCAAT/enhancer-binding protein alpha 
CEL Bile salt-activated lipase 
CEPT1 Choline/ethanolaminephosphotransferase 1 
CES1 Carboxylesterase1 
CES2 Carboxylesterase 2 
CES3 Carboxylesterase 3 
CES5a Carboxylesterase 5A 
CES6 Carboxylesterase 6 
CETP Cholesteryl ester transfer protein 
CFTR Cystic fibrosis transmembrane conductance regulator 
CH25H Cholesterol 25-hydroxylase 
CHAT Choline O-acetyltransferase 
CHDH Choline dehydrogenase, mitochondrial 
CHKA Choline kinase alpha 
CHKB Choline/ethanolamine kinase 
CHPT1 Cholinephosphotransferase 1 
CLN3 Battenin 
CLN6 Ceroid-lipofuscinosis neuronal protein 6 
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CLPS Colipase, pancreatic 
CNBP Cellular nucleic acid-binding protein 
COQ2 4-hydroxybenzoate polyprenyltransferase, mitochondrial 
COQ3 Hexaprenyldihydroxybenzoate methyltransferase, mitochondrial 
CUBN Cubilin 
CYB5R1 NADH-cytochrome b5 reductase 1 
CYB5R2 NADH-cytochrome b5 reductase 2 
CYB5R3 NADH-cytochrome b5 reductase 3 
CYP11A1 Cholesterol side-chain cleavage enzyme, mitochondrial 
CYP11B1 Cytochrome P450 11B1, mitochondrial 
CYP11B2 Cytochrome P450 11B2, mitochondrial 
CYP17A1 Steroid 17-alpha-hydroxylase/17,20 lyase 
CYP19A1 Aromatase 
CYP1A1 Cytochrome P450 1A1 
CYP1B1 Cytochrome P450 1B1 
CYP21A2 cytochrome P450, family 21, subfamily A, polypeptide 2 
CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1 
CYP27A1 cytochrome P450, family 27, subfamily A, polypeptide 1 
CYP2E1 cytochrome P450, family 2, subfamily E, polypeptide 1  
CYP2R1 Vitamin D 25-hydroxylase 
CYP39A1 24-hydroxycholesterol 7-alpha-hydroxylase 
CYP3A4 Cytochrome P450 3A4 
CYP46A1 Cholesterol 24-hydroxylase 
CYP51A1 Lanosterol 14-alpha demethylase 
CYP7A1 Cholesterol 7-alpha-monooxygenase 
CYP7B1 25-hydroxycholesterol 7-alpha-hydroxylase 
CYP8B1 7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase 
DBI Diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) 
DEGS2 Sphingolipid delta(4)-desaturase/C4-hydroxylase DES2 
DGAT1 Diacylglycerol O-acyltransferase 1 
DGAT2 Diacylglycerol O-acyltransferase 2 
DHCR24 Delta(24)-sterol reductase 
DHCR7 7-dehydrocholesterol reductase 
DHRS3 Short-chain dehydrogenase/reductase 3 
DHRS4 Dehydrogenase/reductase SDR family member 4 
DHRS9 Dehydrogenase/reductase SDR family member 9 
DKK3 Dickkopf-related protein 3 
DMGDH Dimethylglycine dehydrogenase, mitochondrial 
DPAGT1 UDP-N-acetylglucosamine--dolichyl-phosphate  
N-acetylglucosaminephosphotransferase 
DPM1 Dolichol-phosphate mannosyltransferase subunit 1 
DPM2 Dolichol phosphate-mannose biosynthesis regulatory protein 
EBP 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase 
EBPL Emopamil-binding protein-like 
ENPP2 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 
The Role of Genetic Variation in Predisposition to Alcohol-related Chronic Pancreatitis                             2015 
Appendix – Genes of Interest 215 
ENPP6 Ectonucleotide pyrophosphatase/phosphodiesterase family member 6 
ENPP7 Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 
EPHX2 Bifunctional epoxide hydrolase 2 
EPM2A Laforin 
FABP1 Fatty acid-binding protein 1 
FABP2 Fatty acid-binding protein 2 
FABP3 Fatty acid-binding protein 3 
FABP5 Fatty acid-binding protein 5 
FABP6 Fatty acid-binding protein 6 
FADS1 Fatty acid desaturase 1  
FADS2 Fatty acid desaturase 2 
FADS3 Fatty acid desaturase 3  
FDFT1 Farnesyl-diphosphate farnesyltransferase 1 
FDPS Farnesyl pyrophosphate synthase 
FDX1 Adrenodoxin, mitochondrial 
FDXR Ferredoxin reductase 
FECH Ferrochelatase, mitochondrial 
FGF1 Fibroblast growth factor 1 
FGF2 Fibroblast growth factor 2 
FGF23 Fibroblast growth factor 23 
FGL1 Fibrinogen-like protein 1 
G6PD Glucose-6-phosphate 1-dehydrogenase 
GALK1 Galactokinase 
GALNT2 Polypeptide N-acetylgalactosaminyltransferase 2 
GBA Glucosylceramidase 
GC Vitamin D-binding protein 
GCKR Glucokinase regulator  
GDE1 Glycerophosphodiester phosphodiesterase 1 
GDPD1 Glycerophosphodiester phosphodiesterase domain-containing protein 1 
GDPD2 Glycerophosphoinositol inositolphosphodiesterase GDPD2 
GDPD3 Glycerophosphodiester phosphodiesterase domain-containing protein 3 
GDPD4 Glycerophosphodiester phosphodiesterase domain-containing protein 4 
GDPD5 Glycerophosphodiester phosphodiesterase domain-containing protein 5 
GFI1 Zinc finger protein Gfi-1 
GGPS1 Geranylgeranyl pyrophosphate synthase 
GK Glycerol kinase 
GK2 Glycerol kinase 2 
GK5 Putative glycerol kinase 5 
GOT1 Aspartate aminotransferase, cytoplasmic 
GPD2 Glycerol-3-phosphate dehydrogenase, mitochondrial 
GPER1 G-protein coupled estrogen receptor 1 
GPLD1 Phosphatidylinositol-glycan-specific phospholipase D 
HAO1 Hydroxyacid oxidase 1 
HDLBP high density lipoprotein binding protein 
HMGCR 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
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HMGCS1 Hydroxymethylglutaryl-CoA synthase, cytoplasmic 
HMGCS2 Hydroxymethylglutaryl-CoA synthase, mitochondrial 
HRH1 Histamine H1 receptor 
HSD17B1 Estradiol 17-beta-dehydrogenase 1 
HSD17B3 Testosterone 17-beta-dehydrogenase 3 
HSD17B7 3-keto-steroid reductase 
IDI1 Isopentenyl-diphosphate Delta-isomerase 1 
IDI2 Isopentenyl-diphosphate delta-isomerase 2 
IFNG Interferon gamma 
IGF1 Insulin-like growth factor I 
IL1a Interleukin-1 alpha 
IL1B Interleukin-1 beta 
IL4 Interleukin-4 
IMPA2 Inositol monophosphatase 2 
IMPAD1 Inositol monophosphatase 3 
INPP1 Inositol polyphosphate 1-phosphatase 
INPP5D Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 
INPP5E 72 kDa inositol polyphosphate 5-phosphatase 
INPP5J Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A 
INPP5K Inositol polyphosphate 5-phosphatase K 
INPPL1 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 
INSIG1 Insulin-induced gene 1 protein 
INSIG2 Insulin-induced gene 2 protein 
IP6K1 Inositol hexakisphosphate kinase 1 
IP6K2 Inositol hexakisphosphate kinase 2 
IP6K3 Inositol hexakisphosphate kinase 3 
IPMK Inositol polyphosphate multikinase 
IPPK Inositol-pentakisphosphate 2-kinase 
ISYNA1 Inositol-3-phosphate synthase 1 
ITPK1 Inositol-tetrakisphosphate 1-kinase 
ITPKA Inositol-trisphosphate 3-kinase A 
ITPKB Inositol-trisphosphate 3-kinase B 
ITPKC Inositol-trisphosphate 3-kinase C 
CPT1A Carnitine palmitoyltransferase 1A (liver) 
LBR Lamin-B receptor 
LCAT Phosphatidylcholine-sterol acyltransferase 
LDLR Low-density lipoprotein receptor 
LDLRAP1 Low density lipoprotein receptor adapter protein 1 
LEP Leptin 
LEPR Leptin receptor 
LGMN Legumain 
LHCGR Lutropin-choriogonadotropic hormone receptor 
LIPA Lipase A, lysosomal acid, cholesterol esterase 
LIPC Hepatic triacylglycerol lipase 
LIPE Hormone-sensitive lipase 
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LMF1 Lipase maturation factor 1 
LPCAT1 Lysophosphatidylcholine acyltransferase 1 
LPCAT2 Lysophosphatidylcholine acyltransferase 2 
LPCAT3 Lysophospholipid acyltransferase 3 
LPCAT4 Lysophospholipid acyltransferase 4 
LPIN1 Phosphatidate phosphatase LPIN1 
LPIN2 Phosphatidate phosphatase LPIN2 
LPIN3 Phosphatidate phosphatase LPIN3 
LPL Lipoprotein lipase  
LRAT Lecithin retinol acyltransferase 
LRP1 Prolow-density lipoprotein receptor-related protein 1 
LRP2 Low-density lipoprotein receptor-related protein 2 
LRP5 Low-density lipoprotein receptor-related protein 5 
LSS Lanosterol synthase 
MAS1 Proto-oncogene Mas 
MBOAT2 Lysophospholipid acyltransferase 2 
MBTPS1 Membrane-bound transcription factor site-1 protease 
MBTPS2 Membrane-bound transcription factor site-2 protease 
MECP2 Methyl-CpG-binding protein 2 
MGLL Monoglyceride lipase 
MINPP1 Multiple inositol polyphosphate phosphatase 1 
MIOX Myo-Inositol oxygenase 
MOGAT1 2-acylglycerol O-acyltransferase 1 
MOGAT2 2-acylglycerol O-acyltransferase 2 
MOGAT3 2-acylglycerol O-acyltransferase 3 
MSMO1 Methylsterol monooxygenase 1 
MT3 Metallothionein-3 
MTMR2 Myotubularin-related protein 2 
MTMR7 Myotubularin-related protein 7 
MVD Diphosphomevalonate decarboxylase 
MVK Mevalonate kinase 
NFKB1 Nuclear factor NF-kappa-B p105 subunit 
NPC1 Niemann-Pick C1 protein 
NPC1L1 Niemann-Pick C1-like protein 1 
NPC2 Epididymal secretory protein E1 
NQO1 NAD(P)H dehydrogenase, quinone 1 
NQO2 NAD(P)H dehydrogenase, quinone 2 
NR0B2 Nuclear receptor subfamily 0 group B member 2 
NR1H4 Bile acid receptor 
NSDHL Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating 
NUDT10 Diphosphoinositol polyphosphate phosphohydrolase 3-alpha 
NUDT11 Diphosphoinositol polyphosphate phosphohydrolase 3-beta 
NUDT3 Diphosphoinositol polyphosphate phosphohydrolase 1 
NUDT4 Diphosphoinositol polyphosphate phosphohydrolase 2 
OCRL Inositol polyphosphate 5-phosphatase OCRL-1 
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OSBPL1A Oxysterol-binding protein-related protein 1 
OSBPL5 Oxysterol-binding protein-related protein 5 
P2RY1 P2Y purinoceptor 1 
PAFAH1B1 Platelet-activating factor acetylhydrolase IB subunit alpha 
PARK7 Protein DJ-1 
PCK1 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] 
PCSK9 Proprotein convertase subtilisin/kexin type 9 
PCTP Phosphatidylcholine transfer protein 
PCYT1A Choline-phosphate cytidylyltransferase A 
PCYT1B Choline-phosphate cytidylyltransferase B 
PECR Peroxisomal trans-2-enoyl-CoA reductase 
PEMT Phosphatidylethanolamine N-methyltransferase 
PEX2 Peroxisome biogenesis factor 2 
PHOSPHO1 Phosphoethanolamine/phosphocholine phosphatase 
PLA2G10 Group 10 secretory phospholipase A2 
PLA2G12A Group XIIA secretory phospholipase A2 
PLA2G15 Group XV phospholipase A2 
PLA2G16 Phospholipase A2, group XVI 
PLA2G1B phospholipase A2, group IB  
PLA2G2A Phospholipase A2, membrane associated 
PLA2G2D Group IID secretory phospholipase A2 
PLA2G2E Group IIE secretory phospholipase A2 
PLA2G2F Group IIF secretory phospholipase A2 
PLA2G3 Group 3 secretory phospholipase A2 
PLA2G4A Cytosolic phospholipase A2 
PLA2G4B Cytosolic phospholipase A2 beta 
PLA2G4C Cytosolic phospholipase A2 gamma 
PLA2G4D Cytosolic phospholipase A2 delta 
PLA2G4E Cytosolic phospholipase A2 epsilon 
PLA2G4F Cytosolic phospholipase A2 zeta 
PLA2G5 Calcium-dependent phospholipase A2 
PLA2G6 85/88 kDa calcium-independent phospholipase A2 
PLB1 Phospholipase B1, membrane-associated 
PLBD1 Phospholipase B-like 1 
PLCB1 phospholipase C, beta 1  
PLCB2 phospholipase C, beta 2  
PLCB3 phospholipase C, beta 3  
PLCB4 phospholipase C, beta 4  
PLCD1 phospholipase C, delta 1 
PLCD3 phospholipase C, delta 3 
PLCE1 phospholipase C, epsilon 1 
PLCG1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 
PLCG2 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 
PLCH1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-1 
PLCH2 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-2 
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PLCZ1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase zeta-1 
PLD4 Phospholipase D4 
PLEK Pleckstrin 
PMVK Phosphomevalonate kinase 
PNLIP Pancreatic lipase 
PNLIPRP1 Pancreatic lipase-related protein 1 
PNLIPRP2 Pancreatic lipase-related protein 2 
PNPLA6 Neuropathy target esterase 
PNPLA8 Calcium-independent phospholipase A2-gamma 
PON1 Serum paraoxonase/arylesterase 1 
POR NADPH--cytochrome P450 reductase 
POU1F1 Pituitary-specific positive transcription factor 1 
PPARD Peroxisome proliferator-activated receptor delta 
PPIP5K1 Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 
PPIP5K2 Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2 
PRKAA1 5'-AMP-activated protein kinase catalytic subunit alpha-1 
PRKAA2 5'-AMP-activated protein kinase catalytic subunit alpha-2 
PRKAG2 5'-AMP-activated protein kinase subunit gamma-2 
PRKCD Protein kinase C delta type 
PTAFR Platelet-activating factor receptor 
PTH1R Parathyroid hormone/parathyroid hormone-related peptide receptor 
PTK2B Protein-tyrosine kinase 2-beta 
PTPMT1 Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1 
PTPRR Protein tyrosine phosphatase, receptor type, R 
RBP4 Retinol-binding protein 4 
RDH10 Retinol dehydrogenase 10 
RDH11 Retinol dehydrogenase 11 
RDH12 Retinol dehydrogenase 12 
RDH5 Retinol dehydrogenase 5 
RDH8 Retinol dehydrogenase 8 
REST RE1-silencing transcription factor 
RETSAT All-trans-retinol 13,14-reductase 
RPE65 Retinoid isomerohydrolase 
RXRA Retinoic acid receptor RXR-alpha 
SAMD8 Sphingomyelin synthase-related protein 1 
SC5D Lathosterol oxidase 
SCAP Sterol regulatory element-binding protein cleavage-activating protein 
SCARB1 Scavenger receptor class B member 1 
SCARF1 Scavenger receptor class F member 1 
SCP2 Non-specific lipid-transfer protein 
SDR16C5 Epidermal retinol dehydrogenase 2 
SEC14L2 SEC14-like protein 2 
SGMS1 Phosphatidylcholine:ceramide cholinephosphotransferase 1 
SGMS2 Phosphatidylcholine:ceramide cholinephosphotransferase 2 
SGPP1 Sphingosine-1-phosphate phosphatase 1 
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SGPP2 Sphingosine-1-phosphate phosphatase 2 
SLC27A1 Long-chain fatty acid transport protein 1 
SLC34A1 Sodium-dependent phosphate transport protein 2A 
SLC5A3 Sodium/myo-inositol cotransporter 
SMPD1 Sphingomyelin phosphodiesterase 1 
SMPD2 Sphingomyelin phosphodiesterase 2 
SMPD3 Sphingomyelin phosphodiesterase 3 
SMPD4 Sphingomyelin phosphodiesterase 4 
SMPDL3A Acid sphingomyelinase-like phosphodiesterase 3a 
SMPDL3B Acid sphingomyelinase-like phosphodiesterase 3b 
SNAI1 Zinc finger protein SNAI1 
SNAI2 Zinc finger protein SNAI2 
SNCA Alpha-synuclein 
SNX17 Sorting nexin-17 
SOAT1 Sterol O-acyltransferase 1 
SOAT2 Sterol O-acyltransferase 2 
SOD1 Superoxide dismutase [Cu-Zn] 
SORD Sorbitol dehydrogenase 
SORL1 Sortilin-related receptor 
SPHK1 Sphingosine kinase 1 
SPHK2 Sphingosine kinase 2 
SPTLC1 Serine palmitoyltransferase 1 
SPTLC2 Serine palmitoyltransferase 2 
SQLE Squalene monooxygenase 
SRD5A3 Polyprenol reductase 
SREBF1 Sterol regulatory element-binding protein 1 
SREBF2 Sterol regulatory element-binding protein 2 
STAR Steroidogenic acute regulatory protein, mitochondrial 
STARD3 StAR-related lipid transfer protein 3 
SYNJ1 Synaptojanin-1 
TM7SF2 Transmembrane 7 superfamily member 2 
TNF Tumor necrosis factor 
TNFSF4 Tumor necrosis factor ligand superfamily member 4 
TRERF1 Transcriptional-regulating factor 1 
TTR Transthyretin 
VDR Vitamin D3 receptor 
VLDLR Very low-density lipoprotein receptor 
WNT4 Protein Wnt-4 
IMPA1 inositol(myo)-1(or 4)-monophosphatase 1 
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10.2.2 Background on Genes of Interest 
Information presented on the chosen Genes of Interest. Data obtained from the NCBI website 
(http://www.ncbi.nlm.nih.gov/gene and http://www.ncbi.nlm.nih.gov/omim). 
10.2.2.1 ABO - ABO blood group  
Also known as GTB; NAGAT; A3GALNT; A3GALT1 
Gene ID: 28     Location: 9q34.2 
Summary Encodes for proteins related to the ABO blood group system. The 'O' blood group is 
caused by a deletion of guanine at position 258 resulting in a frameshift, leading to production of 
different protein.  
10.2.2.2 ACACA - Acetyl-CoA carboxylase alpha 
Also known as ACC; ACAC; ACC1; ACCA; ACACAD 
Gene ID: 31    Location: 17q21 
Summary Encodes an enzyme which catalyses the carboxylation of acetyl-CoA to malonyl-CoA which 
is the rate limiting step in the synthesis of fatty acids. ACC-alpha is highly enriched in lipogenic 
tissues.  
10.2.2.3 ACACB - Acetyl-CoA carboxylase beta  
Also known as ACC2; ACCB; HACC275 
Gene ID: 32     Location: 12q24.11 
Summary Like ACACA, encodes an enzyme which catalyses the carboxylation of acetyl-CoA to 
malonyl-CoA which is the rate limiting step in the synthesis of fatty acids. ACACB controls fatty acid 
oxidation by preventing the rate-limiting step in fatty acid uptake and mitochondrial oxidation. 
ACACB may in fact be involved in the regulation of fatty acid oxidation, rather than fatty acid 
synthesis. Increased concentrations of catecholamines promote the ultilisation of lipid stores from 
adipose tissue during fast, which is the rate-limiting enzyme in fatty acid synthesis.  
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10.2.2.4 ACSS2 - Acyl-CoA synthetase short-chain family member 2  
Also known as ACS; ACSA; ACAS2; ACECS; dJ1161H23.1 
Gene ID: 55902    Location: 20q11.22 
Summary Encodes for a cytosolic enzyme that helps catalyses activation of acetate, which is use for 
lipid synthesis and generation of energy. The protein acts as a monomer and produces acetyl-CoA 
from acetate in a reaction that requires ATP.  
10.2.2.5 ADH1A - Alcohol dehydrogenase 1A (class I), alpha polypeptide  
Also known as ADH1 
Gene ID: 124    Location: 4q23 
Summary Encodes for a protein member of the alcohol dehydrogenase family, which catalyses the 
oxidation of alcohols to aldehydes. This gene is active in the liver in early fetal life but only weakly 
active in adult liver. This gene is clustered with six other alcohol dehydrogenase genes, on 
chromosome 4. Mutations in this gene are associated with substance dependence.  The class I ADH 
genes account for the majority of the ethanol-oxidizing capacity of the liver.  
10.2.2.6 ADH1B - Alcohol dehydrogenase 1B (class I), beta polypeptide 
Also known as ADH2; HEL-S-117 
Gene ID: 125    Location: 4q23 
Summary Encodes for a protein is a member of the alcohol dehydrogenase family, which includes a 
wide variety of substrates, including ethanol, retinol, other aliphatic alcohols, and lipid peroxidation 
products. It is highly active in ethanol oxidation and plays a major role in ethanol catabolism.  
10.2.2.7 ADH1C - Alcohol dehydrogenase 1C (class I), gamma polypeptide  
Also known as ADH3 
Gene ID: 126     Location: 4q23 
Summary Encodes for class I alcohol dehydrogenase, which is a member of the alcohol 
dehydrogenase family. Similar properties to ADH1B. 
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10.2.2.8 ADH4 - Alcohol dehydrogenase 4 (class II), pi polypeptide 
Also known as ADH-2; HEL-S-4 
Gene ID: 127    Location: 4q22 
Summary Encodes class II alcohol dehydrogenase 4 (pi subunit), a member of the alcohol 
dehydrogenase family. Has high oxidation activity with aliphatic and aromatic alcohols but is less 
sensitive with pyrazole. There is cluster of alcohol dehydrogenase genes chromosome 4 in relation 
to this gene.  It is a distinct from other human liver alcohol dehydrogenases and this therefore 
termed it Pi-alcohol dehydrogenase. This enzyme accounts for up to 40% of the total ethanol 
oxidation when intoxicating levels of alcohol have been consumed.  
10.2.2.9 ADH5 - Alcohol dehydrogenase 5 (class III), chi polypeptide  
Also known as FDH; ADHX; ADH-3; FALDH; GSNOR; GSH-FDH 
Gene ID: 128     Location: 4q23 
Summary Encodes a protein for a member of the alcohol dehydrogenase family. It oxidizes ethanol 
very poorly but oxidases long-chain primary alcohols well.  The human genome contains several non-
transcribed pseudogenes related to this gene. 
10.2.2.10 ADH6 - Alcohol dehydrogenase 6 (class V)  
Also known as ADH-5 
Gene ID: 130     Location: 4q23 
Summary This gene encodes class V alcohol dehydrogenase, which is a member of the alcohol 
dehydrogenase family. This gene is expressed in the stomach as well as in the liver, and it contains a 
glucocorticoid response element upstream of its 5' UTR, which is a steroid hormone receptor-
binding site.  
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10.2.2.11 ADH7 - Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide  
Also known as ADH4 
Gene ID: 131     Location: 4q23-q24 
Summary This gene encodes class IV alcohol dehydrogenase 7 mu or sigma subunit, which is a 
member of the alcohol dehydrogenase family. The enzyme encoded by this gene is inefficient in 
ethanol oxidation, but is the most active as a retinol dehydrogenase; thus it may participate in the 
synthesis of retinoic acid, a hormone important for cellular differentiation. The expression of this 
gene is much more abundant in stomach than liver, thus differing from the other known gene family 
members.  
10.2.2.12 ALDH1A2 - Aldehyde dehydrogenase 1 family, member A2  
Also known as RALDH2; RALDH2-T; RALDH(II) 
Gene ID: 8854    Location: 15q21.3 
Summary This protein belongs to the aldehyde dehydrogenase family of proteins. The product of 
this gene is an enzyme that catalyzes the synthesis of retinoic acid from retinaldehyde. Retinoic acid, 
the active derivative of vitamin A (retinol), is a hormonal signaling molecule that functions in 
developing and adult tissues.  
10.2.2.13 ALDH1A3 - Aldehyde dehydrogenase 1 family, member A3 
Also known as ALDH6; MCOP8; RALDH3; ALDH1A6 
Gene ID: 220     Location: 15q26.3 
Summary Encodes for an enzyme, part of aldehyde dehydrogenase isozymes, playing a major role in 
the detoxification of aldehydes generated by alcohol metabolism and lipid peroxidation. 
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10.2.2.14 ALDH1L1 - Aldehyde dehydrogenase 1 family, member L1 
Also known as FDH; FTHFD; 10-fTHF; 10-FTHFDH 
Gene ID: 10840     Location: 3q21.3 
Summary The loss of expression or function of this enzyme is associated with reduced apoptosis, 
increased cell motility, and as a consequence, progression of cancer.  
10.2.2.15 ALDH1L2 - Aldehyde dehydrogenase 1 family, member L2  
Also known as mtFDH 
Gene ID: 160428     Location: 12q23.3 
Summary It has an essential role in the distribution of carbon groups between cytosolic and 
mitochondrial cell compartments.  
10.2.2.16 ALDH2 - Aldehyde dehydrogenase 2 family (mitochondrial) 
Also known as ALDM; ALDHI; ALDH-E2  
Gene ID: 217     Location: 12q24.2 
Summary Aldehyde dehydrogenase is the second enzyme of the main oxidative pathway for 
metabolism of alcohol. The higher frequency of acute alcohol intoxication with the Oriental 
population compared to Caucasians may be related to the mitochondrial isozyme that is absence of 
catalytic activity; these individuals may also have a greater susceptibility to many types of cancer.  
10.2.2.17 ALDH3B1 - Aldehyde dehydrogenase 3 family, member B1 
Also known as ALDH4; ALDH7 
Gene ID: 221     Location: 11q13 
Summary This gene is expressed in kidney and lung, however, the functional significance of this gene 
is unknown. It shares a close evolutionary relationship with ALDH7 and ALDH8.  
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10.2.2.18 ALDH5A1 - Aldehyde dehydrogenase 5 family, member A1  
Also known as SSDH; SSADH 
Gene ID: 7915      Location: 6p22 
Summary A deficiency of this enzyme is a rare inborn error in the metabolism of the 
neurotransmitter 4-aminobutyric acid. In response to the defect, physiologic fluids from individuals 
accumulate GHB, a compound with numerous neuromodulatory properties.  
10.2.2.19 ALDH6A1 - Aldehyde dehydrogenase 6 family, member A1 
Also known as MMSDH; MMSADHA  
Gene ID: 4329     Location: 14q24.3 
Summary Encodes a protein that plays a role in the valine and pyrimidine catabolic pathways. This 
protein catalyzes the irreversible oxidative decarboxylation of malonate and methylmalonate 
semialdehydes to acetyl- and propionyl-CoA.  
10.2.2.20 APOA1 - Apolipoprotein A-I  
Gene ID: 335     Location: 11q23-q24 
Summary Encodes for the major protein component of high-density lipoprotein. IT promotes the 
movement of cholesterol to the liver from tissues for excretion, and is responsible for the formation 
of most plasma cholesteryl esters. This gene is closely linked with two other apolipoprotein genes on 
chromosome 11.  Furthermore to removing cholesterol from cells, HDL also delivers cholesterol to 
cells through cholesteryl esters that are selectively transferred from HDL particles into the cell.  
10.2.2.21 APOA4 - Apolipoprotein A-IV  
Gene ID: 337     Location: 11q23 
Summary This protein is primarily made in the intestine and is associated with chylomicron particles. 
Its exact function is unclear.  
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10.2.2.22 APOA5 - Apolipoprotein A-V  
Also known as RAP3; APOAV 
Gene ID: 116519     Location: 11q23 
Summary Encodes a protein that plays a key role in regulating the plasma triglyceride levels. It is a 
component of high-density lipoprotein.  Mutations in this gene have been associated with 
hypertriglyceridemia and hyperlipoproteinaemia.  
10.2.2.23 APOB - Apolipoprotein B  
Also known as FLDB; LDLCQ4 
Gene ID: 338     Location: 2p24-p23  
Summary Encodes for the main apolipoprotein of chylomicrons and low-density lipoproteins, both 
intestinal and the hepatic forms. Mutations in this gene cause hypobetalipoproteinemia, 
normotriglyceridaemic hypobetalipoproteinemia, and hypercholesterolemia which are all diseases 
affecting plasma cholesterol levels. 
10.2.2.24 APOC3 - Apolipoprotein C-III  
Also known as HALP2; APOCIII 
Gene ID: 345     Location: 11q23.3 
Summary Encodes for a very low-density lipoprotein protein. It inhibits both lipoprotein lipase and 
hepatic lipase, delaying catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 
genes are closely linked. Increased APOC3 levels leads to hypertriglyceridemia.  
10.2.2.25 APOE - Apolipoprotein E 
Also known as AD2; LPG; LDLCQ5 
Gene ID: 348     Location: 19q13.2 
Summary Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on 
liver cells and peripheral cells lowing chylomicron remnants and very low-density lipoprotein 
remnants to be rapidly removed from the circulation. APOE is essential for the normal catabolism of 
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triglyceride-rich lipoprotein constituents. Defects in APOE result in familial dysbetalipoproteinaemia, 
or hyperlipoproteinaemia, which cause increased plasma cholesterol and triglycerides due to 
impaired clearance of chylomicron and VLDL remnants. 
10.2.2.26 CEL - Carboxyl ester lipase 
Also known as BAL; FAP; BSDL; BSSL; CELL; FAPP; LIPA; CEase; MODY8 
Gene ID: 1056   Location: 9q34.3 
Summary Encodes a glycoprotein secreted by the pancreas into the digestive tract, hydrolysing 
cholesterol and lipid-soluble vitamin ester hydrolysis, aiding absorption and promoting large 
chylomicron production in the intestine. It is also thought to modulate the progression of 
atherosclerosis. This gene contains a VNTR in the coding region that may influence the function of 
the encoded protein. 
10.2.2.27 CES1 - Carboxylesterase 1 
Also known as CEH; REH; TGH; ACAT; CE-1; CES2; HMSE; SES1; HMSE1; PCE-1; hCE-1  
Gene ID: 1066     Location: 16q22.2 
Summary Encodes a member of the carboxylesterase large family, which is responsible for the 
hydrolysis or transesterification of various xenobiotics, and endogenous substrates with ester or 
amide bonds. It has a role in fatty acyl and cholesterol ester metabolism.  This enzyme is one of the 
main liver enzymes and is key for liver drug clearance. 
10.2.2.28 CES4A - Carboxylesterase 4A  
Also known as CES6; CES8  
Gene ID: 283848    Location: 16q22.1 
Summary This enzyme is involved in fatty acyl and cholesterol ester metabolism, and may play a role 
in the detoxification of drugs and xenobiotics tissues of the body and in the cerebrospinal fluid.  
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10.2.2.29 CES5A - Carboxylesterase 5A  
Also known as CES5; CES7; CAUXIN; CES4C1 
Gene ID: 221223    Location: 16q12.2  
Summary This enzyme Involved in fatty acyl and cholesterol ester metabolism, regulating the 
production of a pheromone precursor and may contribute to lipid and cholesterol transfer.  
10.2.2.30 CFTR - Cystic fibrosis transmembrane conductance regulator  
Also known as CF; MRP7; ABC35; ABCC7; CFTR/MRP; TNR-CFTR 
Gene ID: 1080     Location: 7q31.2 
Summary Encodes for a protein, which functions as a chloride channel and helps control its 
transport pathway. It is a member of the ATP-binding cassette (ABC) transporter superfamily. ABC 
proteins transport various molecules across extra- and intra-cellular membranes. Mutations in this 
gene are associated with the autosomal recessive disorders cystic fibrosis and congenital bilateral 
aplasia of the vas deferens.  
10.2.2.31 CLPS - Colipase, pancreatic  
Gene ID: 1208      Location: 6p21.31 
Summary Encodes for a protein, which is a cofactor required by pancreatic lipase to efficiently 
hydrolyse dietary lipids. Colipase is thought to help anchor lipase to the surface of lipid micelles, 
negating any destabilising influence of intestinal bile salts.  This gene is only been identified as being 
expressed in pancreatic acinar cells. 
10.2.2.32 CPT1A - Carnitine palmitoyltransferase 1A (liver)  
Also known as CPT1; CPT1-L; L-CPT1 
Gene ID: 1374     Location: 11q13.2 
Summary CPT1A is the key enzyme in the carnitine-dependent transport across the mitochondrial 
inner membrane and its deficiency results in a decreased rate of fatty acid beta-oxidation. 
Alternatively spliced transcript variants encoding different isoforms have been found for this gene.  
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Major control over fatty acid oxidation process is exerted at the level of CPT1 by virtue of the unique 
inhabitability of this enzyme by malonyl-CoA. This fuel 'cross talk' was first recognized in the context 
of hepatic cytogenesis and its regulation and thereafter emerged as a central component of 
metabolism in a variety of tissues. 
10.2.2.33 CTRB1 - Chymotrypsinogen B1 
Gene ID: 1504     Location: 6q23.1 
Also known as CTRB 
Summary This gene encodes for a protein, which is part of a family of serine proteases. It is secreted 
into the gastrointestinal tract as an inactive precursor, and is then activated by proteolytic cleavage 
with trypsin. 
10.2.2.34 CYP2E1 - Cytochrome P450, family 2, subfamily E, polypeptide 1  
Gene ID: 1571     Location: 10q26.3 
Also known as CPE1; CYP2E; P450-J; P450C2E 
Summary This gene encodes a member of the cytochrome P450 superfamily of enzymes, which are 
monooxygenases that catalyze many reactions involved in synthesis of cholesterol and steroids and 
in drug metabolism. This protein localizes to the endoplasmic reticulum and is induced by ethanol, 
the diabetic state, and starvation. The enzyme metabolizes both endogenous substrates, such as 
ethanol, acetone, and acetal, as well as exogenous substrates including benzene, carbon 
tetrachloride, ethylene glycol, and nitrosamines, which are premutagens, found in cigarette smoke. 
Due to its many substrates, this enzyme may be involved in such varied processes as 
gluconeogenesis, hepatic cirrhosis, diabetes, and cancer.217,218,379,380 
10.2.2.35 FABP1 - Fatty acid binding protein 1, liver  
Also known as FABPL; L-FABP 
Gene ID: 2168     Location: 2p11 
Summary This gene encodes the fatty acid binding protein found in liver. Fatty acid binding proteins 
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are a family of small, highly conserved, cytoplasmic proteins that bind long-chain fatty acids and 
other hydrophobic ligands. This protein and FABP6 are also able to bind bile acids. It is thought that 
FABPs roles include fatty acid uptake, transport, and metabolism and is required for cholesterol 
synthesis. 
10.2.2.36 FABP2 - Fatty acid binding protein 2, intestinal  
Also known as FABPI; I-FABP 
Gene ID: 2169     Location: 4q28-q31 
Summary FABPs are divided into at least three distinct types, namely the hepatic-, intestinal- and 
cardiac-type. They form 14-15 kDa proteins and are thought to participate in the uptake, 
intracellular metabolism and/or transport of long-chain fatty acids. They may also be responsible in 
the modulation of cell growth and proliferation. FABP2 contains four exons and is an abundant 
cytosolic protein in small intestine epithelial cells. It may participate in the uptake, intracellular 
metabolism and/or transport of long chain fatty acids.  This gene has a polymorphism at codon 54 
that identified an alanine-encoding allele and a threonine-encoding allele (FABP2_rs1799883). Thr-
54 protein is associated with increased fat oxidation and insulin resistance.  
10.2.2.37 FABP3 - Fatty acid binding protein 3, muscle and heart  
Also known as MDGI; FABP11; H-FABP; M-FABP; O-FABP 
Gene ID: 2170    Location: 1p33-p32 
Summary The intracellular fatty acid-binding proteins (FABPs) belong to a multi-gene family and are 
divided into at least three distinct types, namely the hepatic-, intestinal- and cardiac-type. They form 
14-15 kDa proteins and are thought to participate in the uptake, intracellular metabolism and/or 
transport of long-chain fatty acids. They may also be responsible in the modulation of cell growth 
and proliferation. FABP3 contains four exons and its function is to arrest growth of mammary 
epithelial cells. This gene is a candidate tumor suppressor gene for human breast cancer. 
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10.2.2.38 FABP6 - Fatty acid binding protein 6, ileal  
Also known as ILBP; I-15P; I-BAP; ILBP3; ILLBP; I-BABP; I-BALB 
Gene ID: 2172    Location: 5q33.3-q34 
Summary This gene encodes the ileal fatty acid binding protein. Fatty acid binding proteins are a 
family of small, highly conserved, cytoplasmic proteins that bind long-chain fatty acids and other 
hydrophobic ligands. FABP6 and FABP1 (the liver fatty acid binding protein) are also able to bind bile 
acids. It is thought that FABPs roles include fatty acid uptake, transport, and metabolism.  
10.2.2.39 FADS1 - Fatty acid desaturase 1  
Also known as D5D; TU12; FADS6; FADSD5; LLCDL1 
Gene ID: 3992    Location: 11q12.2-q13.1  
Summary The protein encoded by this gene is a member of the fatty acid desaturase (FADS) gene 
family. Desaturase enzymes regulate unsaturation of fatty acids through the introduction of double 
bonds between defined carbons of the fatty acyl chain. FADS family members are considered fusion 
products composed of an N-terminal cytochrome b5-like domain and a C-terminal multiple 
membrane-spanning desaturase, both of which are characterized by conserved histidine motifs. This 
gene is clustered with family members FADS1 and FADS2 at 11q12-q13.1; this cluster is thought to 
have arisen evolutionarily from gene duplication based on its similar exon/intron organization.  The 
FADS1 substrate/product pair ratio is associated with LDL cholesterol, HDL cholesterol and 
triglycerides. 
10.2.2.40 FADS2 - Fatty acid desaturase 2  
Also known as D6D; DES6; TU13; FADSD6; LLCDL2; SLL0262 
Gene ID: 9415     Location: 11q12.2 
Summary Desaturase enzymes regulate unsaturation of fatty acids through the introduction of 
double bonds between defined carbons of the fatty acyl chain. Similar profile to FADS1. 
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10.2.2.41 FADS3 - Fatty acid desaturase 3  
Also known as CYB5RP; LLCDL3 
Gene ID: 3995    Location: 11q12-q13.1 
Summary Desaturase enzymes regulate unsaturation of fatty acids through the introduction of 
double bonds between defined carbons of the fatty acyl chain. Similar profile to FADS1.  
10.2.2.42 GALNT2 - UDP-N-acetyl-alpha-D-galactosamine: N-acetylgalactosaminyltransferase 2  
Also known as GalNAc-T2 
Gene ID: 2590    Location: 1q41-q42 
Summary This gene encodes polypeptide N-acetylgalactosaminyltransferase 2, a member of the 
GalNAc-transferases family. This family transfers an N-acetyl galactosamine to the hydroxyl group of 
a serine or threonine residue in the first step of O-linked oligosaccharide biosynthesis. Individual 
GalNAc-transferases have distinct activities and initiation of O-glycosylation in a cell is regulated by a 
repertoire of GalNAc-transferases.  
10.2.2.43 GCKR - Glucokinase (regulator) 
Also known as GKRP; FGQTL5 
Gene ID: 2646     Location: 2p23 
Summary Encodes for a regulatory protein that inhibits glucokinase by forming an inactive complex 
with the enzyme in both the liver and pancreatic islet cells. This gene is considered a susceptibility 
gene candidate for a form of maturity-onset diabetes of the young (MODY).  
10.2.2.44 IL1A - Interleukin 1, alpha 
Also known as IL1; IL-1A; IL1F1; IL1-ALPHA 
Gene ID: 3552    Location: 2q14 
Summary Encodes for a protein by this gene is a member of the interleukin 1 cytokine family. This 
cytokine is involved in various immune responses and inflammatory processes. It is released in 
response to cell injury-causing apoptosis.  
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10.2.2.45 IL1B - Interleukin 1, beta  
Also known as IL-1; IL1F2; IL1-BETA 
Gene ID: 3553     Location: 2q14 
Summary Encodes for a protein by this gene is a member of the interleukin 1 cytokine family. This 
cytokine is produced by activated macrophages, which is proteolytically processed to its active form 
by caspase 1. This cytokine is an important mediator of the inflammatory response, and is involved 
in a variety of cellular activities, including cell proliferation, differentiation, and apoptosis. The 
induction of cyclooxygenase-2 (by this cytokine in the central nervous system is found to contribute 
to inflammatory pain hypersensitivity. This gene and eight other interleukin 1 family genes form a 
cytokine gene cluster on chromosome 2.  The IL1 system contains genetic polymorphisms that are 
associated with fat mass in young men.381 
10.2.2.46 LDLR - Low density lipoprotein receptor 
Also known as FH; FHC; LDLCQ2 
Gene ID: 3949    Location: 19p13.2  
Summary The low-density lipoprotein receptor gene family consists of cell surface proteins involved 
in receptor-mediated endocytosis of specific ligands. LDL is normally bound at the cell membrane 
and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is 
made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A 
reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation 
of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant 
disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants. 
10.2.2.47 LIPA - Lipase A, lysosomal acid, cholesterol esterase  
Also known as LAL; CESD 
Gene ID: 3988    Location: 10q23.2-q23.3  
Summary This gene encodes lipase A, the lysosomal acid lipase (cholesterol ester hydrolase). This 
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enzyme functions in the lysosome to catalyze the hydrolysis of cholesteryl esters and triglycerides. 
Mutations in this gene can result in Wolman disease and cholesteryl ester storage disease. 
Alternatively spliced transcript variants encoding the same protein have been found for this gene. 
10.2.2.48 LIPC- Lipase, hepatic  
Also known as HL; HTGL; LIPH; HDLCQ12 
Gene ID: 3990    Location: 15q21-q23  
Summary LIPC encodes hepatic triglyceride lipase, which is expressed in liver. LIPC has the dual 
functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein 
uptake.  SNPs in the LIPC gene (LIPC_rs369262181, LIPC_rs12594375, LIPC_rs8023503, 
LIPC_rs4775047, and LIPC_rs11634134) are linked with HDL cholesterol levels.  
10.2.2.49 LPL - Lipoprotein lipase  
Also known as LIPD; HDLCQ11 
Gene ID: 4023    Location: 8p22  
Summary Lipoprotein lipase is expressed in heart, muscle, and adipose tissue. LPL functions as a 
homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for 
receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I 
hyperlipoproteinaemia, while less extreme mutations in LPL are linked to many disorders of 
lipoprotein metabolism.  
10.2.2.50 LIPE - Lipase, hormone-sensitive   
Also known as HSL; LHS 
Gene ID: 3991     Location: 19q13.2 
Summary The protein encoded by this gene has a long and a short form, generated by use of 
alternative translational start codons. The long form converts cholesteryl esters to free cholesterol 
for steroid hormone production. The short form is expressed in adipose tissue, among others, where 
it hydrolyzes stored triglycerides to free fatty acids.   Hormone-sensitive lipase has a vital role in the 
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mobilization of free fatty acids from adipose tissue by controlling the rate of lipolysis of the stored 
triglycerides. LIPE regulates energy homeostasis by catalyzing the rate-limiting step in adipose tissue 
lipolysis. Like glycogen phosphorylate, the corresponding enzyme in carbohydrate metabolism, LIPE 
is under acute neuronal and hormonal control. In both cases activation by catecholamines occurs 
through the cAMP-mediated phosphorylation of a single serine residue. The dephosphorylation of 
LIPE by insulin is responsible for the antilipolytic effect of this hormone, one of its most important 
actions. 
10.2.2.51 MGLL - Monoglyceride lipase  
Also known as MGL; HUK5; MAGL; HU-K5 
Gene ID: 11343    Location: 3q21.3 
Summary This gene encodes a serine hydrolase of the AB hydrolase superfamily that catalyzes the 
conversion of monoacylglycerides to free fatty acids and glycerol. The encoded protein plays a 
critical role in several physiological processes including pain and nociperception through hydrolysis 
of the endocannabinoid 2-arachidonoylglycerol. Expression of this gene may play a role in cancer 
tumour genesis and metastasis. MGLL functions together with LIPE; to hydrolyze intracellular 
triglyceride stores in adipocytes and other cells to fatty acids and glycerol. MGLL may also 
complement LPL in completing hydrolysis of Monoglyceride resulting from degradation of 
lipoprotein triglycerides. 
10.2.2.52 NQO1 - NAD(P)H dehydrogenase, quinone 1 
Also known as DTD; QR1; DHQU; DIA4; NMOR1; NMORI 
Gene ID: 1728    Location: 16q22.1 
Summary This gene is a member of the NAD dehydrogenase (quinone) family and encodes a 
cytoplasmic 2-electron reductase. This FAD-binding protein forms homodimers and reduces 
quinones to hydroquinones. This protein's enzymatic activity prevents the one electron reduction of 
quinones that results in the production of radical species. Mutations in this gene have been 
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associated with tardive dyskinesia, an increased risk of haematotoxicity after exposure to benzene, 
and susceptibility to various forms of cancer. Altered expression of this protein has been seen in 
many tumors and is also associated with Alzheimer's disease. Alternate transcriptional splice 
variants, encoding different isoforms, have been characterized. 
10.2.2.53 NQO2 - NAD(P)H dehydrogenase, quinone 2  
Also known as QR2; DHQV; DIA6; NMOR2 
Gene ID: 4835    Location: 6p25.2 
Summary NQO2 is a flavoprotein that catalyzes the 2-electron reduction of various quinones, redox 
dyes, and the vitamin K menadione. NQO2 predominantly uses dihydronicotinamide riboside as the 
electron donor. Mutations in this gene have been associated with neurodegenerative diseases and 
several cancers. 
10.2.2.54 PNLIP - Pancreatic lipase 
Also known as PL; PTL; PNLIPD 
Gene ID: 5406    Location: 10q26.1 
Summary This gene is a member of the lipase gene family. It encodes a carboxyl esterase that 
hydrolyzes insoluble, emulsified triglycerides, and is essential for the efficient digestion of dietary 
fats. This gene is expressed specifically in the pancreas. 
10.2.2.55 PNLIPRP1- Pancreatic lipase-related protein 1  
Also known as PLRP1 
Gene ID: 5407    Location: 10q25.3 
Summary Pancreatic lipase fulfills a key function in dietary fat absorption by hydrolyzing triglycerides 
into diglycerides and subsequently into monoglycerides and free fatty acids. 
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10.2.2.56 PNLIPRP2 - Pancreatic lipase-related protein 2  
Also known as PLRP2 
Gene ID: 5408    Location: 10q25.3 
Summary PNLIPRP2 is essential for fat digestions. The expression level of PNLIPRP2 in pancreas was 
approximately 6-fold lower than the expression levels of PNLIPRP1. 
10.2.2.57 PRSS1 - Protease, serine, 1 (trypsin 1) 
Also known as TRP1; TRY1; TRY4; TRYP1 
Gene ID: 5644    Location: 7q34  
Summary This gene encodes a trypsinogen, which is a member of the trypsin family of serine 
proteases. This enzyme is secreted by the pancreas and cleaved to its active form in the small 
intestine. It is active on peptide linkages involving the carboxyl group of lysine or arginine. Mutations 
in this gene are associated with hereditary pancreatitis due to the trypsin self-destruct mechanism of 
trypsin designed to prevent pancreatic autodigestion; active trypsin is inhibited normally by a limited 
supply of trypsin inhibitor (e.g. SPINK1).48  
10.2.2.58 PTPRR - Protein tyrosine phosphatase, receptor type, R  
Also known as PTPRQ; EC-PTP; PCPTP1; PTP-SL; PTPBR7 
Gene ID: 5801    Location: 12q15 
Summary Encodes for a protein that is a member of the protein tyrosine phosphatase (PTP) family. 
PTPs are signalling molecules, regulating a range of cellular processes including cell growth, 
differentiation, mitotic cycle, and oncogenic transformation.  
  
The Role of Genetic Variation in Predisposition to Alcohol-related Chronic Pancreatitis                             2015 
Appendix – Genes of Interest 239 
10.2.2.59 SCARB1 - Scavenger receptor class B, member 1  
Gene ID: 949     Location: 12q24.31 
Also known as CLA1; SRB1; CLA-1; SR-BI; CD36L1; HDLQTL6 
Summary Encodes a protein that is a plasma membrane receptor for HDL cholesterol. The encoded 
protein mediates cholesterol transfer to and from HDL.  A polymorphism (p.P297S) has been 
associated with familial HDL hypercholesterolaemia. 
10.2.2.60 SPINK1 - Serine peptidase inhibitor, Kazal type  
Gene ID: 6690    Location: 5q32 
Also known as TCP; PCTT; PSTI; TATI; Spink3 
Summary Encodes a protein that inhibits trypsin, an enzyme that is secreted by pancreatic acinar 
cells into pancreatic juice. It prevents the premature trypsin-catalyzed activation of zymogens within 
the pancreas. Mutations in this gene are associated with pancreatitis. 
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10.2.3 Coverage of Genes of Interest 
Table 44 Selected genes for Next Generation Sequencing with Haloplex Coverage 
Table displaying number of exons/regions covered by the Haloplex capture, the number of base 
pairs in the combined sequence, and overage coverage and the number of regions with either 90% 
total coverage or less than 90% total coverage. 
Gene Regions Size Coverage >90% <90% 
ABO 7 1064 100% 7 0 
ACACA 58 7205 100% 58 0 
ACACB 53 7377 100% 53 0 
ACSS2 22 2145 100% 22 0 
ADH1A 9 1128 100% 9 0 
ADH1B 10 1128 99.41% 10 0 
ADH1C 9 1128 99.54% 9 0 
ADH4 11 1143 100% 11 0 
ADH5 11 1125 100% 11 0 
ADH6 9 1132 100% 9 0 
ADH7 10 1239 100% 10 0 
ALDH1 13 1506 100% 13 0 
ALDH18A1 17 2388 100% 17 0 
ALDH1A2 17 1557 100% 17 0 
ALDH1A3 14 1539 100% 14 0 
ALDH1L1 24 2709 100% 24 0 
ALDH1L2 24 2772 100% 24 0 
ALDH2 14 1554 100% 14 0 
ALDH3B1 9 1404 100% 9 0 
ALDH5A1 11 1647 100% 11 0 
ALDH6A1 12 1608 100% 10 0 
APOA1 3 804 100% 3 0 
APOA4 3 1191 99.52% 3 0 
APOA5 3 1101 100% 3 0 
APOB 30 13692 100% 3 0 
APOC3 3 300 100% 3 0 
APOE 4 954 100% 4 0 
CEL 11 2271 80.21% 8 3 
CES1 15 1707 83.09% 11 4 
CES2 12 1872 100% 12 0 
CES3 14 1716 100% 14 0 
CES5a 17 1888 100% 17 0 
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CES6 15 1404 100% 15 0 
CFTR 27 4443 100% 27 0 
CLPS 4 339 100% 4 0 
CYP2E1 9 1482 100% 9 0 
FABP1 4 384 100% 4 0 
FABP2 4 399 100% 4 0 
FABP3 4 402 100% 4 0 
FABP6 7 534 100% 7 0 
FADS1 15 1506 100% 15 0 
FADS2 17 1335 100% 17 0 
FADS3 12 1338 100% 10 0 
GALNT2 18 1716 100% 18 0 
GCKR 21 1878 100% 21 0 
IL1a 6 816 100% 6 0 
IL1b 6 810 100% 6 0 
L-CPT1 20 2358 100% 20 0 
LDLR 19 2583 100% 19 0 
LIPA 10 1200 93.98% 9 1 
LIPC 10 1500 100% 10 0 
LIPE 10 3231 99.91% 10 0 
LPL 11 1428 100% 11 0 
MGLL 11 942 100% 11 0 
NQO1 7 825 100% 7 0 
NQO2 8 696 98.07% 7 1 
PNLIP 12 1398 100% 12 0 
PNLIPRP1 13 1404 100% 13 0 
PNLIPRP2 14 1412 100% 14 0 
PRSS1 6 744 100% 6 0 
PTPRR 17 1974 100% 17 0 
SCARB1 15 1650 98.44% 14 1 









  Ion Torrent™ Coverage 10.3
10.3.1 By Chip  
Table 45 Assessment of SNP coverage of samples by chip run on the Ion Torrent™ 





















1 69 4.09 136 472 557 69.8 99.0 89.2 15/15 
2 78 4.24 129 507 551 81.1 99.0 92.1 15/15 
3 71 5.02 153 652 768 50.2 100.0 83.5 6/15 
4 86 5.2 141 623 735 59.3 99.2 90.5 13/15 
5 82 4.12 148 518 610 61.8 98.3 90.5 8/16 
6 80 4.24 155 562 658 84.5 99.8 95.5 15/16 
7 76 6.21 148 779 920 44.6 100.0 93.0 16/16 
10 73 3.07 141 372 435 64.7 97.7 89.8 12/16 
11 83 3.4 97 269 331 60.6 98.8 80.2 8/16 
12 76 3.13 120 325 378 47.6 99.6 84.8 11/16 
13 86 6.44 139 781 898 66.4 100.0 93.5 12/16 
14 84 3.88 114 374 446 57.7 99.8 90.2 14/16 
15 76 5.30 142 671 754 25.3 100.0 78.2 15/16 
16 84 4.35 132 509 577 6.9 98.5 65.8 15/16 
17 61 3.23 88 234 286 42.5 98.0 83.2 5/16 
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10.3.2 By Sample 
Table 46 Assessment of coverage of the SNPs within the Genes of Interest 
Those with less than six reads coverage were classed as not covered. 
CP patients include CP numbers, L numbers, M numbers, R numbers and T numbers 
Control patients include Ctrl numbers, CEM numbers and S numbers 
 
Patient ID Reads Mean read 
(bp) 
Mapped reads No. of SNPs 
read 
% of SNPs 
read 
Chips used 
CP007 19911886 117 192076 2768 75.6 Single 
CP012 43848817 152 342043 3540 96.6 Single 
CP013 26484080 154 202046 3630 99.1 Single 
CP014 191589 139 170691 3427 93.6 Single 
CP017 13254499 135 113741 2556 69.8 Single 
CP018 7452426 130 69539 2746 75 Combined 
CP022 9159246 125 88639 2644 72.2 Single 
CP027 34680040 135 278106 3546 96.8 Single 
CP028 13493242 142 109875 3346 91.3 Combined 
CP040 31152624 150 243265 3632 99.2 Single 
CP042 19262379 146 151977 3360 91.7 Single 
CP043 26476979 154 203744 3532 96.4 Single 
CP044 245083936 152 1909228 3573 97.5 Combined 
CP051 18805688 140 155140 3571 97.5 Combined 
CP052 17681752 150 139128 3213 87.7 Single 
CP056 10839376 95 141307 2645 72.2 Combined 
CP061 51394225 143 413499 3443 94 Single 
CP064 31368678 137 271408 3254 88.8 Single 
CP077 76388158 148 600871 3599 98.3 Single 
CP078 45846323 136 391590 3602 98.3 Single 
CP079 5984144 102 71327 2834 77.4 Combined 
CP080 36563513 146 291702 3641 99.4 Single 
CP081 27310654 158 205072 2872 78.4 Combined 
CP083 72860853 150 567479 3534 96.5 Single 
CP085 36602136 121 372470 3620 98.8 Single 
CP086 8512676 161 62742 3485 95.1 Combined 
CP090 21464466 151 166953 3470 94.7 Single 
CP092 25565426 129 213748 2811 76.7 Single 
CP094 52213300 150 410378 2227 60.8 Combined 
CP097 38264283 158 288810 3430 93.6 Combined 
CP101 33237521 161 241343 3097 84.5 Single 
CP108 27660642 127 251984 3451 94.2 Single 
CP122 49752488 152 385131 3662 100 Single 
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CP135 21777358 140 181040 3566 97.4 Combined 
CP136 29262359 163 209141 3549 96.9 Single 
CP140 39197526 160 285029 3606 98.4 Single 
CP141 61873692 153 473188 3661 99.9 Single 
CP147 33890556 160 248496 3647 99.6 Single 
CP151 18909506 143 155684 3532 96.4 Single 
CP152 11990284 151 95300 3312 90.4 Single 
CP153 20330747 153 157513 3509 95.8 Single 
CP154 18060625 152 140759 3514 95.9 Single 
CP156 18133891 151 140346 3407 93 Single 
CP159 8047163 134 68133 2173 59.3 Single 
CP164 44054545 145 355359 3564 97.3 Single 
CP177 24415643 143 199977 3543 96.7 Single 
CP183 34013071 137 292622 3303 90.2 Single 
CP193 14139595 153 110824 2900 79.2 Combined 
CP199 30851134 133 269847 3243 88.5 Single 
CP203 37787751 140 318543 3132 85.5 Single 
CP207 34243856 132 302539 2969 81.1 Single 
CP212 38421792 141 319121 3628 99 Single 
CP214 768973 159 759278 3064 83.6 Combined 
CP215 91798416 141 751807 3661 99.9 Combined 
CP222 28560266 145 230386 3427 93.6 Single 
CP223 55732646 140 457295 3662 100 Single 
CP224 27919215 158 207533 1839 50.2 Single 
CP227 27230459 140 231042 3566 97.4 Single 
CP229 36121595 161 260703 3542 96.7 Single 
CP234 20174156 151 156435 3605 98.4 Single 
CP241 29636154 112 319443 3637 99.3 Single 
CP245 29763883 155 225516 3641 99.4 Single 
CP254 75859428 154 584976 3654 99.8 Single 
CP257 34249599 162 245336 3595 98.1 Single 
CP264 36269771 160 266252 3459 94.4 Single 
CP269 8610050 125 82715 3149 86 Single 
CP278 53699131 153 409486 3662 100 Single 
CP287 39208649 153 301129 3205 87.5 Single 
CP292 48668322 148 386452 3662 100 Single 
CP299 22038260 134 179671 3256 88.9 Single 
CP310 25104659 136 200904 3098 84.6 Single 
CP315 44833595 136 378456 3611 98.6 Single 
CP316 22105237 137 175039 3527 96.3 Single 
CP322 26385564 136 209737 3607 98.5 Single 
CP328 31113267 137 245041 3552 97 Single 
CP329 48627256 133 397094 3537 96.6 Single 
The Role of Genetic Variation in Predisposition to Alcohol-related Chronic Pancreatitis                             2015 
Appendix – Ion Torrent Coverage 245 
CP330 23609261 160 172686 3292 89.9 Single 
CP333 139218191 123 1087074 2488 67.9 Single 
CP335 14693055 123 128673 2794 76.3 Single 
CP338 65005793 133 528681 3650 99.6 Single 
CP343 64244375 134 519733 3268 89.2 Single 
CP353 44315567 155 341561 2934 80.1 Single 
CP367 52706886 150 409771 2688 73.4 Single 
CP368 33298455 160 242728 3596 98.2 Single 
CP397 43175487 136 366622 3025 82.6 Single 
CP414 46230626 134 392047 3086 84.2 Single 
CP415 62548991 138 525329 2431 66.4 Single 
CP438 35889375 110 388145 3465 94.6 Single 
CP453 1628769 134 14183 1020 27.8 Single 
CP456 3548172 123 34075 3601 98.3 Single 
CP457 2561874 118 25676 1556 42.5 Single 
L1083 23734542 120 227315 3208 87.6 Single 
L1230 9996173 140 83656 2306 63 Single 
M1477 42822362 133 368685 3586 97.9 Single 
M1533 15703008 145 131231 2219 60.6 Single 
M1704 43133700 160 312236 3647 99.6 Single 
M1839 20826945 141 165126 2307 63 Single 
M1847 17081166 125 164655 3503 95.6 Single 
M1861 17356658 158 128783 3320 90.6 Single 
R2404 13052769 142 115834 2542 69.4 Single 
R2431 19692423 144 159069 3343 91.3 Single 
T451 37991108 131 289726 3591 98 Single 
CEM19 3047695 147 23647 3352 91.5 Single 
CEM49 11118780 97 134130 3089 84.3 Single 
CEM60 9579093 99 118159 3280 89.5 Single 
Ctrl027 10749873 129 100492 2335 63.7 Combined 
Ctrl028 17011350 131 153914 3473 94.8 Combined 
Ctrl029 30941898 139 256451 3442 94 Single 
Ctrl030 9621955 132 87562 2547 69.5 Combined 
Ctrl031 32974861 140 273870 3648 99.6 Single 
Ctrl032 9581697 144 77340 2371 64.7 Single 
Ctrl033 33676044 162 248253 3631 99.1 Single 
Ctrl034 32693119 160 242209 3386 92.4 Single 
Ctrl035 22961811 109 250037 3616 98.7 Single 
Ctrl036 38709871 156 294205 2262 61.8 Single 
Ctrl037 14345845 141 119089 3239 88.4 Single 
Ctrl038 39523388 145 317848 3602 98.3 Single 
Ctrl039 192410495 146 1270079 3569 97.4 Single 
Ctrl040 38629209 151 304987 3439 93.9 Single 
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Ctrl041 2911528 127 28230 1987 54.2 Combined 
Ctrl042 71232608 122 723170 3584 97.8 Single 
Ctrl043 3833212 114 39830 2353 64.2 Single 
Ctrl044 6348693 128 59745 2437 66.5 Combined 
Ctrl045 75049692 153 577852 3660 99.9 Single 
Ctrl046 11090860 116 111193 2794 76.3 Single 
Ctrl048 18062276 129 151321 3096 84.5 Single 
Ctrl049 16452443 90 195669 3084 84.2 Single 
Ctrl050 25853741 122 228449 3575 97.6 Single 
Ctrl052 66555893 87 851901 1596 43.6 Single 
Ctrl054 22463420 144 183326 3579 97.7 Single 
Ctrl055 32143885 120 306904 3551 96.9 Single 
Ctrl056 2028618 162 14772 1633 44.6 Single 
Ctrl057 15070029 87 212578 2172 59.3 Single 
Ctrl058 19599204 121 175550 3256 88.9 Single 
Ctrl059 59961311 159 446107 3643 99.5 Single 
Ctrl060 53499194 147 411028 3608 98.5 Single 
Ctrl061 18842916 147 150232 3273 89.4 Single 
Ctrl062 43401843 161 319627 3654 99.8 Single 
Ctrl065 45459346 148 360991 3662 100 Single 
Ctrl066 76672912 154 579649 3648 99.6 Single 
Ctrl067 34472167 132 297945 3432 93.7 Single 
Ctrl068 29310907 141 238442 3538 96.6 Single 
Ctrl070 36600822 122 358918 3654 99.8 Single 
Ctrl071 39371273 146 317250 3550 96.9 Single 
Ctrl073 95054783 131 857178 3653 99.7 Single 
Ctrl074 17081903 118 174871 3392 92.6 Single 
Ctrl075 23465798 137 198480 3340 91.2 Single 
Ctrl076 7860989 136 67564 1743 47.6 Single 
Ctrl077 29502445 154 223415 3601 98.3 Single 
Ctrl078 63225638 143 518176 3285 89.7 Single 
Ctrl079 24583770 133 213354 3296 90 Single 
Ctrl080 34563885 147 276103 3480 95 Single 
Ctrl081 31850865 145 258233 3572 97.5 Single 
Ctrl082 19745228 143 160690 3169 86.5 Single 
Ctrl083 24042183 152 186364 3537 96.6 Single 
Ctrl085 10213130 144 81891 2988 81.6 Single 
Ctrl086 25866066 152 201105 3305 90.2 Single 
Ctrl087 42828878 148 339741 3562 97.2 Single 
Ctrl089 31625921 141 257510 2992 81.7 Single 
Ctrl090 71534815 136 591031 2343 64 Single 
Ctrl091 29862027 139 248123 3187 87 Single 
Ctrl092 22872559 146 178653 3346 91.3 Single 
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Ctrl093 14820102 97 184711 3408 93 Single 
Ctrl095 18968843 144 153432 3489 95.2 Single 
Ctrl096 25928521 142 211407 3577 97.7 Single 
Ctrl097 21551164 147 171567 3393 92.6 Single 
Ctrl099 27037512 147 206219 3443 94 Single 
Ctrl100 6750860 145 54784 2803 76.5 Single 
Ctrl103 16370113 139 137794 2913 79.5 Single 
Ctrl104 46518318 141 385476 3647 99.6 Single 
Ctrl105 37674270 145 300981 3640 99.4 Single 
Ctrl108 47948723 130 423241 3401 92.8 Combined 
Ctrl111 14447003 142 120070 2606 71.1 Single 
Ctrl113 67121077 148 509786 784 21.4 Single 
Ctrl116 58989418 138 492367 3622 98.9 Single 
Ctrl117 69177009 145 538919 927 25.3 Single 
Ctrl118 3719003 128 33744 963 26.3 Single 
Ctrl119 45297531 149 344345 3239 88.4 Single 
Ctrl121 8280025 144 67782 3167 86.5 Single 
Ctrl122 95976251 142 757842 3663 100 Single 
Ctrl123 30899611 137 251190 2197 60 Single 
Ctrl124 34615355 120 330951 3489 95.2 Single 
Ctrl128 73082706 145 568212 3643 99.5 Single 
Ctrl130 28760925 136 248725 3503 95.6 Single 
Ctrl131 99933399 143 789911 3546 96.8 Single 
Ctrl136 89660544 142 714274 2030 55.4 Single 
Ctrl138 4354294 125 40773 1697 46.3 Single 
Ctrl141 5219456 114 53145 3562 97.2 Single 
Ctrl151 4238081 122 40795 2575 70.3 Single 
Ctrl152 1711571 133 14904 252 6.9 Single 
S038305 14591406 140 119867 3512 95.9 Single 
S038310 42607252 135 351857 2982 81.4 Single 
S038312 13486193 121 127499 3516 96 Single 
S038324 50993582 135 432986 3633 99.2 Single 
S038327 35838234 133 308785 3569 97.4 Single 
S038330 44598485 134 374320 2421 66.1 Single 
S038334 3057051 133 26502 2115 57.7 Single 
S038336 92781017 138 752359 3641 99.4 Single 
S038341 58970491 135 504539 3635 99.2 Single 
S038342 50997197 140 418151 3655 99.8 Single 
S038344 2046388 141 16298 3585 97.9 Single 
S038345 2786863 136 23526 2592 70.8 Combined 








10.3.3 Comparison of SNP Calls Removing Results from Concatenated Samples 
Table 47 Sensitivity analysis excluding results that had been concatenated from two runs  
The sensitivity analysis contains 85 patients in the alcohol-related chronic pancreatitis group and 89 patients in the alcoholic control group. 
  Original analysis Sensitivity analysis 
SNP Amino OR Lower CI Upper CI p value OR Lower CI Upper CI p value 
ACACB_rs17848835 p.T2027I 4.094 1.965 8.530 0.002 3.507 1.665 7.385 0.001 
ADH1C_rs1693482 p.R272Q 0.489 0.279 0.858 0.013 0.483 0.267 0.875 0.016 
ADH5_rs116010022 Intron 7.444 0.907 61.080 0.051 6.035 0.719 50.658 0.098 
ADH6_rs4147545 Intron 0.591 0.373 0.935 0.025 0.646 0.397 1.050 0.078 
APOB_novel p.L3820L 1.729 1.045 2.860 0.033 1.914 1.108 3.307 0.020 
APOB_rs72653066 Intron 0.073 0.004 1.303 0.067 0.069 0.004 1.230 0.062 
APOC3_rs4520 p.G34G 0.603 0.400 0.910 0.016 0.625 0.405 0.964 0.018 
CES5A_rs7500040 Intron 0.543 0.277 1.065 0.076 0.670 0.332 1.352 0.264 
CES5A_rs200911306 p.V45I 0.210 0.059 0.743 0.016 0.337 0.090 1.269 0.108 
FABP1_rs2241883 p.T94A 0.509 0.314 0.826 0.006 0.442 0.262 0.746 0.002 
FABP3_rs11578034 Intron 8.667 1.073 69.981 0.043 8.244 1.020 66.649 0.048 
FABP6_rs10056214 Intron 0.481 0.321 0.721 <0.001 0.428 0.278 0.659 <0.001 
IL1B_rs1143633 Intron 0.481 0.295 0.782 0.003 0.916 0.530 1.583 0.753 
LDLR_rs1003723 Intron 1.685 1.126 2.520 0.011 1.608 1.051 2.461 0.029 
LIPA_rs1051338 p.T16P 0.293 0.115 0.751 0.011 0.277 0.108 0.716 0.008 
LIPC_rs690 p.V155V 0.606 0.403 0.910 0.016 0.636 0.414 0.978 0.039 
LIPC_rs3751542 Intron 0.746 0.461 1.206 0.232 0.841 0.505 1.401 0.506 
MGLL_rs116367069 Intron 0.185 0.040 0.846 0.025 0.221 0.047 1.038 0.056 
PRSS1_rs6666 p.D162D 0.554 0.369 0.832 0.030 0.559 0.364 0.858 0.008 
PTPRR_rs10506608 p.F54F 0.340 0.140 0.825 0.004 0.358 0.145 0.881 0.025 
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 Tagging SNPs 10.4
Table 48 Tagging SNPs for the SNPs of Interest 
Data on the SNPs of Interest identify recognised tagging SNPs with r2>0.8 and D’ >0.9. Data taken for 
1000 genomes website (http://browser.1000genomes.org/index.html) 
 
Reference SNP Tagging SNPs Amino acid r2 D' 
ACACB_rs17848835 NA non coding   
ADH1C_rs1693482 rs1789892 non coding 1 1 
rs1154433 non coding 1 1 
rs1229978 non coding 1 1 
rs1662031 non coding 1 1 
rs1612735 non coding 1 1 
rs1789898 non coding 1 1 
rs1442479 non coding 1 1 
rs1442480 non coding 1 1 
rs1789900 non coding 1 1 
rs1442481 non coding 1 1 
rs1693456 non coding 1 1 
rs1662060 non coding 1 1 
rs1789902 non coding 1 1 
rs1693476 non coding 1 1 
rs1662059 non coding 1 1 
rs698 p.I350V 1 1 
CM033593 non coding 1 1 
rs3114048 non coding 1 1 
rs1693471 non coding 1 1 
rs1662058 non coding 1 1 
rs1693477 non coding 1 1 
rs1789906 non coding 1 1 
rs904093 non coding 1 1 
rs904094 non coding 1 1 
rs904095 non coding 1 1 
rs1662057 non coding 1 1 
rs1789908 non coding 1 1 
rs904096 non coding 1 1 
rs1789910 non coding 1 1 
rs1693480 non coding 1 1 
rs1789911 non coding 1 1 
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rs1693481 non coding 1 1 
rs1789912 non coding 1 1 
CM860053 non coding 1 1 
rs1631460 non coding 1 1 
rs41496344 non coding 1 1 
rs1693424 non coding 1 1 
rs1625439 non coding 1 1 
rs62307297 non coding 1 1 
rs62307298 non coding 1 1 
rs1789914 non coding 1 1 
rs1693425 p.V158V 1 1 
rs1693426 non coding 1 1 
rs1662053 non coding 1 1 
rs1662052 non coding 1 1 
rs1789916 non coding 1 1 
rs1693427 non coding 1 1 
rs1693428 non coding 1 1 
rs1789917 non coding 1 1 
rs1662051 non coding 1 1 
rs1693430 non coding 1 1 
rs1789919 non coding 1 1 
rs1693431 non coding 1 1 
rs1629270 non coding 1 1 
rs1662049 non coding 1 1 
rs1789924 non coding 1 1 
rs1629838 non coding 1 1 
rs2584453 non coding 1 1 
rs1789925 non coding 1 1 
rs2453980 non coding 1 1 
rs980972 non coding 1 1 
rs1693470 non coding 1 1 
rs1662039 non coding 1 1 
rs2851300 non coding 1 1 
rs1234584 non coding 1 1 
rs1662021 non coding 1 1 
rs1662020 non coding 1 1 
rs1235415 non coding 1 1 
rs1229858 non coding 1 1 
rs1229856 non coding 1 1 
rs1229855 non coding 1 1 
rs1229854 non coding 1 1 
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rs1229851 non coding 1 1 
rs1154435 non coding 1 1 
rs1154438 non coding 1 1 
rs1154439 non coding 1 1 
rs1154440 non coding 1 1 
rs1229973 non coding 1 1 
rs1583974 non coding 1 1 
rs1154442 non coding 1 1 
rs1154444 non coding 1 1 
rs1154445 non coding 1 1 
rs1154447 non coding 1 1 
rs2851299 non coding 0.978 1 
rs1789913 non coding 0.978 1 
rs1662048 non coding 0.978 1 
rs1693469 non coding 0.978 1 
rs1238015 non coding 0.978 1 
rs1229857 non coding 0.978 1 
rs1693483 non coding 0.956 1 
rs283415 non coding 0.935 1 
rs283408 non coding 0.935 1 
rs11499826 non coding 0.893 1 
rs4093924 non coding 0.872 1 
ADH5_rs116010022 rs144904000 non coding 1 1 
rs142452522 non coding 1 1 
rs148416104 non coding 1 1 
rs149709952 non coding 1 1 
rs146788033 non coding 1 1 
rs146829324 non coding 1 1 
ADH6_rs4147545 rs4333190 non coding 0.95 1 
rs2903166 non coding 0.95 1 
rs3857224 non coding 0.95 1 
rs10030920 non coding 0.95 1 
APOB_rs72653066 rs116359745 non coding 1 1 
rs113190464 non coding 1 1 
APOC3_rs4520 NA non coding   
CES5A_rs7500040 rs3859105 non coding 0.957 1 
rs3859106 non coding 0.957 1 
rs3933468 non coding 0.957 1 
rs8049600 non coding 0.957 1 
rs8048974 non coding 0.957 1 
rs6499794 non coding 0.957 1 
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rs12445603 non coding 0.957 1 
rs6499792 non coding 0.957 1 
rs6416762 non coding 0.916 1 
rs6499793 non coding 0.871 0.954 
rs11647975 non coding 0.811 1 
FABP1_rs2241883 rs1545223 non coding 1 1 
CM042701 non coding 1 1 
FABP3_rs11578034 rs34406633 non coding 1 1 
rs34278290 non coding 1 1 
rs11589125 non coding 1 1 
rs12744206 non coding 1 1 
rs12749261 non coding 1 1 
rs2275437 p.A109A 1 1 
rs35961897 non coding 1 1 
rs4949405 non coding 1 1 
rs12756878 non coding 0.829 1 
FABP6_rs10056214 rs10071871 non coding 1 1 
rs10071756 non coding 0.847 1 
rs10056227 non coding 0.847 1 
rs10079413 non coding 0.847 1 
rs10058512 non coding 0.847 1 
rs4921267 non coding 0.847 1 
rs4921268 non coding 0.847 1 
rs4921122 non coding 0.847 1 
rs2042259 non coding 0.847 1 
IL1B_rs1143633 rs3917368 non coding 0.971 1 
rs3181067 non coding 0.971 1 
rs1143643 non coding 0.971 1 
LDLR_rs1003723 rs12983082 non coding 1 1 
rs12710260 non coding 1 1 
CS022877 non coding 1 1 
CS040544 non coding 1 1 
rs1962352 non coding 0.889 0.976 
rs688 p.N591N 0.889 0.976 
CM984053 non coding 0.889 0.976 
rs28786710 non coding 0.889 0.976 
rs2738448 non coding 0.889 0.976 
rs2738449 non coding 0.889 0.976 
rs2738450 non coding 0.889 0.976 
rs2738452 non coding 0.889 0.976 
rs2915967 non coding 0.889 0.976 
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rs9789302 non coding 0.889 0.976 
rs9789303 non coding 0.889 0.976 
rs34554139 non coding 0.889 0.976 
rs5925 p.V653V 0.889 0.976 
CM080431 non coding 0.889 0.976 
rs17248819 non coding 0.872 1 
rs111867267 non coding 0.868 0.975 
rs9789328 non coding 0.845 0.93 
rs10422256 non coding 0.816 1 
rs67475684 non coding 0.808 0.974 
rs2738453 non coding 0.808 0.974 
LIPA_rs1051338 rs2246828 non coding 1 1 
rs2250645 non coding 1 1 
rs1332327 non coding 1 1 
rs2243547 non coding 0.977 1 
rs1412444 non coding 0.954 1 
rs2246833 non coding 0.932 1 
rs1332328 non coding 0.932 1 
rs1412445 non coding 0.932 1 
rs2246941 non coding 0.911 1 
rs2246942 non coding 0.911 1 
rs1332329 non coding 0.911 1 
rs2250644 non coding 0.908 0.975 
LIPC_rs690 NA non coding   
LIPC_rs3751542 rs3829460 non coding 1 1 
rs7175421 non coding 1 1 
rs4562992 non coding 1 1 
rs190316834 non coding 0.843 1 
rs28619338 non coding 0.831 1 
rs2242064 non coding 0.831 1 
MGLL_rs116367069 NA non coding   
PRSS1_rs6666 rs6667 p.N246N 1 1 
rs10258394 non coding 1 1 
rs4726576 non coding 1 1 
rs10273639 non coding 1 1 
rs9969188 non coding 1 1 
rs2855972 non coding 0.978 1 
rs13246726 non coding 0.956 0.978 
rs35031873 non coding 0.956 0.978 
rs13230029 non coding 0.956 0.978 
rs13230134 non coding 0.956 0.978 
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rs28706856 non coding 0.956 0.978 
rs1969595 non coding 0.956 0.978 
rs13225332 non coding 0.956 0.978 
rs11765409 non coding 0.956 0.978 
rs12534573 non coding 0.956 0.978 
rs12534595 non coding 0.956 0.978 
rs4726580 non coding 0.956 0.978 
rs11769872 non coding 0.956 0.978 
rs11770572 non coding 0.956 0.978 
rs10952531 non coding 0.956 0.978 
rs4726581 non coding 0.956 0.978 
rs4726582 non coding 0.956 0.978 
rs4726583 non coding 0.956 0.978 
rs71529533 non coding 0.956 0.978 
rs4726586 non coding 0.956 0.978 
rs34500324 non coding 0.956 0.978 
rs4726587 non coding 0.956 0.978 
rs4726588 non coding 0.956 0.978 
rs13229600 non coding 0.956 0.978 
rs13229701 non coding 0.956 0.978 
rs13228878 non coding 0.956 0.978 
rs2367484 non coding 0.956 0.978 
rs2886990 non coding 0.956 0.978 
rs10952532 non coding 0.956 0.978 
rs1811090 non coding 0.895 1 
rs1985888 non coding 0.895 1 
rs2011216 non coding 0.895 1 
rs4726578 non coding 0.895 1 
rs4726575 non coding 0.853 0.976 
rs375656559 non coding 0.853 0.976 
rs71529532 non coding 0.853 0.976 
rs10246334 non coding 0.853 0.976 
rs2367343 non coding 0.853 0.976 
rs34708921 non coding 0.853 0.976 
rs10081384 non coding 0.853 0.976 
rs2187629 non coding 0.853 0.976 
rs10447734 non coding 0.853 0.976 
rs3757377 non coding 0.819 1 
rs3757378 non coding 0.819 1 
PTPRR_rs10506608 rs11178395 non coding 1 1 
rs10506607 non coding 1 1 
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rs73144109 non coding 1 1 
rs11178397 non coding 1 1 
rs11178399 non coding 1 1 
rs138264731 non coding 1 1 
rs145149665 non coding 1 1 
rs149570049 non coding 1 1 
rs7313937 non coding 1 1 
rs7132092 non coding 1 1 
rs7299834 non coding 1 1 
rs12369285 non coding 1 1 
rs73144199 non coding 1 1 
rs11178394 non coding 1 1 
rs59474063 non coding 0.941 1 
rs138137514 non coding 0.878 1 
rs11178393 non coding 0.841 1 
 
